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Psoriasis is a complex skin disorder that has been classified into several forms. These 
include common psoriasis vulgaris (PsV), a T-cell mediated disease, and Generalised 
Pustular Psoriasis (GPP), a rare condition associated with neutrophilic inflammation. 
While the genetic basis of PsV has been extensively studied, only a few innate immune 
genes have been associated with GPP. 
Neutrophils are the first cells to migrate toward sites of infection, where they recruit 
and activate T cells, as well as keratinocytes, thus amplifying the cutaneous 
inflammatory response. Hence, the current project sought to investigate the role of 
abnormal neutrophil activation in psoriasis. 
The initial focus of the study was the identification of new disease genes by means of 
whole-exome-sequencing. A Chinese-Malay family where several members suffered 
from PsV and/or GPP was first analysed, in order to identify new genetic determinants 
of neutrophilic skin inflammation. This uncovered a candidate disease variant in PRR13, 
with a second damaging change observed in an unrelated individual sequenced by the 
100,000 Genomes Project. While the function of PRR13 is poorly understood, alleles at 
this locus have been associated with neutrophil count variation in a genome-wide study. 
Next, the analysis of 147 pustular psoriasis patients uncovered two individuals with a 
homozygous splicing variant in MPO, a gene that is crucial to the microbicidal activity of 
neutrophils. Importantly, the variant was associated with increased neutrophil counts. 
In the final stage of the project, neutrophil RNA-sequencing was undertaken in 8 GPP 
cases vs. 11 controls. This identified an unexpected type-I IFN signature in patient 
neutrophils, an observation that was also validated in a PsV cohort. Mechanistic 
experiments demonstrated that the up-regulation of type-I IFN genes is driven by IL-36, 




Taken together, these findings identify new molecular pathways causing abnormal 
neutrophil activation in plaque and pustular forms of psoriasis.   
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1.1 Psoriasis  
1.1.1 Overview 
Psoriasis is a chronic inflammatory skin disease affecting around 2% of the population 
worldwide, and occurring with a prevalence as high as 4% in North-European countries1. 
Several studies report a bimodal distribution of age of onset, with peaks around 30–39 
and 50–69 years of age. Conversely, no significant sex difference is observed in disease 
frequency2. 
Psoriasis is generally considered a multifactorial condition caused by the interaction of 
environmental triggers (e.g. mechanical skin trauma, stress, smoking, infections and 
drugs) and inherited susceptibility alleles3,4. 
Psoriasis is characterised by skin lesions varying from papules, macules, plaques to 
pustules and is classified into six clinical types (Table 1.1, Figure 1.1)5. As the focus of 
this thesis is on psoriasis vulgaris and on pustular forms of the disease, these two disease 




Table 1.1 Classification of psoriasis clinical variants 
Subtype Affected sites Clinical manifestations 
Psoriasis vulgaris 
Scalp, limbs, trunk, genitalia, 
extensor surfaces 
Dry, sharply demarcated 
oval plaques with adherent 
silvery scales 
Guttate psoriasis Trunk and extremities 
Small, round erythematous 
plaques often preceded by 
streptococcal infection 
Pustular psoriasis 
Palms, soles and distal 
phalanxes (in localised 
disease) or trunk and limbs 
(in generalised pustular 
psoriasis) 
Small, sterile pustules on 









Intertriginous  and flexural 
areas 
Well-defined plaques with 
minimal scale and a shiny 
surface 









Figure 1.1 Clinical presentation of psoriasis 
The heterogeneous spectrum of psoriasis includes psoriasis vulgaris (A), flexural 
psoriasis (B), erythrodermic psoriasis (C) and guttate psoriasis (D)4,6. Pustular 




1.1.2 Psoriasis Vulgaris 
1.1.2.1 Clinical features  
Psoriasis vulgaris (PsV) is the most common form of the disease and accounts for 
approximately 90% of cases. It usually manifests with well-demarcated, red, scaly oval 
plaques that mostly affect the scalp, limbs, trunk, sacral region and extensor aspects of 
knees and elbows6. 
Histological staining of psoriatic lesions shows thickening of the epidermis (acanthosis), 
retention of keratinocyte nuclei in the stratum corneum (parakeratosis) and a mixed 
cellular infiltrate composed of T lymphocytes and dendritic cells7. Neutrophils collect 
within the stratum corneum and stratum spinosum of lesions, forming Munro’s 
microabscesses and Kogoj pustules, respectively. Plaques are also highly vascularised, 
with tortuous capillaries surfacing and dilating, which causes skin redness5. 
Disease severity can be roughly evaluated as the percentage of body surface area (BSA) 
that is affected by lesions. In this context, BSA values >10% correspond to “moderate to 
severe” psoriasis. The Psoriasis Area Severity Index (PASI) is a more sophisticated scoring 
method, which takes into account the affected surface area as well as the intensity of 
erythema, desquamation and skin induration within plaques8.  
Severe PsV is also associated with several comorbidities4, including type 2 diabetes, 
cardiovascular disorders, depression and psoriatic arthiritis9–11. The latter is observed in 
up to 30% of psoriatic patients12. It is a chronic inflammatory disorder affecting the 
spine, peripheral joints, tendon insertions and fingers13,14. All these concomitant 
illnesses can lead to occupational or functional disability, thus compounding  the impact 




It has long been recognised that psoriasis vulgaris is caused by the interplay between 
environmental and genetic factors, and can therefore be considered a complex trait3,16. 
Epidemiological studies have demonstrated that PsV has a higher incidence among 
relatives of affected individuals, particularly in early onset and childhood cases, 
compared to the general population1,17. Moreover, disease concordance is increased in 
monozygotic compared to dizygotic twins, with heritability estimates ranging between 
60 and 90%18. 
While linkage studies identified 9 genomic regions (PSORS 1-9) co-segregating with 
psoriasis, only 3 could be reliably validated in wider patient cohorts and therefore 
considered genuine susceptibility loci19,20.  
PSORS1 maps to the Major Histocompatibility Complex (MHC) class I region on 
chromosome 6p21. The HLA-Cw*0602 allele, which maps to this region, is the strongest 
genetic determinant of the disease (35-50% prevalence among patients) and has 
consistently been associated with odds ratios >2.0 21–25. While CDSN also maps to the 
MHC I region, subsequent studies have demonstrated that CDSN alleles are unlikely to 
play a causal pathogenic role25,26.  
The PSORS2 locus on chromosome 17q25 encompasses CARD14, which encodes an 
adaptor protein activating NF-κB signalling in keratinocytes27. While common CARD14 
variants have been associated with sporadic disease, rare deleterious alleles cause 
monogenic forms of PsV28. However, these mutations are only found in a small number 
of extended pedigrees29.  
The PSORS4 region on chromosome 1q21 spans the Epidermal Differentiation Cluster 
(EDC) and contains several genes involved in terminal keratinocyte differentiation30,31. 
Among these LCE3B and LCE3C (which encode late cornified envelope proteins) harbour 
variants associated with PsV and disruption of skin barrier function32,33. 
With technological advances in high-throughput genotyping and the advent of genome 
wide association studies (GWAS), the analysis of large case-control cohorts has 
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uncovered over 60 of psoriasis susceptibility loci. These include genes involved in 
antigen presentation (HLA-C, ERAP1), Th17 cell activation (IL23R, IL23A, IL12B, 
TRAF3IP2), innate antiviral responses (IFIH1, RNF114) and skin barrier function 
(LCE3B/D)24,25,32,34–37. Of note, evidence of a genetic interaction between HLA-C and 
ERAP1 has been identified, as ERAP1 variants confer disease susceptibility only in 
individuals carrying the HLA-Cw*0602 allele25.  
Further susceptibility alleles have been identified through targeted studies, using 
platforms such as the immunochip (which affords deep coverage of susceptibility 
regions associated with immune diseases) and the exome chip (which only contains 
coding SNPs). These analyses have confirmed the fundamental pathogenic role of the 
IL23/Th17 axis and increased the number of known disease regions (now exceeding 
6038–40). However, on average only 5% of autoimmune diseases susceptibility SNPs 
documented to date are likely to be causal41, with only a small fraction of PsV heritability 
(~25%) accounted for by known loci42. Hence, there is still a clear need to uncover new 





The pathophysiology of PsV is multifactorial and involves epidermal hyperproliferation, 
abnormal keratinocyte differentiation and dysregulation of the immune system.  
Skin trauma (Koebner phenomenon), infections (e.g. streptococcus) or medications 
(IFNα, corticosteroid) can all act as PsV triggers. These agents cause keratinocytes to 
produce the anti-microbial peptide LL37, which can bind self-RNA and self-DNA. The 
LL37/self nucleic acid complexes activate plasmacytoid dendritic cells (pDCs) through 
Toll-like receptor (TLR) -7 or -9, leading to the secretion of IFNα46,47. This can in turn 
activate myeloid dendritic cells (mDCs), which migrate into draining lymph nodes and 
produce TNFα, IL-12 and IL-23, triggering the differentiation of naïve T lymphocytes into 
Th17 and Th1 cells47–50. mDCs can also be activated through direct binding of LL37/RNA 
complexes to TLR-847.  
Th17 cells infiltrate skin lesions and secrete IL-17, which binds its receptor on the surface 
of keratinocytes. The engagement of IL-17R leads to STAT1 and NF-κB activation and the 
production of several cytokines and chemokines, such as IL-36, CCL20 and IL-8. While IL-
36 acts on DCs to promote the activation of further Th17 cells, CCL20 and IL-8 drive the 
recruitment of additional Th17 cells and neutrophils, contributing to the formation of a 
cutaneous plaque51–53. For an in-depth overview, I refer to excellent reviews on this 
subject54,55. Thus, IL-17 and IL-36 activate keratinocytes and Th17 cells, respectively, 
thereby promoting a positive feedback loop that leads to a sustained inflammatory 
state. Vascular endothelial growth factor (VEGF) is also secreted by keratinocytes: it 
induces angiogenesis and vascular dilation, facilitating the flux of inflammatory 
cytokines and infiltrating leukocytes56.  
The identity of the antigens presented to T cells by activated mDCs remains poorly 
understood. However, recent studies have shown that peptides derived from LL37 may 
act as autoantigens and be recognised by T lymphocytes in an HLA-Cw*0602 restricted 
manner57,58. A potential role for lipid antigens generated by phospholipase A2 and 
presented by skin-resident Langerhans cells has also been suggested59. 
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In conclusion, genetic and immunological studies have demonstrated that the 
pathogenesis of PsV is driven by a cross-talk between immune activation and skin barrier 





Figure 1.2 Current understanding of PsV pathogenesis 
Environmental triggers and loss of tolerance to self nucleic acids lead to activation 
of pDCs, which in turn activate mDCs. The latter secrete IL-23 and present psoriasis 
autoantigens, triggering T cells differentiation. Activated Th1 and Th17 produce IL-
17 and TNFα that act on keratinocytes to promote the production of further 
antimicrobial peptides, cytokines and chemokines. This drives the recruitment of 
additional T lymphocytes, neutrophils and macrophages, to promote a state of 
chronic inflammation55.  
pDC, plasmacytoid dendritic cell; mDC, myeloid dendritic cell; AMPs, Antimicrobial 




1.1.2.4 Treatment  
The best treatment for PsV will depend on disease severity and the presence of any co-
morbidities62.  
Topical corticosteroids are the first-line therapy: they are often used in conjunction with 
vitamin D analogues in patients with mild to moderate psoriasis (<10% BSA) and no 
concurrent psoriatic arthritis. Short term phototherapy, which works by inhibiting T cell 
activation, is recommended for patients with moderate to severe psoriasis63. 
The most commonly prescribed systemic medications for severe psoriasis are 
methotrexate (MTX), cyclosporine and acitretin. These act by inhibiting T cell activation 
and (in the case of MTX) neutrophil chemotaxis64–66. The use of these agents however, 
is associated with risks of organ toxicity and drug-drug interactions.  
As recent studies have started to uncover the mechanisms underlying the pathogenesis 
of PsV, new therapeutics which inhibit specific inflammatory cytokines (biologics) have 
been developed67.  
The first biologic agents showing efficacy in PsV were TNFα antagonists (adalimumab, 
etanercept and infliximab), which block the production of IL-23 by mDCs and the 
subsequent differentiation of Th17 cells 68,69. However, the risk of serious adverse events 
such as opportunistic infections (tuberculosis), demyelination and a higher incidence of 
certain skin cancers, cannot be disregarded when prescribing these drugs70,71. 
Following the success of genetic studies carried in recent years, the IL-23/Th17 axis has 
become the key target for the development of new biologics (Figure 1.3). 
Ustekinumab, an inhibitor of the p40 subunit shared by IL-12 and IL-23, has shown 
remarkable safety and efficacy, with >60% of patients achieving a 75% reduction in their 
baseline PASI (PASI75)72,73. While a superior clinical effect compared to etanercept has 
also been reported, monitoring of long term adverse events is still ongoing74,75. 
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Selective IL-17 inhibitors have also been extensively studied. Both secukinumab and 
ixekizumab are monoclonal antibodies that bind IL-17A and have shown higher efficacy 
than etanercept and ustekinumab76–78. Brodalumab, which blocks the common IL-17 
receptor and therefore antagonises IL-17F as well as IL- 17A, has also shown superior 
efficacy to ustekinumab79,80. In keeping with the indirect role of IL-17 in neutrophil 
activation, secukinumab induces a rapid reduction in cutaneous neutrophil numbers. 
However, it  can also cause mild neutropenia81,82. IL-17 inhibitors are also associated 
with greater incidence of Candida and upper respiratory tract infections, likely due to 
the important role of IL-17A in anti-fungal immunity76. Moreover, increased suicide rates 
have been reported in patients treated with IL-17 inhibitors77,78. 
Building on the success of ustekinumab, three selective IL-23p19 blockers have been 
recently approved. Risankizumab, tildrakizumab and guselkumab, all lead to rapid and 
sustained improvement of disease symptoms, in the absence of major safety 
concerns83,84. 
A number of small molecule therapeutics have also been developed in the last few years. 
Apremilast, an oral phosphodiesterase-4 (PDE-4) inhibitor that prevents the conversion 
of cyclic adenosine monophosphate (cAMP) to AMP, is now used for the treatment of 
moderate-to-severe psoriasis. Higher cAMP levels help reduce inflammation by 
downregulating TNFα and IL-23 while increasing the production of the anti-
inflammatory molecule IL-1085. While apremilast is less efficacious than biologic 
injectable agents (PASI75 is only achieved by 33% of patients), its oral administration 
and safety are favoured by patients and prescribers86.  
Lastly, Janus kinase (JAK) inhibitors are a new class of small molecules inhibitors acting 
on the tyrosine kinases that mediate the activation of STAT proteins, downstream of IL-
23R. Tofacitinib (an oral JAK1 and JAK3 inhibitor) has demonstrated a PASI75 response 
in 67% of patients with moderate to severe plaque psoriasis, and sustained efficacy over 
1 year87,88. Ruxolitinib, a JAK1 and JAK2 inhibitor, has also shown encouraging clinical 
results and has been tested as a topical formulation89. Trials of selective inhibitors of 
tyrosine kinase 2 (TYK2, another JAK family member), are underway90. 
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In conclusion, the recent advances in elucidating the pathogenesis of PsV have led to the 
development of more successful and targeted drugs. However, current therapies are 
still not sufficient to treat all PsV cases due to the heterogeneity of the disease, the 
presence of concomitant illnesses and individual variation in response rates91. 
Therefore, the pathogenesis of PsV needs to be further investigated to better 





Figure 1.3 The IL23/Th17 axis as a therapeutic target for psoriasis 
Diagram illustrating the molecules that can be targeted to treat PsV. The most 
effective agents inhibit IL-23 signalling at the receptor complex level (ustekinumab, 
tildrakizumab and guselkumab) or immediately downstream (JAK inhibitors). 
Ixekizumab and secukinumab inhibit Th17 activity by targeting IL-17, while 





1.1.3 Pustular psoriasis 
1.1.3.1 Clinical features  
Pustular psoriasis is a rare disease variant characterised by the eruption of sterile, 
neutrophil-filled pustules appearing on normal or erythematous skin. It can be classified 
into generalised and localised forms (Figure 1.4)5,92,93. 
Generalised pustular psoriasis (GPP) is the most severe form of the disease and affects 
around 2 to 7 individuals per million94,95. It presents with acute and potentially life-
threatening episodes of widespread skin pustulation and systemic upset (e.g. fever, 
malaise, elevated levels of acute phase reactants, neutrophilia). Around 30% of affected 
individuals suffer from concomitants PsV96. The course of the disease can be persistent 
(>3 months) or relapsing (>1 episode), and often requires intensive care admission. 
Flares can be triggered by infection, drugs (e.g. terbinafine and nonsteroidal anti-
inflammatory drugs (NSAIDs)), sunburns, steroid withdrawal, stress or pregnancy97–99.  
Localised or acral pustular psoriasis (APP) is further classified into two subtypes. 
Acrodermatitis continua of Hallopeau (ACH) affects fingers and/or toes, leading to 
osteolysis of the distal phalanx and destruction of the nail apparatus. Conversely, 
palmoplantar pustulosis (PPP) affects palms and soles, where pustules develop on 
erythematous skin92,99. Both disease forms are chronic (>3 months), painful and 
disabling, but not life-threatening.  
As ACH is even rarer than GPP, very little is known about its epidemiology. PPP, on the 
contrary, has a higher incidence (1200/million) and a distinctive demographic 
distribution100–102. The disease shows a marked sex bias, with female to male ratios often 
exceeding 3:1103.  Patients typically present with disease symptoms after the age of 40 
and almost invariably report an history of cigarette smoking104,105. Other triggering 
factors are similar to those seen in GPP, with the addition of skin trauma, thyroid 





Figure 1.4 Clinical presentation of pustular psoriasis 
Pustular psoriasis can present as generalised (GPP: left) or localised disease (PPP: 





The rarity and heterogeneous nature of pustular psoriasis has hindered the recruitment 
of sizeable patient cohorts, so that the identification of disease loci has been 
challenging. An analysis of two North-European PPP cohorts was carried out in 2003. 
This showed a lack of association with PSORS1 markers, suggesting the existence of 
pathogenic pathways that are distinct from those that underlie PsV107. 
 This notion was confirmed following the identification of pustular psoriasis alleles in 
three innate immune genes (IL36RN, AP1S3 and CARD14).  
Autosomal recessive loss of function mutations in IL36RN were first identified in GPP 
through linkage studies of consanguineous pedigrees and whole exome sequencing of 
isolated cases108,109.  
IL36RN encodes the IL-36 receptor antagonist (IL-36Ra). This molecule competes with 
three agonists (IL-36α, IL-36β and IL-36γ) for binding to the IL-36 receptor (IL-36R). Once 
IL-36 cytokines have engaged with IL-36R, this dimerises with IL-1RAcP, a membrane-
bound accessory protein composed of an extracellular ligand-binding domain, a 
transmembrane sequence and a cytoplasmic Toll/IL-1 receptor (TIR) domain. The 
complex then recruits MyD88, Tollip and IRAK, leading to the activation of NF-κB and 
mitogen-activated protein (MAP) kinase pathways. This, in turn, causes the transcription 
of several innate immune genes (such as IL8, IL1, IL6 and TNFA), which then mediate 
inflammatory responses (Figure 1.5, left).  
When IL-36Ra binds to IL-36R, however, the receptor does not dimerise, preventing any 
downstream signalling (Figure 1.5, middle)110,111. In this context, IL36RN mutations 
disrupt the immune modulatory activity of IL-36Ra, causing unrestrained IL-36 signalling, 
excessive IL-1β, IL-6 and IL-8 production, and an enhanced inflammatory response 
(Figure 1.5, right)108,112.  
A total of 20 deleterious alleles have now been identified in IL36RN, including missense, 
stop-gain, splice site and deletion variants113. IL36RN defects have been reported in all 
ethnic groups, with distinct changes dominating the mutational landscape in Asian 
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(c.115+6T>C), European (p.Ser113Leu) and North-African (p.Leu27Pro) 
populations109,114. 
While IL36RN defects are typically recessive, GPP patients harbouring a single 
deleterious change have also been described. Interestingly, these individuals tend to 
show a delayed disease onset115. 
IL36RN alleles account for approximately 25% of GPP cases115 and are more frequent 
among individuals suffering from severe disease (early-onset GPP with high risk of 
systemic inflammation). While homozygous, compound heterozygous, and single 
heterozygous IL36RN mutations have also been observed in subjects with localised 
pustular psoriasis, their frequency is much lower in this patient group (<5%), where they 





Figure 1.5 Disruption of IL-36 signalling in GPP 
The cytokines IL-36α, -β and -γ (green) bind to the interleukin-36 receptor (IL36R, 
purple), which enables the recruitment of the IL-1R accessory protein (IL-1RAcP, 
blue), leading to an NF-κB and MAPK mediated inflammatory response. The IL-
36Ra (red) also binds to IL-36R, which then fails to recruit the accessory protein, 
therefore inhibiting downstream signalling. Patients with IL36RN mutations 
experience exacerbated inflammatory responses due to lack of receptor 








Following the identification of IL36RN as a disease gene, further studies were 
undertaken to uncover other susceptibility loci. Two founder alleles in AP1S3, p.Phe4Cys 
and p.Arg33Trp, were discovered through exome sequencing of pustular psoriasis cases 
and found to be significantly more frequent in affected individuals compared to 
controls116.  
AP1S3 encodes the σ1 subunit of AP-1, an intracellular trafficking complex facilitating 
vesicular transport of proteins and autophagosome formation117. Disease alleles cause 
impaired autophagy, abnormal accumulation of p62 (an NF-kB adaptor) and increased 
production of IL-36 by keratinocytes118. 
Finally, Sugiura et al. described Japanese GPP patients harbouring a missense variant in 
CARD14, a gene that is also mutated in familial PsV (PSORS2) and pityriasis rubra pilaris 
(PRP)27,119,120. The allele described by Sugiura (p.Asp176His) was then uncovered in an 
extended Chinese cohort and in 2 PPP cases29,121, confirming the association with 
pustular psoriasis. The change is a gain-of-function mutation, which causes abnormal 
TRAF-2 dependent activation of NF-κB signalling28,122, which is thought to lead to 
excessive IL-6, IL-8 and IL-36 production. Thus, the effects of disease alleles seem to 
converge on the up-regulation of IL-36 activity.  
In conclusion, genetic studies have shown that pustular psoriasis is mostly associated 
with rare and deleterious alleles. This near-monogenic genetic architecture 
differentiates it from PsV, which is caused by common variants of small effect. While 
there is some overlap between the genetic determinants of GPP and PPP, substantial 
genetic heterogeneity has also been observed, as known genes account for less than 




Nearly all studies of disease pathogenesis have been carried out in GPP. Due to the rarity 
of the disease, however, progress has been slow.  
The transcription profiling of GPP skin biopsies revealed a distinctive pattern of 
differential gene expression, with limited similarities to PsV. In keeping with the results 
of genetic studies, IL-1 and IL-36 were found to be significantly upregulated, together 
with several neutrophil chemokines (IL-8, CXCL1 and CXCL2) and neutrophil-derived 
proteases, such as neutrophil elastase and cathepsin G and S. Of note, the latter are 
responsible for processing IL-36 precursors into their active forms, which further 
validates the fundamental role that IL-36 plays in the pathogenesis of GPP123–126.  
Two studies have also demonstrated that the pathways that are induced in 
keratinocytes stimulated with IL-36 significantly overlap with those that are abnormally 
active in GPP skin123,127. A notable example of this phenomenon is the infiltration of 
neutrophils into inflamed skin, a hallmark of GPP, which is mediated by genes that are 
up-regulated by IL-36.  
Taken together, these findings suggest that high levels of IL-1 and IL-36 cause the 
activation of GPP keratinocytes. These then produce chemokines (IL-8, CXCL1 and 
CXCL2) that attract neutrophils to the site of inflammation. As neutrophil proteases can 
process IL-36 into its bioactive form, their recruitment sustains and propagates 
inflammation in GPP skin. 
 While systemic inflammation is a key feature of GPP, its causes remain poorly 




1.1.3.4 Treatment  
Treatment options for pustular psoriasis are profoundly limited, owing to the limited 
understanding of disease pathways and the difficulty of running clinical trials for such a 
rare condition. There is therefore a clear unmet need for effective therapeutics128. 
First line treatments for GPP include acitretin, cyclosporin, methotrexate and the TNF 
blocker infliximab, which has been reported to rapidly improve fever and skin 
symptoms. Second line therapies include the TNF inhibitors adalimumab and 
etanercept, topical agents and phototherapy97. However, the efficacy of these agents 
(which are used to good effect in PsV) is limited. Conversely, promising results have been 
obtained with the IL-17A antagonist secukinumab129,130. 
IL-1 blockers (e.g. anakinra) have also been used in the treatment of GPP, based on their 
efficacy in other autoinflammatory conditions presenting with recurrent fevers and skin 
rashes131,132. Anakinra initially caused rapid clinical improvement, but full disease 
remission was not observed. This is in keeping with the notion that IL-1 is not the 
dominant disease driver, but is rather involved in a pro-inflammatory feedback loop 
driven by IL-36133.  
Therapies for acral pustular psoriasis include psoralen/UVA photochemotherapy (PUVA) 
and topical corticosteroids. In more severe cases, where multiple digits/nails are 
involved, dermatologists might prescribe cyclosporin and retinoids97. Successful 
treatment of ACH with TNF antagonists has been reported106,134, while there are 
conflicting reports regarding the use of ustekinumab in acral pustular psoriasis135,136. 
Finally, the results of genetic studies are driving the clinical development of two IL-36 
inhibitors. These agents, which act by blocking the IL-36 receptor, have shown a 
favourable safety profile, with one trial also reporting substantial improvement of GPP 
symptoms137,138. Such progresses highlight the translational potential of gene 





1.2.1 Life cycle 
Neutrophils, also known as polymorphonuclear leukocytes (PMNs) or neutrophilic 
granulocytes, are an essential part of the innate and adaptive immune system, 
protecting the host from bacterial and fungal pathogens. They provide the first line of 
defence of the innate immune system by phagocytosing, killing and digesting bacteria 
and fungi. In addition, they recruit and activate other cells of the immune system. 
Neutrophils are the most abundant cell type in human blood, comprising 60-70% of all 
circulating white blood cells139. 
Every day more than 1011 neutrophils are produced in the bone marrow, in a process 
called granulopoiesis140. Hematopoietic stem cells (HSC) differentiate into multipotent 
progenitor cells (MPP) and then into lymphoid-primed multipotent progenitors (LMPP). 
These become granulocyte-monocyte progenitors (GMP), which, in the presence of the 
granulocyte colony-stimulating factor (G-CSF), differentiate into myeloblasts. These cells 
then follow a multi-step maturation process that includes the stages of promyelocyte 
(characterised by a round nucleus and relatively dark cytoplasm), myelocyte (round 
nucleus with initial dents and less-dark cytoplasm), metamyelocyte (kidney-shaped 
nucleus and clear cytoplasm), band cell (horseshoe-shaped nucleus and clear 
cytoplasm), leading to a mature neutrophil with its characteristic segmented nucleus 
(Figure 1.6)141,142.  
Granulopoiesis is under the control of several transcription factors, such as Runx1 





Figure 1.6 The stages of granulopoiesis 
Neutrophils are produced in the bone marrow. A multipotent progenitor (MPP) cell 
originates from a hematopoietic stem cell (HSC). MPPs generate lymphoid-primed 
multipotent progenitors (LMPPs), which differentiate into granulocyte-monocyte 
progenitors (GMPs). In the presence of the granulocyte colony-stimulating factor (G-
CSF), GMPs turn into myeloblasts, which then follow a maturation process that 
comprises the stages of promyelocyte, myelocyte, metamyelocyte, band cell, and 
mature neutrophil. Primary granules appear at the myeloblast to promyelocyte 
stage, secondary granules at the myelocyte and metamyelocyte stages, tertiary 
granules at the band cell stage, while secretory vesicle only present in mature PMNs. 





The secretory vesicles and granules found within mature neutrophils are also formed 
during granulopoiesis145.  
Primary (azurophilic) granules, containing myeloperoxidase (MPO) and serine proteases 
(proteinase 3, cathepsin G and neutrophil elastase (NE)), appear at the myeloblast to 
promyelocyte stage. Secondary (specific) granules, which contain high levels of the iron-
binding protein lactoferrin, are detected at myelocyte and metamyelocyte stages. 
Tertiary (gelatinase) granules, containing matrix metalloproteinase 9 (MMP9, also 
known as gelatinase B) are formed at the band cell stage. Finally, secretory vesicles, 
which contain plasma-derived proteins such as albumin, are only present in mature 
neutrophils (Figure 1.6)146,147. 
Once neutrophils mature, they are released into the circulation in a process that is 
tightly regulated by chemokines. These include CXCL12 and CXCL1/CXCL2, which act 
through their respective receptors, CXCR4 and CXCR2, to modulate the release of 
neutrophils from the bone marrow. Thus, CXCR4–CXCL12 signalling promotes neutrophil 






Quiescent neutrophils are short-lived cells, which continuously probe their 
microenvironment, seeking signs of infection and inflammation. They typically die within 
a day of entering the circulation149. PMNs can however be recruited to sites of infection 
or inflammation, where their lifespan is extended by local cytokines and microbial 
products150. 
Neutrophils become activated through a two-stage process. First, bacterial products, 
cytokines and chemokines (e.g. IL-8, IFN-γ TNF- α and GM-CSF) prime resting cells, and 
these are then mobilised to the site of infection or inflammation, where they encounter 
the signals that trigger microbial killing151.  
Bacterial compounds (e.g. lipopolysaccharide (LPS) and N-Formylmethionyl-leucyl-
phenylalanine (fMLP)) and cytokines (e.g. TNF-α and IL-1β) also stimulate vascular 
endothelial cells to produce E- and P-selectins. As neutrophils come into contact with 
these adhesion receptors, they “roll” along the endothelium, causing the partial 
activation of surface β2 integrin (also known as CD11/CD18). Binding of integrins to 
intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 stops the rolling and promotes 
the adhesion of neutrophils to the endothelium. Crawling along the vessel wall, PMNs 
then reach endothelial cell junctions and extravasate into tissues (Figure 1.7). There, 
they move towards sites of inflammation following a chemotactic gradient driven by 
host-produced (e.g. IL-8) and pathogen-derived (e.g. fMLP) molecules. As they near their 
target, neutrophils become fully activated and finally release their antimicrobial arsenal 






Figure 1.7 Neutrophil recruitment cascade 
The figure shows the steps mediating neutrophil extravasation from blood vessel to 
sites of inflammation. Neutrophils adhere to the vascular endothelial wall using 
selectins, integrins and adhesion molecules. They then roll, arrest (adhesion) and 
transmigrate through endothelial cell junctions into peripheral tissues. Adapted 





1.2.3.1 Elimination of microbes 
Neutrophils can eliminate microbes through degranulation, phagocytosis or the release 
of neutrophil extracellular traps (NETosis, Figure 1.8). All three processes are tightly 
regulated. 
1.2.3.1.1 Degranulation 
Neutrophil granules contain a plethora of antimicrobial proteins and peptides. These 
can be divided into three main classes: i) cationic peptides and proteins binding to 
microbial membranes, ii) enzymes and iii) proteins that deplete microorganisms of 
essential nutrients152. The first group comprises defensins, cathelicidins, 
bactericidal/permeability-increasing protein (BPI) and histones. Apart from histones, 
which act through poorly understood mechanisms, all exert their function by 
permeabilising the bacterial membrane, hydrolysing bacterial phospholipids or 
inhibiting nucleic acid, protein and cell wall synthesis153. Of note, the LL37 cathelicidin 
may also potentiate the activation of plasmacytoid dendritic cells, as described in 
section 1.1.2.346.  
The second group of antimicrobial proteins includes lysozymes and proteolytic enzymes 
such as serine proteases (proteinase 3, cathepsin G and neutrophil elastase). While 
lysozymes destroy the bacterial wall, serine proteases can cleave bacterial virulence 
factors and bind the bacterial membrane152.  
Finally, the third group encompasses metal chelator proteins such as lactoferrin and 
calprotectin, which sequester essential nutrients (iron, manganese and zinc) and/or bind 
LPS causing increased membrane permeability148,154. 
As PMNs become activated, granules are gradually mobilised. They then fuse with the 
phagosome (see section 1.2.3.1.2) or neutrophil plasma membrane, thus releasing their 
toxic content. Interestingly, several granule proteins (e.g. azurocidin, proteinase 3, 
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cathepsin G and LL37) can also mediate the recruitment of other cells involved in the 
inflammatory response155. 
Secretory vesicles are the first to be released, followed by gelatinase, secondary and 
azurophilic granules. While the mechanisms underlying this differential mobilisation are 
not fully understood, changes in cytosolic calcium levels are thought to be necessary for 
granule secretion156,157. Of note, the engagement of secretory vesicles also sustains PMN 
activation, as the secretion of membrane-bound proteins (β2 integrin, FcγR, 
complement and fMLP receptors) promotes the transition to firm endothelium 
adhesion158–160. Likewise, metalloproteases contained in tertiary granules may help 
neutrophils cross the endothelial membrane161.  
Another component of the degranulation process is the oxidative burst. Neutrophils 
produce reactive oxygen species (ROS) through a process mediated by the nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase complex. When this is assembled on 
the phagosomal and PMN plasma membranes, it reduces molecular oxygen to 
superoxide. Superoxide alone is not a strong oxidant, but it can either dismutate and 
form hydrogen peroxide, or react with nitric oxide to form peroxynitrite. Once 
myeloperoxidase (MPO) is released by azurophilic granules, it reacts with hydrogen 
peroxide and Cl- to produce hypohalous acids that have direct antimicrobial effects148,162. 
Of note, loss of function NADPH oxidase mutations cause chronic granulomatous 








Figure 1.8 Neutrophil antimicrobial functions 
Once neutrophils migrate to the site of inflammation, they phagocytose and digest 
their target. They then release granules and neutrophil extracellular traps (NETs) to 
kill invading pathogens. PMNs also produce pro-inflammatory cytokines. From 








Phagocytosis is the main method to eliminate pathogens and cell debris148.  
Neutrophils can internalise both opsonised and non-opsonised particles. Opsonins are 
pattern-recognition receptors that facilitate the attachment of particles to professional 
phagocytic cell, enhancing the efficacy of the phagocytic process148. Once activated, 
neutrophil opsonic receptors such as FcγR, β2 integrin, C-type lectins or complement 
receptors, situated on PMN membrane, bind to IgG or complement-coated particles, 
which are then engulfed. During this process, protein and lipid kinases promote actin 
polymerization, leading to the formation and sealing of a phagosomal cup164.  
The nascent phagosome subsequently acquires its antimicrobial effects through 
calcium-dependent fusion with secretory vesicles and granules156. The SNARE (soluble 
N-ethylmaleimide-sensitive-fusion-protein attachment protein receptor) family of 
proteins also contributes to this process, as a v-SNARE on the target membrane interacts 
with a similar protein on the phagosome154.  
Once primary and secondary granules have fused with the phagosome, they unload their 
antimicrobial enzyme content. Meanwhile, the NADPH oxidase complex is assembled on 
the phagosomal membrane, leading to the production of ROS (see section 1.2.3.1.1). 
Together, granule fusion and ROS formation create a toxic, alkaline environment 
(despite the entry of acidic granule contents) for the pathogens engulfed in the 
phagosome, resulting in rapid microbial killing148,164,165. 
1.2.3.1.3 NETosis 
Neutrophil extracellular traps (NETs) are fibrous structures containing histones as well 
as antimicrobial proteins, such as LL37, neutrophil elastase (NE), cathepsin G, MPO and 
lactoferrin. In inflammatory conditions, neutrophils can release NETs into the 
extracellular space through a cell-death program called NETosis. 
While the mechanism of NET formation is poorly understood, ROS are likely to play an 
important role, given  that NETosis can be inhibited by NADPH oxidase blockade166.  
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NETosis starts when activated neutrophils attach to their microbial targets. This causes 
nuclear and granular membranes to dissolve and release their content in the cytoplasm, 
leading to histone decondensation. Finally, PMN cell membrane ruptures, allowing the 
extracellular release of chromatin decorated with granular proteins.  
NETs are sticky and voluminous. This enables them to trap microbes and expose them 
to  the synergistic action of antimicrobial agents167,168. Thus, NETs contribute to the fight 
against parasites, Gram-positive and Gram-negative bacteria. They also play a role in 
eliminating pathogens such as fungi ,which are too large to be phagocytosed168. At the 
same time, NETs contain the systemic spread of antimicrobial agents and prevent them 
from damaging the surrounding tissue.  
While neutrophils initiate phagocytosis within moments of engaging their targets, 
degranulation occurs approximately 10 minutes later and NETosis is a more prolonged 
process. This suggests that that the three defence strategies may be activated 




1.2.3.2 Cross talk with other immune cells  
Although neutrophils have a short lifespan, several signals (e.g. cytokines and microbial 
products) can extend their survival, allowing them to efficiently eliminate pathogens, 
release immunoregulatory molecules and recruit other cells. In fact, once neutrophils 
reach inflamed tissues, they participate in complex interactions with DCs, macrophages, 
natural killer (NK) cells, lymphocytes and mesenchymal stem cells, as summarised in 
Figure 1.9148,169.  
Even though neutrophils have a limited range of expression at the transcriptional level, 
their abundance within inflammatory sites means that they significantly contribute to 
cytokine production148,170. IL-8, which is released in the largest quantities, serves to 
recruit further PMNs, while TNF-α and IL-1β stimulate other leukocytes to produce 
neutrophil chemoattractants171,172. Neutrophil serine proteases can also activate 
cytokines produced by epithelial cells, such as IL-1α and, notably, IL-36124–126,173. 
Neutrophils can promote monocyte recruitment by expressing MIP (macrophage 
inflammatory protein) family chemokines and inducing monocyte extravasation through 
LL37, azurocidin and cathepsin G release174–177.  
Neutrophils can also affect the function of DCs (Figure 1.9C). For example, supernatants 
of neutrophil cultures exposed to Toxoplasma gondii induced DC maturation and 
activation, as demonstrated by the up-regulation of TNF-α and IL-12178. The DC-SIGN 
and Mac-1 (CD11b) receptors are thought to be responsible for the interaction between 
PMNs and DCs179,180.  
Neutrophils influence the responses of marginal zone B cells (MZB) by sequestering and 
transporting bacteria to the splenic marginal zone (Figure 1.9A)181. Activated neutrophils 
also express B-Cell-Activating Factor (BAFF) and produce APRIL (A proliferation-inducing 
ligand), a B cell-stimulating cytokine182,183. In keeping with these observations, Puga et 




Neutrophils can regulate T cell function indirectly through pDCs or directly, by releasing 
chemoattractants (CCL2, CXCL9,CXCL10 and CCL20)169,185,186. Of note, neutrophils also 
express molecules required for antigen processing and presentation to T cells187.  
Neutrophils can influence cytokine production by NK cells. For example, Legionella 
pneumophila infection up-regulates IFN-γ production by murine NK cells, in a process 
that is dependent on neutrophil-derived IL-18 and DC-derived IL-12 (Figure 1.9D)188,189. 
Likewise, depletion of PMNs by anti-Ly6G antibodies reduces NK cells 
responsiveness190,191.  
Neutrophils are in turn influenced by cytokines produced by other leukocytes. For 
example, IFN-γ, GM-CSF and TNF (all released by T cells) control survival and expression 
of activation markers192,193. In addition, IL-17 cytokines can promote the release of 
granulopoietic factors and neutrophil chemoattractants by epithelial cells, thus 
augmenting PMN recruitment and activation169. Finally, type-I-IFN can exert multiple 
effects on neutrophils. It can delay apoptosis194 and modulate neutrophil differentiation, 
activation, and migration. It has also been reported to drive CXCL10 production, thus 






Figure 1.9 Interactions of neutrophils with other immune cells 
A) Neutrophils (PMN) in the splenic marginal zone promote the activation and 
maturation of marginal zone B cells (MZB); B) Netting neutrophils stimulate pDCs to 
release IFN-α, which in turn up-regulates antibody production by B cells and causes 
further NET release; C) Neutrophils present antigens to T cells directly or through 
DCs; D) Neutrophils and DCs jointly activate NK cells. From Mocsai 2013149. 
PMN, polymorphonuclear cells; NET, neutrophil extracellular traps; MZB, marginal 
zone B cells; BAFF, B-cell activating factor; APRIL, a proliferation-inducing ligand; 
pDC, plasmacytoid dendritic cells; TLR9, toll-like receptor 9; TCR, T-cell receptor; 
MHC, major histocompatibility complex; DC-SIGN, Dendritic Cell-
Specific Intercellular adhesion molecule-3-Grabbing Non-integrin; Mac-1, 




1.2.3.3 Resolution of inflammation 
During the late phases of inflammation, PMNs start to produce lipoxins, resolvins, and 
protectins. These lipids enhance monocyte and macrophage activation while limiting 
neutrophil migration196–198. Lipoxin also reduces neutrophil adhesion to the 
endothelium by inhibiting L-selectin shedding and β2 integrin production. At the same 
time, it modulates neutrophil activation by down-regulating ROS production, IL-8 
expression and NF-B activation199–201.  
Neutrophils also limit inflammation by expressing decoy receptors for several 
inflammatory chemokines and cytokines, including IL-1202,203.  
Aging neutrophils undergo apoptosis, a cell-death program which controls the numbers 
of PMNs in the circulation204,205.  Apoptosis is tightly controlled by intrinsic and extrinsic  
signalling pathways, which are mediated by caspases 9 and 8, respectively151. Given that 
the prolonged release of proinflammatory molecules from dying PMNs can cause tissue 
damage, apoptotic neutrophils are promptly recognised and removed by 
macrophages206–208. This process is up-regulated by lipid mediators197,201 and requires 
the presence of thrombospondin (TSP-1). The latter is thought to function as a bridge 






1.2.3.4 Anti-tumour functions 
Neutrophils are essential components of the tumour microenvironment and have been 
implicated in both the progression and resolution of several solid tumours169,211.  
Tumour-associated macrophages (TAMs) and chemokines released by tumour cells can 
recruit tumour-associated neutrophils (TANs). These are different from naïve bone 
marrow neutrophils, and two distinct subsets have been identified, N1 and N2212.  
N1 neutrophils have anti-tumoural functions: they are characterised by increased 
expression of TNF-α and reduced production of VEGF and MMP9. The latter are key 
angiogenic factors, contributing to tumour growth and progression211. Conversely, N2 





1.2.4 Disorders of neutrophil function 
Diseases caused by inherited neutrophil defects are classified into four categories, as 
summarised in Table 1.2214. 
Severe combined neutropenia is the only condition that is considered a disorder of 
neutrophil homeostasis. It is caused by dominant mutations in NE or recessive mutations 
in VPS45, HAX1 or G6PC3, leading to neutropenia and arrested neutrophil maturation215.  
PMN recruitment disorders (also known as leukocyte adhesion deficiencies) form a 
distinct disease group. They are caused by defective extravasation and impaired 
migration to inflammatory sites, due to abnormalities in selectin and integrin 
genes216,217. 
Neutrophil activation disorders are associated with disease alleles in four distinct genes. 
Recessive mutations in MYD88 and IRAK4 affect adhesion molecule expression, ROS 
formation, PMN survival and cytokine production in response to TLR agonists218,219. 
Conversely, deficiencies in Dectin-1 (CLEC7A) have a more restricted effect, as they 
disrupt a receptor that specifically recognises β -glucans in the fungal cell wall220,221. 
Likewise, recessive mutations in CARD9 cause recurrent fungal infections, since they 










Table 1.2 Congenital disorders of neutrophil function214 
 
 
Disease Causes Neutrophil defects Clinical manifestations 




Mutations in NE, 
VPS45, HAX1 or 
G6PC3 
Prominent neutropenia and 
arrested neutrophil maturation 
Recurrence of bacterial and 
fungal infections; leukaemia 
incidence ~25% after 20 years 








Abnormalities in diapedesis and 
complement-dependent 
phagocytosis 
Leucocytosis and neutrophilia, 

















Absence of integrin–mediated 
neutrophil adhesion and 
migration 







Defects in adhesion molecule 
expression, oxidative burst, 
cytokine production and cell 
survival in response to TLR 




(meningitis and septicaemia) 
and localized 
(skin and upper respiratory 















occurrence of fatal candidal 
meningitis 







Absence of oxidative burst 
Severe bacterial (S. aureus) 
and fungal (Aspergillus and 







mutations in LYST 
Abnormally large granules due 
to lysosomal trafficking defects 
Neutropenia, susceptibility to 
pyogenic infections (S. 






CEBPE or GFI1 
Defective chemotaxis; reduced 
release of MPO and other 
granule proteins 
Recurrence of cutaneous, ear, 







Negligible, unless combined 




Chronic granulomatous diseases (CGD) are the most common defects of pathogen 
killing. They are caused by mutations in NADPH oxidase subunits, which lead to defective 
ROS production and microbial killing abnormalities163. Other disorders can result from 
defects in granule formation and/or loss of granule enzymes. For example, Chédiak-
Higashi syndrome is characterised by the presence of abnormally large granules, due to 
mutations in the LYST lysosomal trafficking regulator222. Likewise, loss of function alleles 
in the CEBPE or GFI1 transcription factors cause defective neutrophil chemotaxis and 
reduced release of granule proteins (neutrophil-specific granule deficiency). Finally, 
MPO deficiency causes enhanced phagocytosis and degranulation223–225.  
The majority of patients affected by congenital neutrophil abnormalities present with 
recurrent bacterial and fungal infections, mostly caused by Staphylococcus aureus, 
Aspergillus fumigatus and Candida albicans. The impact of disease alleles is highly 
variable. While individuals with MPO deficiency do not necessarily present with any 
clinical symptoms,  patients bearing CARD9 or MYD88 mutations can suffer from life-




1.2.5 Role of neutrophils in psoriasis 
The accumulation of neutrophils in the stratum corneum and the consequent formation 
of Munro’s microabscesses are key features of plaque and pustular psoriasis. PMNs are 
recruited to the lesional epidermis by several chemokines secreted by 
hyperproliferating keratinocytes (e.g. CXCL1, CXCL2, IL-8 and IL-18)226. In turn, these 
activated neutrophils release pro-inflammatory mediators (e.g. IL-1, IL-8, IFN-α, MIP-1, 
LL37) and proteases through degranulation and NETosis, as described in section 
1.2.3.1227–229. 
Some of the proteases released by degranulating blood neutrophils cleave IL-36 
cytokines into their active forms. Cathepsin G can process IL-36α and -, while NE 
recognizes IL-36 and -. Finally proteinase 3 cleaves IL-36γ and to a lesser extent, IL-
36124–126,230. Given the role of IL-36 cytokines in propagating the effects of abnormal IL-
17 signalling (see 1.1.2.3), their activation by neutrophil proteases is critical to disease 
pathogenesis. Proteinase 3 was also shown to cleave hCAP-18 to generate LL37, while 
NE can promote keratinocyte proliferation by proteolytic activation of EGFR 
signalling231,232. 
Epidermal neutrophils are major producers of VEGF and IL-18, which contribute to 
angiogenesis and vascular dilation, thus facilitating the recruitment of further 
leukocytes to skin lesions. Moreover, neutrophil gelatinase granules contain MMP9, an 
enzyme that has been associated with new vessel formation227,233. 
PMNs are particularly important in pustular forms of psoriasis, which are characterised 
by IL-36 driven neutrophilic skin inflammation93. In GPP, unrestrained IL-36R signalling 
also causes systemic inflammation and peripheral neutrophilia234. The underlying 
pathways, however, remain poorly understood. 
Of note, the IL-17 blocker secukinumab, which has shown efficacy in both plaque and 
pustular psoriasis, reduces neutrophil infiltration and down-regulates the production of 
keratinocyte-derived neutrophil chemoattractants81. 
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While these data suggest that activated neutrophils have a prominent role in the 





1.3 Aim and overview of the study 
The hypotheses underlying this study are:  
i) the identification of novel genetic determinants for psoriasis can uncover 
new immune pathogenic pathways;  
ii) neutrophils are inappropriately activated in psoriasis.  
The aim of the PhD  was to validate these propositions by uncovering new disease genes 
and investigating the immunological pathways that mediate abnormal neutrophil 
function in psoriasis. Particular attention was paid to pustular forms of the disease, given 
that neutrophilic inflammation is especially prominent in these clinical variants. 
Thus, the objectives of my project were: 
- To carry out whole-exome sequencing in an extended pedigree and in a collection 
of unrelated cases in order to uncover novel disease variants; 
- To investigate the function of the newly identified disease genes, through ex-vivo 
and in-silico studies; 
as well as: 
- To analyse the neutrophil transcriptome of patients with GPP and compare it with 
that of healthy individuals and disease controls; 
- To investigate the link between excessive IL-36 signalling and neutrophil activation 






2 MATERIALS AND METHODS 
2.1 Materials 
Reagent Manufacturer 
5 ml round-bottom polystyrene tubes Corning 
7-AAD (7-Aminoactinomycin D) BioLegend 
100bp DNA Ladder New England BioLabs 
1kb DNA Ladder New England BioLabs 
10X DreamTaq buffer Thermo Scientific 
2-Mercaptoethanol Sigma-Aldrich 
Agarose Severn Biotech 
Agencourt AMPure XP Beckman Coulter 
B2M (Beta-2-Microglobulin, human) PrimerDesign 
Big Dye Terminator v3.1 Cycle 
Sequencing Kit 
Applied Biosystems 
Bovine Serum Albumin (BSA) New England Biolabs 
Brefeldin A BioLegend 
Bromophenol blue Sigma-Aldrich 
dNTP nucleotides Fisher Scientific 
DreamTaq DNA polymerase Thermo Scientific 
Ethanol VWR 
Ethidium bromide Sigma-Aldrich 
Ficoll GE 
FIX & PERM™ Cell Permeabilization Kit Invitrogen 
FBS (Foetal Bovine Serum) Gibco 
GeneJET RNA Purification Kit Thermo Fisher Scientific 
GeneScan 500 TAMRA Size Standard Life Technologies 
Herculase II Fusion DNA Polymerase Kit Agilent Technologies 
Hi-DiTM Formamide Applied Biosystems 
IL-1β Miltenyi 
IL-6 PeproTech 
Illustra ExoProStar 1-Step GE Healthcare/Fisher 
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LIVE/DEAD™ Fixable Near-IR (APC-Cy7) Thermo Fisher Scientific 
Loading dye 
3% Glycerol, 2.5% (w/v) Bromophenol 
blue, ddH20 
MACSxpress® Neutrophil Isolation Kit 
for human 
Miltenyi 
NaOAc (Sodium Acetate) Sigma-Aldrich 
ODN-A CpG InVivoGen 
Oragene DNA kit DNA Genotek 
PBS Gibco 
Penicillin-Streptomycin (P/S) Life technologies 
Plasmacytoid Dendritic Cell Isolation Kit 
II for human 
Miltenyi 
Precipitation solution 95% Ethanol, 0.12M NaOAc (pH 4.6) 
Precision nanoScript2 Reverse 
Transcription kit 
PrimerDesign 
PrecisionPlus SYBR and ROX qPCR Mix PrimerDesign 
Recombinant Human IL-36 alpha/IL-1F6 
(aa 6-158) Protein 
R&D Systems 
Red Blood Cell lysis solution Miltenyi 
RNA TapeStation kit Agilent 
RNaseZap™ RNase Decontamination 
Solution 
Invitrogen 
NaOAc (Sodium Acetate) Hettich 
RPL13A (Ribosomal Protein L13a, 
human) 
PrimerDesign 
RPMI 1640 Medium Gibco 
RPMI Medium 1640 - GlutaMAX™ Gibco 
SB-203580 VWR 
Staining buffer 
Phosphate-buffered saline (PBS) pH 7.2, 
2% FBS, and 2 mM EDTA 
SureSelect Library Prep Kit Agilent Technologies 
SureSelect Human All Exome Kit v.4 and 
v.6 
Agilent Technologies 




2.2 Human Subjects 
2.2.1 Ethics statement 
The study was performed according to the principles of the Helsinki Declaration. All 
cases were recruited as part of the FAP study (Functional Annotation of Psoriasis 
susceptibility alleles, approved by the London - Chelsea Research Ethics Committee, 
reference 14/LO/2169, 20th January 2015) or the PLUM study (Pustular psoriasis: 
eLucidating Underlying Mechanisms, approved by the London - London Bridge Research 
Ethics Committee (reference 16/LO/2190, 30th January 2017). All participants granted 
their written informed consent. 
2.2.2 Recruitment to the study 
Patients were ascertained at St John’s Institute of Dermatology and Royal Free Hospital 
(London, UK), Leicester Royal Infirmary (Leicester, UK), University Hospital of North 
Durham (Durham, UK) and Hospital Sultanah Aminah (Johor Bahru, Malaysia). All cases 
were physically examined and diagnosed by trained dermatologists. Patient 
demographic and clinical details were recorded in a standardised Case Report Form 
(Appendix I). Healthy controls were recruited among the personnel of St John’s Institute 
of Dermatology. 
2.2.3 Gene discovery study cohort 
Family 8GPP included nine affected individuals suffering from GPP, PsV and or psoriatic 
arthritis. Demographics and clinical details are summarised in Table 2.1. A family 
pedigree is provided in Chapter 3 (Figure 3.1).  
The psoriasis cohort consisted of 375 unrelated individuals, including 140 GPP, 105 PPP, 
9 ACH and 121 PsV patients. Details of the patient groups that were included in exome 
sequencing experiments, follow-up studies and mutation screens are reported in the 



















GPP, generalised pustular psoriasis; PsV, psoriasis vulgaris; PsA, psoriatic arthritis 
F, female; M, male; Y, yes; N, no  
Patient ID Sex Age of onset GPP PsV PsA 
8GPP1 F 32 Y Y Y 
8GPP2 F 19 Y N Y 
8PsV1 M unknown N Y N 
8PsV2 M unknown N Y N 
8PsV3 F 33 N Y Y 
8PsV4 M 39 N Y N 
8PsV5 M 25 N Y Y 
8PsV6 M 23 N Y N 
8PsV7 F unknown N Y N 
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2.2.4 RNA-sequencing study cohort 
2.2.4.1 Generalised Pustular Psoriasis cases 
Eight unrelated GPP patients (1 male and 7 females, average age: 51) were ascertained 
for neutrophil RNA-sequencing. For the validation studies, fresh blood was obtained 
from 17 GPP individuals (2 males and 15 females, average age: 56.5), 7 of whom had 
also been included in the RNA-sequencing experiment (Table 2.2). 
2.2.4.2 Plaque psoriasis cases 
Seventeen unrelated PsV individuals (13 males and 4 females, average age: 45.2) were 
recruited for the validation of RNA-sequencing results. The main inclusion criterion was 
a diagnosis of moderate-to-severe psoriasis vulgaris (Psoriasis Area Severity Index >10) 
(Table 2.3).  
2.2.4.3 Disease controls  
Thirteen individuals with acral pustular psoriasis (APP) (3 males and 10 females, average 
age: 54.3) and nine with cryopyrin associated periodic syndrome (CAPS) (3 males and 6 
females, average age: 44.6) were recruited for the validation of RNA-sequencing results 
(Table 2.4) in order to investigate whether the signature found in the GPP RNA-seq was 
also observed in other dermatological conditions. 
2.2.4.4 Healthy controls 
Eleven healthy controls (1 male and 10 females, average age: 50) were recruited for 
neutrophil RNA-sequencing. For the validation studies, fresh blood samples were 
obtained from 26 control individuals (3 males and 23 females, average age: 46.4), 10 of 
whom had been included in the RNA-sequencing cohort (Table 2.5). 
2.2.5 DNA isolation and plating 
DNA was isolated from 2 ml of saliva (using an Oragene DNA kit) or 5 ml of blood (salting 
out method235) by technical staff at St John’s Institute of Dermatology. Sample 
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concentrations were quantified with a NanoDrop ND-1000 Spectrophotometer. DNAs 
were diluted to 25 ng/μl, aliquoted in 96-well plates and stored at -20°C.  
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Table 2.2 Demographics and clinical characteristics of GPP patients recruited for the RNAseq and validation studies 













GYFAP0011 European F 42 Y Y none S113L/- 50 
RNA-seq and 
validation 
GYFAP0014 European F 36 N Y infliximab wild-type 50 
RNA-seq and 
validation 
GYFAP0016 European M 5 N Y MTX S113L/S113L 48 RNA-seq 
GYFAP0029 European F 7 N Y 





GYFAP0032 European F 82 N Y acitretin wild-type 89 
RNA-seq and 
validation 
GYFAP0089 European F 29 N Y MTX wild-type 40 
RNA-seq and 
validation 
GYFAP0096 European F 19 Y Y adalimumab wild-type 71 
RNA-seq and 
validation 
GYPLM0001 European F 17 N Y topicals wild-type 30 
RNA-seq and 
validation 
GYFAP0041 Indian F 31 Y unknown 
ustekinumab and 
MTX 
wild-type 48 Validation 
GYFAP0100 European F 35 Y unknown 
adalimumab and 
MTX 
wild-type 43 Validation 
GYFAP0157 European F 78 Y unknown ciclosporin wild-type 78 Validation 
GYFAP0159 European M 60 Y Y ciclosporin wild-type 65 Validation 
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GYFAP0163 European F 76 Y unknown topicals wild-type 76 Validation 
GYPLM0002 European F 73 N unknown prednisolone wild-type 75 Validation 
GYPLM0003 Asian/Indian F 29 Y unknown 
adalimumab and 
ciclosporin 
wild-type 31 Validation 
GYPLM0004 Indian F 41 Y unknown topicals wild-type 44 Validation 
GYPLM0006 Asian F 21 Y unknown 
certolizumab and 
MTX 
wild-type 44 Validation 
GYPLM0013 European M 74 Y unknown topicals wild-type 76 Validation 
1Systemic upset was defined as the concurrence of two of the following: fever > 38°C, neutrophil count >  15x109/L, CRP> 100mg/L 








Table 2.3 Demographics and clinical characteristics of PsV patients recruited for the 
validation studies. 
Patient ID Ethnicity Sex Treatment PASI Age at recruitment 
P338 Indian M topicals 23.2 31 
P341 European M topicals 10.4 37 
GYFAP0172 Unknown M ixekizumab 19.9 55 
GYFAP0180 European F topicals 14 48 
GYPLM0044 European F MTX 12.4 58 
GYPLM0045 European M ustekinumab 12.6 40 
GYPLM0052 European M topicals 14.2 43 
GYPLM0053 Asian/Indian M ustekinumab 10 54 
GYPLM0054 African M PUVA 19 46 
GYPLM0055 European M ustekinumab 12.5 38 
GYPLM0057 African F topicals 30 37 
GYPLM0058 European M topicals 27 63 
GYPLM0059 European F etanercept 11.4 49 
GYPLM0060 European M secukinumab and MTX 19 50 
GYPLM0062 Asian M infliximab and MTX 22.2 23 
GYPLM0063 European M apremilast 35 53 
GYPLM0064 European M ustekinumab and MTX 12.2 48 










Table 2.4 Demographics and clinical characteristics of disease controls recruited for the 
validation studies. 
Patient ID Ethnicity Sex Disease Treatment Age at recruitment 
GYFAP0012 European F PPP secukinumab and MTX 55 
GYFAP0017 European F ACH infliximab and MTX 65 
GYFAP0079 European M PPP topicals 55 
GYFAP0103 European M ACH adalimumab 80 
GYFAP0113 European F PPP topicals 51 
GYFAP0156 European F PPP no treatment 41 
GYFAP0160 European F PPP no treatment 81 
GYFAP0166 European F PPP topicals 30 
GYFAP0174 European M PPP 
infliximab, MTX and 
topicals 
42 
GYPLM0012 European F ACH adalimumab 54 
GYPLM0019 European F PPP acitretin 51 
GYPLM0030 European F PPP unknown 54 
GYPLM0033 European F PPP no treatment 47 
RFPLM0001 European F CAPS canakinumab 30 
RFPLM0002 European F CAPS canakinumab 57 
RFPLM0003 European M CAPS canakinumab 51 
RFPLM0004 European F CAPS canakinumab 48 
RFPLM0005 European F CAPS anakinra 34 
RFPLM0006 European M CAPS canakinumab 35 
RFPLM0007 European F CAPS anakinra 64 
RFPLM0008 European M CAPS canakinumab 35 
RFPLM0009 European F CAPS canakinumab 47 
PPP, Palmoplantar Pustular Psoriasis; ACH, Acrodermatitis Continua of Hallopeau; CAPS, 







Table 2.5 Demographics of healthy control individuals recruited for the RNAseq and 
validation studies 
Patient ID Ethnicity Sex Age at recruitment Analysis group 
GYFAP0035 European F 48 RNA-seq and validation 
GYFAP0036 European M 58 RNA-seq and validation 
GYFAP0039 European F 53 RNA-seq and validation 
GYFAP0040 European F 56 RNA-seq and validation 
GYFAP0042 European F 56 RNA-seq and validation 
GYFAP0175 European F 41 RNA-seq and validation 
GYFAP0176 European F 43 RNA-seq and validation 
GYPLM0009 European F 37 RNA-seq and validation 
GYPLM0011 European F 65 RNA-seq and validation 
GYPLM0016 European F 53 RNA-seq 
GYPLM0031 European F 44 RNA-seq and validation 
GYFAP0038 Indian F 49 Validation 
GYPLM0010 European F 37 Validation 
GYPLM0014 European F 37 Validation 
GYPLM0015 European M 38 Validation 
GYPLM0017 European F 49 Validation 
GYPLM0018 Chinese F 40 Validation 
GYPLM0020 European F 43 Validation 
GYPLM0021 European F 42 Validation 
GYPLM0022 European F 49 Validation 
GYPLM0023 European F 45 Validation 
GYPLM0024 European F 63 Validation 
GYPLM0025 Asian/Indian F 32 Validation 
GYPLM0026 European F 38 Validation 
GYPLM0027 Chinese M 41 Validation 
GYPLM0028 Indian M 52 Validation 
GYPLM0029 European F 37 Validation 
F, female; M, male
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2.3 Whole-exome sequencing  
Whole-exome sequencing was performed by technical staff within the Genomics Core 
facility of Guy’s and St Thomas’ Hospital Biomedical Research Centre (BRC). Briefly, 3 μg 
of genomic DNA were diluted in 130 μl of 1X TE buffer and sheared into 150-200 bp 
fragments using an ultrasonicator (Covaris M220). Libraries were then prepared with 
the SureSelect Library Prep Kit. Agencourt AMPure XP beads were used to purify the 
DNA fragments, which were next repaired to produce blunt-ended 5’-phosphorylated 
ends and purified. Once 3’-dA overhangs were added and indexing-specific paired-end 
adapters were ligated, the fragments underwent a further purification with Agencourt 
AMPure XP beads. Next, the library was amplified using the Herculase II Fusion DNA 
Polymerase Kit as follows: 2 min at 98°C, (30 sec at 98°C, 30 sec at 65°C, 1 min at 72°C) 
x 5, 10 min at 72°C. Once the library was again purified, its quality and concentration 
were determined with a TapeStation 2200 (Agilent) and a Qubit 4 fluorometer (Thermo 
Fisher Scientific), respectively. 
Whole-exome capture was performed using the Agilent SureSelect Human All Exome Kit 
v4 or v6, according to the manufacturer’s instructions. Briefly, a 24-hour library 
hybridisation at 65°C was performed, followed by purification on a Dynal magnetic 
separator. The resulting products were amplified with the following cycling conditions: 
2 min at 98°C, (30 sec at 98°C, 30 sec at 57°C, 1 min at 72°C) x 10, 10 min at 72°C. Once 
index tags were added, the quality and concentration of the preparation were 
determined with the Agilent 2100 Bioanalyzer High Sensitivity DNA assay. Lastly, the 
samples were pooled for multiplex sequencing and prepared for cluster amplification. 
Whole-exome sequencing was performed on an Illumina HiSeq1000 or HiSeq3000/4000. 
2.4 Sanger sequencing and microsatellite genotyping  
2.4.1 Primer design  
PCR and real-time PCR primers were designed using Primer3Plus (http://primer3.ut.ee/) 
to amplify the appropriate exons and intron/exon junctions. The primer specificity was 
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ensured by aligning each oligonucleotide to the human genome sequence using BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers were purchased from 
Sigma Aldrich-Merck and reconstituted in nuclease-free water as 100 μM stock 
solutions. PCR were then carried out using 10 μM working dilutions. 
2.4.2 Polymerase Chain Reaction  
All PCR were performed in an Eppendorf Mastercycler Pro and were set up as 15 μl 
reactions containing 1X reaction buffer, 0.3 μM forward and reverse oligonucleotide 
primers, 0.2 mM dNTPs, 25 ng of DNA template and 0.625 U DreamTaq DNA polymerase. 
Cycling conditions were as follows: 5 min initial denaturation at 95°C; 30 replication 
cycles at 95°C for 30 sec, 62-64°C for 30 sec, 72 °C for 30 sec, followed by a final 
extension at 72 °C for 10 min. Primer annealing temperatures were optimized by means 
of gradient PCR and are reported in Appendix II.  
2.4.3 Agarose gel electrophoresis  
The results of the PCR reactions were visualised by agarose gel electrophoresis. Each 
PCR product (3 μl) was mixed with 1.5 μl of 5X loading dye, then loaded on a 2% agarose 
gel containing 0.5 mg/ml ethidium bromide. The amplicons were run at 200 volts 
alongside the 100bp or 1Kb molecular weight marker. After 25 min gels were visualised 
under UV light, using a “GelDoc-It310 Imaging System” trans-illuminator from UVP. 
2.4.4 Sanger sequencing 
To remove unincorporated dNTPs and oligonucleotides, 2 l of each amplicon was 
purified using the Illustra ExoStart kit. Next, the sequencing reaction was set up by 
adding 1.75 μl of sequencing mastermix (1.25 μl 5X BigDye Terminator sequencing 
buffer, 0.25 μl of 10 μM primer and 0.25 μl of BigDye Terminator v 3.1) to the purified 
PCR products. The following cycling conditions were used: (96°C for 30 sec, 55°C for 15 
sec, 60°C for 60 sec) x 35. The resulting products were purified by incubating them with 
26 μl of precipitation solution (50 ml of 95% ethanol solution mixed with 2ml of 3M 
NaOAc, pH=4.6) for 10 min at room temperature. After 30 min centrifugation (Rotanta 
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460 R benchtop centrifuge, Hettich) at 3,000 rpm, the supernatants were removed by 
spinning inverted plates for 5 sec at 500 rpm. The pellets were then washed with 100 μl 
of 70% ethanol, followed by 10 min centrifugation at 3,000 rpm. Finally, the washing 
solution was removed as described above, the pellets were air-dried and 10 μl of HiDi 
Formamide were added to each sample. Following a 2 min denaturation at 90°C, the 
samples were run on a 3730xl ABI Sequencer (Applied Biosystems) and the results were 
analysed with the Sequencher software (v 4.9, Genecodes). 
2.4.5 Microsatellite genotyping  
The regions spanning the three microsatellites of interest (D6S273, AP1S3-TG and 
D2S2299) were amplified by PCR using primers labelled with 5’-FAM. The amplification 
products were then diluted 1:5, 1:50 or 1:100, based on the intensity of the band 
observed by agarose gel electrophoresis. Next, 1μl of diluted sample was mixed with 
8.75 μl HiDi Formamide and 0.25 μl of GeneScan 500 TAMRA Size Standard. Samples 
were run on a 3730xl ABI Sequencer (Applied Biosystems) and results analysed with Peak 
scanner (v2.0, Thermo Fisher Scientific). 
2.5 Transcript analysis  
2.5.1 RNA extraction  
RNA was extracted from freshly isolated neutrophils or frozen PBMCs, using a GeneJET 
RNA purification kit and pipettes that had been cleaned with RNaseZap RNase 
Decontamination Solution. The RNAs were eluted in 30 μl of nuclease-free water, 
quantified using a Qubit 4 fluorometer (Invitrogen) and stored at -80°C. Samples were 
prepared with the RNA TapeStation kit and RNA quality was measured using a 
TapeStation2200, according to the manufacturer’s instructions. 
2.5.2 cDNA synthesis  
Between 100 and 200 ng of total RNA were reverse-transcribed in a final volume of 20 
μl, using the Precision nanoScript2 Reverse Transcription kit according to the 
manufacturer's instructions. The reactions were incubated at 65°C for 5 min, placed on 
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ice for 5 min, then again heated at 42°C for 20 min and at 75°C for 10 min. Each cDNA 
sample was then diluted to 50 μl with nuclease-free water. 
2.5.3 Real-time PCR  
Gene expression was assessed by real-time PCR using the primers listed in Appendix II. 
RPL13A and B2M were analysed as endogenous controls, using oligonucleotide 
purchased from PrimerDesign. Reactions were set up in a final volume of 20 μl 
containing 70 nM of primers, 1X PrecisionPLUS qPCR Master Mix with ROX and 
SYBRgreen and 2 μl of diluted cDNA. All reactions were prepared in duplicate. Samples 
were analysed with a 7900HT Fast Real Time PCR System (Applied Biosystems) under 
the following cycling conditions: 95° for 2 minutes, (95° for 10 seconds, 60° for 60 
seconds) x 40 cycles. Relative gene expression was quantified using the ΔΔCt method236. 
2.6 Cell isolation, culture and stimulation 
2.6.1 Neutrophils 
2.6.1.1 Neutrophil isolation 
Neutrophils were isolated by negative selection, using the MACSxpress® Neutrophil 
Isolation Kit for human (Miltenyi) to process 4ml of whole blood. Erythrocyte 
contamination was removed with a Red Blood Cell lysis solution (Miltenyi). Cells were 
resuspended in Roswell Park Memorial Institute (RPMI 1640 medium) containing 1% 
Bovine Serum Albumin (BSA) and counted with a Marienfeld Superior haemocytometer. 
2.6.1.2 Purity assessment by flow cytometry 
Neutrophil purity was assessed on 8 independent samples. 
Neutrophils were seeded in 5 ml round-bottom polystyrene tubes at a concentration of 
1x106 cells/100 μl. Cells were centrifuged at 300 x g for 10 min and the supernatants 
were discarded. For live cell detection, 5 μl of 7-AAD were used.  
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The pellets were resuspended in staining buffer and placed on ice. After 20 min, 5 μl of 
the appropriate antibody were added to the samples (Table 2.6). Following 20 min 
incubation in the dark at 4°C, the samples were washed with 200 µl of staining buffer 
and centrifuged at 300 × g for 10 min. Cells were then resuspended in 400 µl of staining 
buffer, passed through a 40 μm cell strainer (BD Falcon) and analysed on a BD FACSCanto 
II machine. The results were analysed using FlowJo v10 software 
(https://www.flowjo.com/). 
2.6.1.3 Neutrophil culture and stimulation 
Cells were cultured under aseptic conditions at 37°C and 5% CO2 in a NUAire Air-Jacketed 
Automatic CO2 (NU-5500) incubator.  
Neutrophils isolated from the blood of healthy donors (4 females and 1 male, average 
age: 30) were seeded in 48-well plates at a density of 1x106 cells per well, in 500 μl of 
RPMI medium supplemented with 1% BSA. Cells were stimulated with 50ng/ml IL36-α 
or 50ng/ml IL-1β (positive control), or vehicle (RPMI medium ) for 2 hours. To investigate 
the possibility of a synergy between IL-36 and other IL-1 family cytokines, cells were 
treated with 25ng/ml IL-1β and 25ng/ml IL-6 for 4 hours followed by 50ng/ml IL36-α or 
vehicle for 2 hours. At the end of each stimulation, cells were harvested and centrifuged 
at 300 x g for 10 min. The response to treatment was then measured by real-time PCR, 
as described in section 2.5.3. Each experiment was performed three times in triplicate. 
2.6.2 Peripheral blood mononuclear cells (PBMCs) 
2.6.2.1 PBMC isolation 
PBMCs were isolated from 20 ml of blood via Ficoll density gradient centrifugation 
(carried out in the absence of Red Blood Cells lysis). Cells were resuspended in 
RPMI/GlutaMAX medium supplemented with 10% FBS and 1% penicillin/streptomycin 




2.6.2.2 PBMC culture and stimulation 
Freshly isolated PBMCs obtained from healthy donors (see 2.6.1.3) were seeded in 48-
well plates at a density of 1x106 cells per well. Cells were incubated overnight in 500 l 
of RPMI/GlutaMAX medium supplemented with 10% FBS and 1% 
penicillin/streptomycin. The next day, the PBMCs were stimulated for 6 hours with 
50ng/ml IL36-α or vehicle followed by 6 hours with 1.6μg/ml of ODN-A CpG or vehicle. 
Alternatively, PBMCs were pre-incubated for 1 hour with 1 μM SB-203580 followed by 
6 hours with 50ng/ml IL36-α or vehicle. Afterwards, cells were harvested and 
centrifuged at 3000 rpm for 7 min. The cell pellets were then stored at -80°C. The 
response to stimulation was measured by real-time PCR. Each experiment was carried 
out at least three times in triplicate. 
2.6.3 Plasmacytoid dendritic cells (pDCs) 
2.6.3.1 pDC isolation 
Plasmacytoid dendritic cells were purified by negative selection, using the Plasmacytoid 
Dendritic Cell Isolation Kit II for human (Miltenyi) to process 400 l of freshly isolated 
PBMCs. Cells were resuspended in RPMI/GlutaMAX medium supplemented with 10% 
FBS and 1% penicillin/streptomycin solution, then counted with a Marienfeld Superior 
haemocytometer. 
2.6.3.2 pDC culture and stimulation 
Freshly isolated pDCs obtained from healthy donors were seeded in 96-well plates at a 
density of 1x105 cells per well. Cells were incubated overnight in 500 l of 
RPMI/GlutaMAX medium supplemented with 10% FBS and 1% penicillin/streptomycin.  
The next day, pDCs were stimulated for 6 hours with 50ng/ml IL36-α or vehicle. After 3 
hours, 1:1,000 of Brefeldin A (BioLegend) was added to IL36-α stimulated pDCs.  At the 




2.6.3.3 PLSCR1 intracellular staining for flow cytometry 
Cells were washed with PBS, stained with the appropriate pDC antibodies (Table 2.7) 
and incubated for 20 min in the dark at 4°C. Following another PBS wash, 500 μl of the 
Perm/Fix solution were added for 30 min and cells were washed with PERM buffer (FIX 
& PERM™ Cell Permeabilization Kit). Next, cells were incubated for 20 min with 1.5 μl of 
anti-PLSCR1, washed with PBS and treated with 1 μl of anti-Rabbit IgG for a further 20 
min in the dark at 4°C. After a final wash in PBS, cells were resuspended in PERM buffer 
and kept in the fridge overnight. The next day, data was acquired on a BD Fortessa LSR. 
2.6.4 IL36R expression analysis  
PBMCs and neutrophils were obtained from 4 GPP cases (3 females and 1 male, average 
age: 54) and 4 controls (3 females, and 1 male, average age: 36). Neutrophils were 
stimulated as described in section 2.6.1.3. 
Cells were first incubated with 10 nM LIVE/DEAD™ Fixable Near-IR (APC-Cy7) for 15 min 
at 4°C. After a PBS wash, cells were mixed with Monocytes and Fc blocker (1:40) for 20 
min. Following a further PBS wash, cells were incubated for 20 min at 4°C with three 
separate sets (panels) of antibodies (Table 2.6), in order to identify the different 
leukocyte populations present in the samples. Once washed, cells were incubated with 
the secondary antibody (2ng/μl, final volume of 100 μl) for 20 min at 4°C, washed again 
and resuspended in 300 μl of PBS. Data was analysed on a BD Fortessa LSR machine, 




Table 2.6 Flow cytometry antibodies 
1CD3/CD14/CD19/CD20/CD56; 2Target of secondary biotinylated antibody used for 
IL36R detection; 3Target of secondary antibody used for PLSCR1 detection 
Panel 1: HLA-DR, CD11c, CD123, CD141, CD127, Lineage, L/D marker; Panel 2: CD3, CD16, 
CD20, CD56, CD19, CD14, L/D marker; Panel 3: CD14, CD16, CD15, L/D marker. 
 
Target Dilution Fluorochrome Supplier Application 
CD16 
1:20 Efluor450 ThermoFisher Panel 1/3 
1:22 APC Miltenyi Biotec Neutr purity 
CD56 1:33 Alexa Fluor 700 BioLegend Panel 1 
CD19 
1:20 BV510 BioLegend Panel 1 
1:22 FITC BD Neutr purity 
CD20 1:33 PE-Cy7 Miltenyi Biotec Panel 1 
CD14 1:20 PE BD Panel 1/3 
CD3 
1:33 FITC BioLegend Panel 1 
1:22 FITC Miltenyi Biotec Neutr purity 
CD127 1:20 PE-Cy7 BioLegend Panel 2 
HLA-DR 1:33 BV421 BioLegend Panel 2 
CD11c 1:20 BV650 BioLegend Panel 2 
CD123 1:30 BV711 BioLegend Panel 2 
Lineage 
marker1 
1:10 PE Beckman Coulter Panel 2 
CD15 
1:33 FITC BioLegend Panel 3 
1:22 PE Miltenyi Biotec Neutr purity 
IL36R 1:10 Streptavidin BD Panel 1/2/3 
Streptavidin2 1:100 APC BioLegend Panel 1/2/3 
CD45 1:22 VioBlue Miltenyi Biotec Neutr purity 
CD24 1:22 APC Vio770 Miltenyi Biotec Neutr purity 
PLSCR1 1:50 Rabbit-IgG Abcam PLSCR1 intracell staining 
Rabbit IgG3 1:100 Alexa Fluor 488 BioLegend PLSCR1 intracell staining 
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B cells CD3-,CD14-,CD16-,CD20+,CD19+ 
T cells CD14-,CD16-,CD19-,CD20-,CD3+ 
Monocytes - Classical CD20-,CD3-,CD14+,CD16- 
Monocytes - Intermediate CD20-,CD3-,CD14+,CD16+ 
Monocytes - Proinflammatory CD20-,CD3-,CD14-,CD16+ 
pDCs Lineage-, HLA-DR+,CD123+,CD11c- 
mDCs Lineage-, HLA-DR+,CD123-,CD11c+ 




2.7 Statistics and bioinformatics analyses 
2.7.1 Publicly available databases 
The data generated by the Blueprint Consortium (http://www.blueprint-
epigenome.eu/) and the Fantom5 project (http://fantom.gsc.riken.jp/zenbu/) were 
queried to investigate cell-specific patterns of gene expression237,238. The Genotype-
Tissue Expression (GTex) database (https://gtexportal.org/home/) was used to retrieve 
tissue-specific expression data, while the GWAS catalogue 
(https://www.ebi.ac.uk/gwas/) was utilized to search for the results of published 
genome-wide association studies239,240.  
The Ensembl Genome browser was used to obtain reference DNA and protein 
sequences, as well as orthologue and paralogue sequences for genes of interest 
(https://www.ensembl.org/index.html)241. Minor Allele Frequencies (MAFs) were 
obtained from the Exome Aggregation Consortium browser (ExAC, 
http://exac.broadinstitute.org/)242. 
A list of MPO deficiency alleles was obtained from OMIM243. Next, the Geneatlas244 was 
used to run the PheWAS analysis on the identified variants. 
2.7.2 Analysis of whole-exome sequence data 
2.7.2.1 Data processing 
Raw whole-exome sequence data was processed by personnel at the BRC Bioinformatics 
Core. Briefly, the paired-end reads were aligned to the hg19 reference genome with 
Novoalign (Novocraft Technologies), then duplicates and low-quality reads were 
removed with MarkDuplicates245. Changes covered by more than 4 reads were called 





2.7.2.2 Step-wise filtering of variant profiles 
ANNOVAR annotated files were imported into Microsoft Excel for step-wise filtering. For 
family 8GPP, after removing unknown and synonymous variants, changes were retained 
if they were: i) heterozygous,  ii) rare (global MAF ≤ 0.01) and iii) shared by the three 
affected relatives. A further filter based on allele frequencies observed in the East Asian 
population was applied to the resulting changes. The reads for the remaining variants 
were visually inspected with Integrative Genomics Viewer (IGV)247, in order to exclude 
alignment artefacts. Finally, the effects of the changes were assessed in-silico (see 
section 2.7.2.3) and only the variants with deleterious potential were retained.  
For the 19 unrelated GPP cases, variants were retained if they were: i) homozygous,  ii) 
splicing, stop-gain, stop-loss and frameshift changes iii) rare (global MAF ≤ 0.01) and iv) 
rare in an in-house sequencing dataset (MAF ≤ 0.05). Finally, the effects of the changes 
were assessed in-silico with CADD (see section 2.7.2.3) and only the variants with 
deleterious potential were retained. 
2.7.2.3 Evolutionary conservation and pathogenicity predictions 
Clustal Omega248 was used to align orthologue sequences obtained from Ensembl 
Genome browser. 
The pathogenic potential of missense changes was determined using PROVEAN249, 
SIFT250, Polyphen-2251, Mutation Taster252 and the Combined Annotation Dependent 
Depletion webserver (CADD)253. MaxEntScan254 and Spliceman255 were used to analyse 
splicing variants.  
The mutational load tolerated by PRR13 has been measured using the Residual Variation 






2.7.3 Analysis of RNA-sequencing data 
2.7.3.1 Data processing 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) was used to 
assess the quality of the sequence data and all reads with a Phred score lower than 30 
were removed from the analysis. The remaining reads were trimmed to remove 
adapters and high-repeat k-mers, while overrepresented sequences were eliminated 
using FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). Once the reads were 
mapped and aligned to the hg38 human genome with TopHat258 and Bowtie2259, they 
were counted with HTseq260 and SAMtools245.  
2.7.3.2 In-silico assessment of neutrophil purity 
The genes identified by RNA-sequencing analysis were over 15,000 in both patient and 
control datasets, in line with published reports261,262. These were compared to those 
expressed in the lymphocytes, monocytes, eosinophils and neutrophils sequenced by 
the Blueprint Consortium. To account for the lower number of genes present in the 
Blueprint dataset (n=7,217 neutrophil expressed genes), those with a median expression 
<0.1 transcript per million (TPM) were discarded. The analysis was carried out using the 
dplyr package in RStudio v.0.8.0.1263. 
2.7.3.3 Differential expression analysis  
Differential expression analysis of the full RNA-sequencing cohort (8 cases vs. 11 
controls) was performed with DESeq2 (R package, v 1.16.1)264, using sex as a covariate. 
Fold changes (FC) were calculated with a zero-centered normal prior and P values were 
derived with the Wald test and a Benjamini–Hochberg265 correction for multiple testing. 
For the differential expression analysis of the case carrying the MPO splicing variant and 
the 11 healthy controls, fold changes were calculated by dividing the gene expression 
levels (measured as RPKM, reads per kilobase per million) observed in the patient by the 
mean RPKM of the controls. Z-scores were calculated and P values were computed from 
the z-scores using the “NORM.S.DIST” function available on Microsoft Excel and 
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corrected for multiple testing (padj, adjusted p value) by multiplying the P value for the 
total number of tests (one for each gene). Genes with padj <0.05 and FC >1.5 were 
considered differentially expressed.  
2.7.3.4 Analysis of blood transcription modules 
Marika Catapano adapted a published script266 to identify blood transcription modules 
that were enriched among genes up-regulated in GPP. Briefly, the 
genetable_to_activityscores function was applied to select the blood modules that were 
active in the neutrophil dataset. The enrichment_test function was then applied to our 
list of differentially expressed genes (DEGs), taking into account the module activity 
score and the FC of the genes mapping to each module. Finally, enrichment P values  
were computed and corrected for multiple testing, using a False Discovery Rate (FDR) 
<0.05 as a significance threshold. 
2.7.3.5 Pathway and upstream regulator enrichment analysis 
Genes with a FC >1.5 and an FDR <0.05 were used as input for Ingenuity Pathway 
Analysis (IPA, Qiagen). Briefly, each DEG was assigned a weight (reflecting the magnitude 
of its up-regulation) and mapped against reference pathways. Enrichment P values were 
then calculated with a Fisher’s exact test, taking into account the weight of the DEGs 
and the size of the pathway. Finally, the Benjamini-Hochberg method was used to 
correct P values for multiple testing. FDR values <0.05 were considered statistically 
significant. 
The “Upstream Analysis” function in IPA was used to perform the upstream regulator 
enrichment analysis. The dataset was examined as a subgraph with unknown a priori 
causal edges in the master network. To identify the regulators, each gene was scored 
based on the downstream targets identified, which were defined by an enrichment P 
value. An activation score built on co-expression values was then assigned to each 
network and the enrichment in the dataset calculated. STAT1- and IRF7-centered 
networks were visualised with the igraph v1.0.1 R Package. 
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2.7.3.6 Interferon score 
The interferon score (IS)267 was computed using five interferon stimulated genes (ISGs: 
PLSCR1, OASL, IFI6, IFIT3 and IFITM3) that had been previously used to establish 
interferon signatures268. They were most up-regulated in a GPP whole-blood dataset 
produced by the Capon lab. A calibrator was used to normalise the expression of each 
gene and the IS was calculated as the median expression of the 5 ISGs.  
2.7.4 Statistical tests 
Experimental data are shown as means +/- standard deviation (SD) or standard error of 
the mean (SEM). Differences in interferon score between cases and controls were 
analysed with an unpaired t-test or one-way ANOVA followed by Dunn’s post-test269, as 
appropriate.  As the assumption of equal variance between samples may not have been 
met, cytokine stimulations were assessed with non-parametric methods, using the 
Wilcoxon signed-rank test (when comparing 2 groups) or Friedman test (when 
comparing 3 groups). The P value of the enrichment for MPO variants in GPP and PPP 
patients was calculated using the Chi-square test with Yates correction. All statistical 





3 IDENTIFICATION OF A NEW PSORIASIS GENE ASSOCIATED WITH 
NEUTROPHIL COUNT VARIATION 
3.1 Genetic analysis of three related patients 
The aim of this project was to uncover novel genetic determinants of psoriasis through 
the analysis of PsV pedigrees and GPP cases that are not accounted for by known disease 
genes. 
An extended pedigree of Chinese-Malay origin was ascertained through a collaboration 
with Dr Siew-Eng Choon from the Sultanah Aminah Hospital in Johor Bahru, Malaysia 
(Figure 3.1, Table 2.1). While several family members suffered from PsV, two were 
affected by GPP, suggesting that neutrophil activation was an important component of 
the phenotype segregating in this pedigree. 
None of the affected individuals carried mutations in IL36RN, AP1S3, or CARD14. Whole-
exome sequencing (WES) was therefore undertaken in three patients (8GPP1, 8GPP2 
and 8PsV3; Figure 3.1) with a view to identifying a new disease gene. The analysis 
identified between 25,782 and 26,467 variants per affected individual. The average 
sequence coverage was 117x, with 94% of the target exome covered at a depth of at 









Figure 3.1 Pedigree of family 8GPP 
8GPP1, 8GPP2 and 8PsV3 (circled in red) were selected for whole-exome sequencing. 
DNA was available for all the individuals labelled in the figure, but the samples for 
8PsV7, 8NC1, 8NC2 and 8NC3 were only collected towards the end of the study. 
Shading of the top left, top right and bottom left quadrants identifies patients 
suffering from GPP, PsV and PsA, respectively. Some individuals presented with more 
than one disease subtypes, therefore multiple areas are shaded in black.  









CCDS, consensus coding sequence 
 
  
 8GPP1 8GPP2 8PsV3 
Variants detected 25,861 25,782 26,467 
Mean Coverage 100.96x 109.78x 140.04x 
CCDS bases with coverage >10x 97.11% 97.28% 98.92% 
CCDS bases with coverage >20x 94.26% 94.84% 98.20% 
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Based on the pedigree structure, an autosomal dominant mode of inheritance was 
assumed. Therefore, the WES data was filtered to remove synonymous and unknown 
variants and retain only variants that were heterozygous, rare (global Minor Allele 
Frequency (MAF) ≤ 0.01) and shared by the three affected relatives. A further filter 
based on allele frequencies observed in the East Asian population was then applied, 
using the data produced by the Exome Aggregation Consortium (ExAC)242. Finally, the 
deleterious potential of the remaining variants was assessed using five pathogenicity 
prediction algorithms. This process uncovered nine damaging variants that were 





Table 3.2 Rare non-synonymous variants shared among the three cases that were exome sequenced 
1CADD scores above 15 are considered pathogenic. MAF, minor allele frequency; NA, not available; pathogenicity prediction tools are described in 






Mutation Taster Provean SIFT PolyPhen2 CADD1 
GLI3 R989W NA disease causing deleterious damaging probably damaging 29.2 DAMAGING 
ITGB6 G593R 0.002 disease causing deleterious damaging possibly damaging 26.8 DAMAGING 
MAN2B2 W967X 0.0002 disease causing / / / 41.0 DAMAGING 
PITPNM3 P339R 0.005 disease causing deleterious tolerated probably damaging 26.3 DAMAGING 
PRR13 K131T 0.0007 disease causing deleterious damaging probably damaging 16.9 DAMAGING 
PTCH1 Y494C NA disease causing neutral tolerated probably damaging 23.5 DAMAGING 
SDK1 A871T 0.005 disease causing deleterious damaging probably damaging 26.2 DAMAGING 
SVIL R747W 0.01 disease causing deleterious damaging benign 24.2 DAMAGING 
TMEM184A T375M 0.01 disease causing deleterious damaging possibly damaging 23.7 DAMAGING 
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3.2 Screening of candidate genes in additional family members 
To determine which of the nine variants could be responsible for the inflammatory skin 
phenotype seen in family 8GPP, the affected individuals who had not been exome 
sequenced were screened by Sanger sequencing. Surprisingly, none of the 9 changes 
was found in all affected relatives (Table 3.3). A closer inspection of the data also 
revealed that 8PsV6 did not share any of the 10 variants with his two sisters (8GPP1 and 
8GPP2; Table 3.3), which suggested that his paternity was questionable.  
To further investigate this possibility, 8PsV6 and his first-degree relatives were 
genotyped for 3 microsatellite markers (D6S273, AP1S3-TG, D2S2299). Four additional 
unrelated individuals whose DNA had arrived in the same shipment as 8PsV6 were also 
examined, to investigate the possibility of a sample swap. 
While the D6S273 and AP1S3-TG genotypes were compatible with paternity, the analysis 
of D2S2299 showed that 8PsV6 carried a 290 bp allele which was not present in the 
paternal or maternal genome. Conversely, the genotype of unrelated patient 135GPP1 
was compatible with that of 8PsV6’s parents (Figure 3.2). These results suggested that 





Table 3.3 Summary of candidate variant screening in all 8GPP family members. 
Y, Yes; N, No  
Gene Variant 8GPP1 8GPP2 8PsV1 8PsV2 8PsV3 8PsV4 8PsV5 8PsV6 
GLI3 R989W Y Y Y Y Y Y N N 
ITGB6 G593R Y Y Y Y Y Y Y N 
MAN2B2 W967X Y Y Y Y Y Y N N 
PITPNM3 P339R Y Y Y Y Y N Y N 
PRR13 K131T Y Y Y Y Y Y Y N 
PTCH1 Y494/645C Y Y Y Y Y N Y N 
SDK1 A871T Y Y Y Y Y N N N 
SVIL R747W Y Y Y Y Y N N N 








Figure 3.2 Microsatellite genotyping identifies a sample swap 
Three microsatellites were typed in 8PsV6, his first-degree relatives (left) and in four 
unrelated GPP individuals who had been recruited in the same centre (right). 
Genotypes are defined by the molecular weight of PCR products (A-B) The genotypes 
of markers D6S273 and AP1S3-TG are compatible with the notion that 8PsV6 is a 
member of family 8GPP. (C) Genotyping of marker D2S2299 revealed that 8PsV6 
harboured a 290 bp allele (red square) that he could not have inherited from either 
parent. Conversely the genotype of 135GPP1 (highlighted in bold) was compatible 




3.3  Identification of PRR13 as a candidate gene 
To confirm that the two DNA samples had been swapped, the nine candidate mutations 
were screened by Sanger sequencing in the four unrelated patients that had been 
included in the microsatellite genotyping experiment. This showed that 135GPP1 shared 
5 changes with the affected individuals from family 8GPP, validating the notion of a swap 
with 8PsV6 (Table 3.4).  
Once the data was re-analysed on the basis of this information, one variant shared by 
all affected relatives was identified (Table 3.4). This was a Lysine to Threonine 
substitution affecting a highly conserved residue in PRR13 (K131T) (Figure 3.3). Of note, 
the screening of further family members who had by then become available (8PsV7, 
8NC1 8NC2 and 8NC3) revealed that the variant was present in the newly recruited case 
and absent from two of the three clinically assessed unaffected relatives (Table 3.5 and 
Figure 3.4). Of note, the unaffected carrier 8NC2 was 48 years old at the time of the 
analysis, so we cannot exclude the possibility that he might develop psoriasis later in 
life. Thus, the K131T substitution in PRR13 is the most likely disease allele segregating in 





Table 3.4 Screening of candidate variants in  family 8GPP and in 4 unrelated individuals recruited from the same centre. 135GPP1 is suggested 
to replace the 8PsV6 sample. 
Y, Yes; N, No  
Gene Variant 8GPP1 8GPP2 8PsV1 8PsV2 8PsV3 8PsV4 8PsV5 135GPP1 8PsV6 133GPP1 134GPP1 136GPP1 
GLI3 R989W Y Y Y Y Y Y N Y N N N N 
ITGB6 G593R Y Y Y Y Y Y Y N N N N N 
MAN2B2 W967X Y Y Y Y Y Y N Y N N N N 
PITPNM3 P339R Y Y Y Y Y N Y Y N N N N 
PRR13 K131T Y Y Y Y Y Y Y Y N N N N 
PTCH1 Y494/645C Y Y Y Y Y N Y N N N N N 
SDK1 A871T Y Y Y Y Y N N N N N N N 




Figure 3.3 Evolutionary conservation of the Lys131 amino acid residue 
Protein sequence alignment showing the evolutionary conservation of the Lys131 
residue. Asterisks (*) indicate positions with a conserved residue; colons (:) indicate 
conservation between groups of amino acids with very similar properties; periods (.) 
indicate conservation between groups of residues with moderately similar properties. 
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Table 3.5 Screening of K131T change in the entire 8GPP family, including the additional available samples. 
Y, Yes; N, No 
Gene Variant 8GPP1 8GPP2 8PsV1 8PsV2 8PsV3 8PsV4 8PsV5 
135GPP1/ 
8PsV6 
8PsV7 8NC1 8NC2 8NC3 




Figure 3.4 Screening of the K131T PRR13 variant in family 8GPP 
Sequence chromatograms of the heterozygous K131T substitution. Asterisks indicate 
the nucleotide change. 
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3.4 Screening of PRR13 in an extended patient cohort 
To further investigate PRR13 as a candidate disease gene, the K131T substitution was 
screened in a dataset selected to match the characteristics of family 8GPP. This included 
107 unrelated subjects affected by GPP and in 121 PsV cases available in house (Table 
3.6). A subset of the above samples (32 GPP and 16PsV cases) was also sequenced for 
the entire PRR13 coding region.  The analysis did not identify any further individuals 
harbouring K131T or any other PRR13 deleterious allele.  
Next, whole-genome sequence data generated by the 100,000 Genomes Project270 for 
11 unrelated GPP cases was queried. This revealed a deleterious PRR13 variant (P16S) 
in a British European child suffering from early onset GPP (Table 3.7, Figure 3.5). Thus, 
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Table 3.7 Rare non-synonymous PRR13 variant identified in a British patient 
1CADD scores above 15 are considered pathogenic. MAF, minor allele frequency; pathogenicity prediction tools are described in the Methods section 






Mutation Taster Provean SIFT PolyPhen2 CADD1 




Figure 3.5 Evolutionary conservation of the Pro16 amino acid residue 
Protein sequence alignment showing the evolutionary conservation of the Pro16 
residue. Asterisks (*) indicate positions with a conserved residue; colons (:) indicate 
conservation between groups of amino acids with very similar properties; periods (.) 




3.5 PRR13 is highly expressed in neutrophils 
PRR13 encodes Proline Rich 13, a poorly understood protein that is also known as TXR1 
(Taxane-Resistance protein 1). To further explore its role in psoriasis, a number of 
publicly available resources were mined.  
The RNA-seq data generated by the Genotype-Tissue Expression (GTex) consortium239 
showed that PRR13 is expressed in a variety of tissues, including skin (median read 
count: 72 Transcripts Per Million (TPM)). Transcript levels, however, were highest in 
whole-blood (median: 337.5 TPM) (Figure 3.6). Further investigation of cell-specific data 
produced by the Blueprint and Fantom5 projects237,238 revealed that PRR13 expression 
was especially abundant in neutrophils and eosinophils (Table 3.8). 
To obtain further insights into gene function, the GWAS catalogue, a curated collection 
of all published genome-wide association studies240 was queried for associations driven 
by PRR13 alleles. This revealed that an intronic PRR13 variant (rs550235164) is 
associated with neutrophil count variation (P=5 x 10-23)271.  
Taken together, these observations indicate that PRR13 is likely to play an important 






Figure 3.6 PRR13 expression in human tissue 
PRR13 is highly expressed in whole blood (337.5 TPM) (Adapted from https://gtexportal.org/home/gene/PRR13) 
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1TPM, Transcripts Per Million; 2FANTOM 5 uses 5'-end cap analysis 





Cell type TPM1 
mature eosinophil 98 
segmented neutrophil of bone marrow 88 
mature neutrophil 82 
conventional dendritic cell 74 
neutrophilic metamyelocyte 66 
inflammatory macrophage 55 
macrophage 50 
regulatory T cell 29 
CD4-positive, alpha-beta T cell 28 
CD8-positive, alpha-beta T cell 23 
FANTOM5 
Cell type Read counts2 
neutrophils 756 
eosinophils 507 
macrophage - monocyte derived 117 
CD8+ T cells  115 
CD4+ T cells  93 




The aim of this study was to identify new genetic determinants of plaque and pustular 
psoriasis, through the analysis of a unique pedigree of Chinese-Malay origin. Whole-
exome sequencing of three affected relatives and follow-up of nine putative disease loci 
highlighted PRR13 as the most likely candidate gene. In keeping with this observation, 
the analysis of WGS data generated by the 100,000 Genomes Project270 revealed a 
deleterious PRR13 allele in a British European child affected by GPP. The Capon lab is 
now seeking to access electronic health records for the proband and their parents, in 
order to establish whether there is a history of plaque or pustular psoriasis within the 
family. 
Difficulties in identifying a candidate variant shared by all affected relatives were initially 
encountered. Due to the elevated cost of whole-exome sequencing more family 
members, the paternity test was successfully performed using microsatellite analysis. 
However, it is important to consider that only 1 of the 3 markers used was informative, 
and that the genotype of 8PsV6 could still be accounted for by de-novo slippage of the 
D2S2299 290 repeat. Therefore, the use of further markers could have helped 
strengthen our thesis that the two DNA samples had been swapped.  
It is also worth noticing that while the filtering strategy applied to the WES data allowed 
me to uncover PRR13 as the most likely candidate gene, the identification of additional 
shared variants could have been hindered by the exclusion of synonymous changes, as 
recent evidence suggests that they may contribute to disease pathogenesis by affecting 
RNA conformation and splicing272,273. 
PRR13 encodes a 148 aa protein which spans 44 Proline residues and terminates with a 
stretch of 10 Serines. Its function is poorly understood, as the protein does not 
encompass known functional domains and has no paralogues. The amino acid sequence 
is conserved across placental mammals, but no orthologues exist in other species. Of 
note, limited variation is presented within the PRR13 sequence, so that the gene is 
classified as likely-to-be-disease-causing, based on its Residual Variation Intolerance 
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score and Gene Damage Index score256,257 (two parameters measuring the mutational 
load tolerated by human genes). 
In the absence of any information on PRR13 structure and functional motifs, it is difficult 
to speculate on the effects of the K131T and P16S mutations. Thus, the over-expression 
of wild-type and mutagenized constructs will be needed, in order to determine whether 
disease alleles disrupt the stability or sub-cellular localization of the protein.  
PRR13 has been implicated in resistance to chemotherapeutics, as cells that overexpress 
the gene are protected from the lethal effects of taxane and oxaliplatin274,275. In keeping 
with these observations, PRR13 up-regulation has been associated with decreased 
survival in ovarian cancer patients receiving platinum-taxane therapy, with similar 
findings reported for gastric cancer suffers treated with oxaliplatin276,277.  
It has been suggested that the above effects reflect a role of PRR13 in the negative 
regulation of thrombospondin 1 (TSP1), which in turn would cause a reduction in 
apoptotic cell clearance278,279. Of note, TSP1 has also been implicated in the clearance 
of apoptotic neutrophils from the circulation. In fact, TSP1 blockade inhibits 
macrophage-mediated neutrophil phagocytosis209,210. 
A recent paper also proposed that PRR13 overexpression could confer resistance to 
oxaliplatin by potentiating autophagy279. The latter plays a crucial role in innate 
immunity by ensuring the degradation of inflammatory mediators and infectious agents, 
as well as regulating cytokine secretion downstream of pattern recognition receptors280. 
For instance, our group and others have shown that mutations in AP1S3 and changes in 
SQSTM1 expression lead to autophagy dysregulation and associate with 
psoriasis118,281,282. Of note, autophagy is also essential to neutrophil homeostasis, as it is 
required for degranulation, NET formation and innate immune effector functions283,284. 
TSP1 is also a potent angiogenic inhibitor which antagonises vascular endothelial growth 
factor (VEGF) through a variety of mechanisms, such as the inhibition of MMP9 
activation285–287. While the anti-angiogenic function of TSP1 has clear relevance to 
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tumour biology, it also suggests a link with psoriasis, which is characterised by new 
vessel formation and increased expression of VEGF61,288,289.  
Therefore, the information that is available in the literature suggest that the PRR13 
variants detected in this study may be gain-of-function alleles, which may promote 
angiogenesis and disrupt neutrophil clearance through constitutive TSP1 inhibition.   
Unfortunately, the difficulty of shipping intact fresh blood from Malaysia and the short 
life-span of neutrophils have prevented me from investigating this disease model in 
patient cells. While this is one of the main limitation of the current study, the Capon lab 
is poised to contact the centre which recruited the British patient carrying a PRR13 P16S 
variant. Owing to the geographical proximity of this hospital (Cambridge, UK), it should 
be possible to obtain fresh patient neutrophils for immune phenotyping and autophagy 
stimulation assays.  
In conclusion, the evidence provided in this chapter show that PRR13 is a likely candidate 





4 MYELOPEROXIDASE MUTATIONS ARE ASSOCIATED WITH PUSTULAR 
PSORIASIS 
4.1 Stepwise filtering of whole-exome sequence profiles 
As described in the previous chapter, the aim of the genetic studies described in this 
thesis was to identify additional candidate genes for pustular psoriasis. While both 
familial and sporadic disease cases have so far been identified108,109,115, the focus of this 
chapter was on the latter. Therefore, the whole-exome profiles of 19 unrelated GPP 
cases were interrogated.  
The 19 exomes contained ~500,000 variants, with an average of 25,000 changes per 
patient. To account for the lack of parent-to-offspring transmission and for the severity 
of the phenotype, the data was analysed by assuming autosomal recessive inheritance 
and only retaining rare homozygous loss-of-function variants (splicing, stop-gain, stop-
loss and frameshift changes with a global Minor Allele Frequency (MAF) ≤ 0.01)). Any 
alleles found at high frequency (MAF ≥ 0.05) in an in-house sequencing dataset were 
also filtered out, as they were likely to represent sequencing artefacts. While this 
analysis identified 37 changes, only six had deleterious potential (CADD ≥ 15) (Table 4.1, 
Appendix IV), none of which was shared between any of the cases. Among the 
pathogenic changes, a homozygous splicing variant in MPO (2031-2A>C) was selected 
for follow-up, due to the fundamental role of the gene in neutrophil microbial killing. 
The change was found in a female of European origin, who also carried a heterozygous 
missense variant in AP1S3. Of note, the possibility of epistasis involving AP1S3 alleles 





Table 4.1 Rare homozygous loss-of-function variants identified in 19 unrelated GPP cases 
1CADD scores above 15 are considered pathogenic. MAF, minor allele frequency








41GPP2 ARAP1 4070+5G>T Splicing  0.0005 22.8 
Modulates actin cytoskeleton remodelling by 
regulating ADP-ribosylation factor (ARF) and 
Ras homologous (RHO) family members; 
might regulate cell-specific trafficking of 
TRAIL receptor thus affecting apoptosis 
8GPP2 CCSER2 1868+5T>A splicing 0.0003 15.8 Might play a role in microtubule bundling 
38GPP1 DMBT1 C1504T Stop-gain 0.00002 35.0 
Might play a role in the interaction of tumour 
cells and the immune system 
17GPP1 EIF4G1 698-3C>T splicing 0.0016 16.5 
Component of the EIF4F protein complex 
that facilitates recruitment of mRNA to the 
ribosome 
GYFAP0029 FAM83A C871T Stop-gain 0.0018 36.0 
Functions in the epidermal growth factor 
receptor (EGFR) signalling pathway 
GYFAP0014 MPO 2031-2A>C splicing 0.0043 32.0 
Major component of neutrophil azurophilic 
granules; produces hypohalous acids central 
to the microbicidal activity of neutrophils 
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4.2 The MPO 2031-2A>C variant is associated with pustular psoriasis 
To further investigate MPO as a candidate disease gene, its coding region was screened 
by Sanger sequencing in 14 additional unrelated subjects affected by GPP. This did not 
identify any further individuals harbouring 2031-2A>C or any other deleterious allele.  
The analysis was then extended to include 105 patients affected by palmoplantar 
pustulosis (PPP) and 9 with Acrodermatitis Continua of Hallopeau (ACH), for whom WES 
data was available. This revealed another individual carrying the homozygous splicing 
variant.  
In both the GPP and PPP patient, the presence of the 2031-2A>C substitution was 
confirmed by Sanger sequencing (Figure 4.1). The clinical and phenotypic characteristics 
of the two cases are summarised in Table 4.2. 
Of note, the 2031-2A>C allele was observed in homozygosity in only one of the 33,217 
healthy European individuals sequenced by the ExAC project290. Thus, the association 








Figure 4.1 Sequence chromatograms of the homozygous 2031-2A>C variant.  
Asterisks indicate the nucleotide change in individuals GYFAP0014 (affected by GPP) 
and DDPLM0001 (affected by PPP) compared to wildtype. 
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Table 4.2 Disease presentation in the two cases carrying the 2031-2A>C variant in MPO 







GYFAP0014 F 36 
First GPP episode during 
pregnancy and subsequent 
severe flare when taken off 
infliximab.  
8.5 x 109/L 
(60.3%)  
DDPLM0001 F 24 
PPP in right heel, ACH in left 
hand with nail loss, crusting 
around lips (occasional pustules 
on lips), fissured tongue, PsV in 
lower limbs, PsA; poorly 
controlled on acitretin 




 Table 4.3 Association test for the 2031-2A>C MPO variant in the European population  




119 GPP, 103 PPP and 9 ACH individuals of European descent;  
2 Control data from ExAC; 3One-tailed Fisher exact test.   
CC homozygous individuals 
(frequency) 
P value3 





4.6 x 10-5 
116 
 
4.3 Literature review strengthens the link between MPO variants and pustular skin 
phenotypes 
The MPO variant observed in the two pustular psoriasis cases had been previously 
described as a myeloperoxidase deficiency allele291. To further investigate the 
significance of this observation, the hypothesis that MPO deficiency is associated with 
neutrophilic skin inflammation was investigated through a systematic literature review 
(Figure 4.2).  
Twenty-three case reports were identified and carefully inspected. This uncovered two 
cases of myeloperoxidase deficiency presenting with generalised pustular 
psoriasis292,293. Two further articles reported MPO deficiency associated with 
disseminated pustular candidiasis294 and pyoderma gangrenosum (PG, a severe 
neutrophilic dermatosis)295. Given the rarity of the above conditions (1-9:1,000,000 for 
GPP and 1-3.3 in 330,000 for PG296,297), these observations strengthen the link between 
















 Figure 4.2 Flow diagram of the literature review 
Out of 242 articles identified, 219 were excluded as they were reviews or did not 
describe patients with MPO deficiency. The 23 remaining papers were retained and 
analysed. 
CTS, cathepsin; NE, neutrophil elastase or ELANE; LAD, leucocyte adhesion deficiency 
  
Full-text articles assessed 
for eligibility 
(n = 242) 
Full-text articles excluded, 
with reasons  
(n=219) 
CTS or NE deficiency n= 2 
LAD deficiency  n=1  
Review n=7 
MPO polymorphisms n=2 
MPO gene function n=207 
 




Key words: ((MPO or Myeloperoxidase) and (skin or dermatol* or cutaneous) and 
(deficien* or mut* or variant* or allele* or KO or knockout* or knockdown* or GWAS 
or genome wide association stud* or genome wide linkage)) 
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Table 4.4 Articles reporting MPO deficiency and pustular skin phenotypes. 
  
Reference Disease presentation 
Stendahl and Lindgren 
Scand. J. Haematol. 16, 
144–153 (1976). 
 
46-year-old man with MPO deficiency. Reported a 
deceased identical twin who suffered from mild pustular 
psoriasis. Patient’s illness started as psoriasis vulgaris. 
Then he developed a GPP flare accompanied by high 
fever.  
De Argila et al. 
Dermatology 193, 
270 (1996) 
61-year-old woman with MPO deficiency. She suffered 
for 2 years from episodes of annular pustular psoriasis. 
Lesions tended to spread and form enlarged rings over 
the trunk and limbs. Flares were accompanied by chills 
and joint inflammation. 
Disdier et al. 
JAAD 24, 
654 (1991) 
81-year-old woman with MPO deficiency. She injured her 
leg and developed a high fever, as well as a necrotic, 
bullous eruption suggestive of  pyoderma gangrenosum. 
Nguyen and Katner 
Clin. Infect. Dis. 24, 
258-260 (1997) 
20-year-old male with MPO deficiency. He was admitted 
to hospital after a motorcycle accident and developed a 
high fever as well as a generalized pustular eruption. 




4.4 MPO disease variants are associated with increased neutrophil count  
To obtain further insights into the phenotypic effects of the 2031-2A>C mutation, I 
interrogated the data generated by UK Biobank, which includes SNP genotypes for 
500,000 individuals ascertained from the general population244,298. Here, I queried the 
results of phenome-wide association scans (PheWAS) carried on the dataset244,299, in 
order to determine whether the mutation was associated with any of the traits that had 
been observed in the study participants. This hypothesis-free approach revealed that 
the phenotypes that are most strongly associated with 2031-2A>C (rs35897051) relate 
to white blood cell homeostasis. In fact, the variant causes a decrease in monocyte 
numbers and an increase in basophil and neutrophil counts (Table 4.5). Of note, the 
largest effect size (beta) was observed for the association with neutrophil percentage. 
To validate this observation, I investigated the effects of other alleles that had previously 
been associated with myeloperoxidase deficiency291,300–302. I found that all the variants 
for which genotype data was available in UK Biobank (4 in total) were strongly associated 
with increased neutrophil percentage (Table 4.6). These findings are in keeping with the 

















Beta represents the effect size; Imputation scores measure the 
reliability of the inferred genotype   
 
 
Table 4.6 Summary of the association between MPO deficiency alleles and 
neutrophil percentage  
1All variants were directly genotyped, therefore no imputation score is reported. 
MAF, minor allele frequency; Beta represents the effect size  
Trait P value Beta 
Imputation 
score 
Monocyte percentage 5.3 x 10-38 -0.31 0.92 
Monocyte count 3.9 x 10-21 -0.02 0.92 
Basophil count 4.6 x 10-11 0.003 0.92 
Basophil percentage 1.1 x 10-9 0.03 0.92 
Neutrophil percentage 5.1 x 10-6 0.45 0.92 
Neutrophil count 3.2 x 10-5 0.07 0.92 
Variant1 MAF P value Beta 
p.Ala332Val 
(rs28730837) 
0.016 4.5 x 10-22 0.57677 
p.Met251Thr 
(rs56378716) 
3.9 x 10-28 0.013 0.74621 
p.Tyr173Cys 
(rs78950939) 
0.0012 0.008 0.57164 
p.Arg569Trp 
(rs119468010) 
0.0036 3.6 x 10-12 0.5261 
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4.5 MPO variants are associated with the up-regulation of genes that modulate 
apoptosis  
To understand how MPO alleles might affect granulocyte counts, gene expression levels 
measured in GYFAP0014 (the GPP patient carrying the 2031-2A>C variant) were 
compared to those of 11 healthy controls, using neutrophil RNA sequencing data 
generated for a related study (see chapter 5). This analysis identified 95 upregulated 
genes (fold change ≥ 1.5) at a False Discovery Rate (FDR) <0.05 (Figure 4.3, Appendix V). 
Of note, most of these transcripts (85/95) were not over-expressed in 7 unrelated GPP 
cases examined in parallel, which suggests that their increased expression is a specific 
consequence of MPO deficiency rather than a secondary effect of inflammation. Of note, 
while the number of differentially expressed genes did not allow me to perform a 
pathway enrichment analysis, two of the five most up-regulated loci (PBK and GUCYA2) 
encode proteins (PDZ binding kinase and soluble guanylate cyclase alpha-2 subunit) that 
can inhibit apoptosis303,304. Thus, RNA sequencing of patient cells suggests that MPO 
deficiency may disrupt the transcriptional networks that regulate neutrophil survival 




Figure 4.3 Differential gene expression in GYFAP0014 neutrophils  
Heatmap showing the 80 genes with the most significant over-expression in 
GYFAP0014 compared to healthy controls. PBK and GUCYA2 (two highly upregulated 




The aim of this study was to identify new genetic determinants of pustular psoriasis 
through the analysis of whole-exome sequencing data. This had been previously 
generated by the group for several affected individuals who lacked a molecular 
diagnosis.  
While mono- and bi-allelic variants have both been reported108,109,115, my filtering 
strategy focused on the latter, as the severity of the disease suggested the involvement 
of recessive loss-of-function alleles. On this occasion, compound heterozygous variants 
were not considered, owing to the difficulty of distinguishing cis and trans inheritance 
in the absence of parental genotypes. Should those become available in the future, the 
variant analysis could be usefully revisited.  
The current filtering approach highlighted a pathogenic MPO splicing change as the most 
promising variant. The same substitution was later uncovered in an unrelated patient of 
European origin, who was affected by PPP and ACH. A literature review and PheWAS 
analysis further suggested that the 2031-2A>C mutation affects neutrophil survival. 
While the genetic analysis did not uncover any shared genes between the 19 GPP cases, 
this was not completely unexpected due to the heterogeneity of the disease. In addition, 
the patient selection was only based on their GPP diagnosis and the absence of psoriasis 
family history. In the future, the application of tighter inclusion criteria (e.g. early age of 
onset or acute disease presentation) might lead to the ascertainment of a more 
homogeneous sample where shared genetic defects may be observed. 
MPO encodes a 745 aa protein, which is synthesised during neutrophil myeloid 
differentiation and constitutes the major component of azurophilic granules. The 
protein was first isolated in 1941 from the purulent fluid of patients with tuberculous 
empyema305. It was initially named verdoperoxidase, due to its intense green colour. 
The term myeloperoxidase was adopted later, once it became apparent that the protein 
is only expressed in myeloid cells225.  
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In 1970, Klebanoff demonstrated that MPO promotes oxygen-dependent killing during 
phagocytosis306,307. Several studies have since shown that MPO catalyses the production 
of hypohalous acid (HOCl) from hydrogen peroxide and Cl-, thus creating a toxic 
environment within phagolysosomes (Figure 4.4)148,308,309. Of note, MPO-mediated 
damage is not restricted to phagosomes, as HOCl and its by-products can harm host 
tissues as well. Thus, excessive MPO activity has been implicated in the pathogenesis of 
several inflammatory disorders, including Alzheimer Disease, multiple sclerosis, 
atherosclerosis and certain tumors310. Conversely, reduced MPO function can affect 
responses to pathogens311, with consequences ranging from very mild immune 
deficiency to the recurrence of life-threatening infections312. 
  
 
Figure 4.4 Reactive oxygen species production within the neutrophil phagosome 
Neutrophil priming triggers the mobilisation of cytoplasmic phagocyte oxidase (phox) 
proteins, Ras-related C3 botulinum toxin substrate (Rac) and membrane-expressed 
cytochrome b558 (Cyt b), leading to the assembly of the NADPH oxidase (NOX2) at the 
phagosomal membrane. NADPH-dependent oxygen reduction by NOX2 produces O2. 
This in turn dismutates into H2O2. PMN priming also stimulates the fusion of neutrophil 
granules with the phagosome. This leads to the release of myeloperoxidase (MPO), 




The 2031-2A>C homozygous change was first identified in 2004 and was shown to cause 
activation of a cryptic 3’ splice site situated 109bp upstream of the authentic 3’ splice 
site of intron 11. This insertion results in a frameshift, leading to a premature stop codon 
and synthesis of an abnormal MPO precursor lacking enzymatic activity291.  
In this chapter I provide evidence for an association between MPO deficiency and 
neutrophil count variation. Firstly, elevated neutrophil numbers were observed in the 
two cases carrying the 2031-2A>C change. Secondly, the PheWAS showed a consistent 
association between MPO deficiency alleles and increased neutrophil percentage in 
white blood cells. Of note, the PheWAS results were further confirmed when mining the 
GWAS catalogue, a curated collection of all published genome-wide association 
studies240. This showed that common non-coding MPO SNPs were also associated with 
neutrophil count variation271. 
Finally, the transcriptomic analysis suggested a link between MPO deficiency and 
apoptosis, which is consistent with the effect on PMN counts. Unfortunately, constraints 
on the amount of blood that could be obtained from affected individuals prevented me 
from directly investigating the regulation of cell death in MPO deficient neutrophils. At 
the same time, the function of the genes that are upregulated in patient cells strongly 
suggests that a disruption of apoptosis would have been observed in such experiments. 
In conclusion, the evidence provided in this chapter shows that deleterious MPO 
variants are linked to pustular skin phenotypes and that they could predispose to the 




5 IDENTIFICATION OF A TYPE-I-IFN TRANSCRIPTIONAL SIGNATURE IN THE 
NEUTROPHILS OF GPP AND PsV PATIENTS 
5.1 RNA-sequencing of a pure neutrophil population 
The aim of this part of the study was to investigate the transcriptional networks that 
drive neutrophil activation in GPP. To achieve this purpose, RNA-sequencing was carried 
out in neutrophils obtained from affected individuals and healthy donors. 
Eight unrelated GPP cases were identified among the patients attending the psoriasis 
clinic at St. John’s Institute of Dermatology, while 11 age and sex-matched healthy 
controls were recruited among the Institute personnel. Untouched neutrophils were 
isolated from whole-blood and cell purity was measured by flow cytometry in 8 
representative samples. Overall, neutrophils accounted for 97% of the isolated cells, 
while the contamination from monocytes, lymphocytes and eosinophils was negligible 





Figure 5.1 Purity of the neutrophil population used for RNA-sequencing 
Representative flow cytometry plots showing that neutrophils represent >97% of live 
cells, whereas contaminating eosinophils, lymphocytes and monocytes account for 
around 1% of the sample. (A) Cells are selected based on their size and granularity, 
while debris and dead cells (bottom left) and doublets (top right) are excluded. (B) 
Single cells are selected and more doublets excluded. (C) Live leukocytes (gated as 
CD45+ and live/dead marker (L/D)-) are selected. (D) Lymphocytes (gated as CD3/19+) 
and monocytes (gated as CD24- and CD3/19-) contamination is quantified. 
Granulocytes (gated as CD24+) are selected. (E) Neutrophils (gated as CD16+ CD15+ 
cells) and eosinophils (gated as CD16- CD15+ cells) are quantified. 
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Next, neutrophil RNA was extracted, and its quality was assessed on a TapeStation 2200. 
As this uncovered an extensive DNA contamination (Figure 5.2), the samples were 
subject to DNase treatment (Figure 5.3). New TapeStation measurements showed that 
the DNase treatment had been successful and had not affected the integrity of the RNA 
(average RNA Integrity Number equivalent (RINe): 8.2). The samples were therefore sent 
to the NGS Facility at St. James's University Hospital in Leeds for library preparation and 





Figure 5.2  Quality of neutrophil RNA prior to DNase treatment 
Two representative TapeStation measurements (samples D1 and E1). Both gel 
electrophoresis (A) and electropherograms (B) show that the RNAs were heavily 
contaminated by DNA. 
 
  
Sample Intensity [FU] 








Figure 5.3 Quality of neutrophil RNA after DNase treatment  
Two representative TapeStation measurements (samples D1 and E1). Both gel 
electrophoresis (A) and electropherograms (B) show that the DNA has been degraded 
by the DNase treatment, while the RNA integrity was not affected, as shown by the 
presence of the 18S and 28S ribosomal RNA subunits.  RNA integrity number equivalent 
(RINE) is given for the two samples. 
 
  
Sample Intensity [FU] 







The analysis of the RNA-sequencing detected an average of 40 million reads per sample. 
After these were aligned to the reference genome and counted, a further purity check 
was carried out by comparing gene expression levels to those observed in the healthy 
neutrophils sequenced by the Blueprint Consortium (a large European collaboration that 
aims to better understand immune gene activation in health and disease)237. This 
analysis showed that all the genes that are transcribed in the Blueprint neutrophils 
(n=3,133) are also found in our samples, with very low expression levels observed for a 
further 252 genes originating from monocytes, eosinophils and lymphocytes (<0.3 
transcript per million (TPM) on average) (Figure 5.4). These results further validated the 





Figure 5.4 In-silico purity of the neutrophil population used for RNA-sequencing 
Venn diagram showing that all neutrophil genes detected by the Blueprint 
consortium (green circle) were present in our neutrophil population (blue). Only 252 
genes found in our dataset originated from other cell types (orange), but those were 





5.2 Type-I-IFN related pathways are enriched among the genes that are up-
regulated in GPP neutrophils 
To identify any outliers or subgroups of samples which might be present in the dataset, 
Principal Component Analysis (PCA) was performed on the normalised read counts.  The 
PCA revealed that the healthy controls tend to cluster together, apart from the males, 
while the patients are a more heterogeneous group (Figure 5.5).  
Next, gene expression levels were compared in the 8 GPP cases versus the 11 healthy 
controls. This analysis identified 231 differentially expressed genes (DEGs, Appendix VI), 
of which 200 were up-regulated (fold change≥1.5) and 31 were down-regulated (fold 





Figure 5.5 Principal Component Analysis (PCA) of neutrophil RNA-sequencing data 
The plot shows the distribution of neutrophil samples along the first two principal 
components. While the female controls seem to cluster together, the cases are more 
spread out and diverse. Neutrophils from the 2 males in the dataset (one affected and 







Figure 5.6 Differential gene expression in GPP neutrophils vs. healthy controls 
Volcano plot showing the genes that are differentially expressed in GPP patients (black 
dots). The horizontal and vertical dashed lines represent the threshold for significance 





The up-regulated genes (Appendix VI) were then mapped to the co-expression modules 
defined by Li et al.266, which describe well characterised features of immune function. 
This revealed a significant over-representation of modules related to innate immune 
activation. Among these, type-I interferon response was the most significantly enriched 
module (10 out of 12 genes found among the DEGs; FDR<10-12), followed by innate 
antiviral response (9 out of 12 genes among the DEGs; FDR<10-10) and antiviral interferon 
signature (11 out of 22 genes among the DEGs; FDR<10-10) (Figure 5.7).  
These results were further confirmed by Ingenuity Pathway Analysis (IPA), which 
identified 4 enriched pathways associated with IFN responses. These included IFN 
signalling (FDR<10-12), Activation of IRF by Cytosolic Pattern Recognition Receptors 
(FDR<10-6) and Role of JAK1, JAK2 and TYK2 in Interferon Signalling (FDR<10-2) (Figure 
5.8). Furthermore, an IPA upstream regulator analysis highlighted IRF7 and STAT1 (two 
known mediators of IFN signal transduction), as the most likely drivers of gene up-
regulation (FDR<10-30 for both) (Figure 5.9). 
Taken together, the results of these analyses demonstrate that type-I-IFN responses are 





Figure 5.7 Genes up-regulated in GPP neutrophils map to type-I-IFN related expression 
modules 
Diagram showing the most significantly enriched transcriptional modules among the 
genes that are up-regulated in GPP. The heat map on the left reports the log10(FDR) 
associated with each module, while the genes belonging to each different module are 
shown on the grid as grey cells. The analysis has been carried out using the co-expression 







Figure 5.8 Results of Ingenuity pathway enrichment analysis  
Bar plot illustrating the most significantly enriched pathways detected among the 




Figure 5.9 Key results of Ingenuity upstream regulator enrichment analysis  
Upstream regulatory network showing that IRF7 and STAT1 drive the up-regulation of 




5.3 The up-regulation of type-I-IFN signature genes can be detected in extended GPP 
and PsV datasets  
To further explore the relevance of these findings, a type-I-IFN score267 was defined by 
calculating the median expression of five IFN-stimulated genes (ISGs; IFI6, IFIT3, IFITM3, 
OASL and PLSCR1) selected as discussed in section 2.7.3.6. As expected, the score was 
higher in GPP cases compared to controls (P=0.01) (Figure 5.10). The expression of the 
same genes was then measured in an expanded dataset, which was characterized by 
means of real-time PCR. 
Freshly isolated neutrophils were obtained from 17 GPP cases, including 7 subjects from 
the RNA-sequencing cohort and 10 newly ascertained patients. To determine whether 
the up-regulation of type-I-IFN genes was also relevant to the pathogenesis of common 
psoriasis vulgaris, 16 individuals with moderate-to-severe PsV (Psoriasis Area Severity 
Index >10) were also recruited. Finally, 3 control groups were included in the analysis: 9 
patients affected by Cryopirin Associated Periodic Syndrome (CAPS, an IL-1-driven 
neutrophilic disease), 13 cases with Acral Pustular Psoriasis (APP, a localised form of the 
disease that solely affects hands and feet) and 26 healthy volunteers (10 of whom had 
been included in the RNA-sequencing cohort).  
Real-time PCR of the 5 ISGs showed that the IFN score was significantly higher in the 
GPP and PsV cohorts compared to unaffected individuals (P=0.0046 and P=0.0021, 
respectively). Conversely, the scores of CAPS and APP patients were similar to those of 
the healthy controls (Figure 5.11). Thus, the type-I-IFN signature can be reproducibly 





Figure 5.10 Analysis of RNA-seq data shows elevated IFN scores in GPP patients 
Dot plots showing an elevated IFN score in the neutrophils of GPP patients, compared 







Figure 5.11 Real-time PCR of the 5 ISGs shows that elevated IFN scores can be detected in 
extended GPP and PsV datasets 
Dot plot showing an elevated IFN score in the neutrophils of GPP and PsV patients, 
compared to healthy individuals (CTR). CAPS and APP cases were analysed as negative 
controls. The data are presented as mean +/- standard deviation; **P<0.01 (one-way 






5.4 Neutrophils do not respond to IL-36 stimulation nor express the IL-36 Receptor  
Given the well-established role of IL-36 signalling in psoriasis123,127,314, we hypothesised 
that the up-regulation of  type-I-IFN responses observed in patient neutrophils may be 
the consequence of abnormal IL-36 activity. 
To explore this possibility and determine whether neutrophils can respond to direct IL-
36 stimulation, freshly isolated cells obtained from three healthy donors were 
stimulated for 2 hours with the cytokine. Of note, as Mahil et al. showed a substantial 
overlap between the genes upregulated by IL-36α, β and γ127, IL-36α was used  in all 
subsequent experiments as a representative cytokine. The response to treatment was 
then determined by measuring the mRNA expression of IL8, a known IL-36 target 
gene108,109.  
While IL8 levels increased after a control IL-1β stimulation, IL-36 did not elicit any 
response. Moreover, since IL-36R expression can be enhanced by the synergistic effects 
of IL-6 and IL-1β315, attempts were also made to stimulate neutrophils in such 
conditions. However, no difference in IL8 induction could be detected between cells 





Figure 5.12 Healthy donor neutrophils don’t respond to direct IL-36 stimulation  
Following treatment of neutrophils with IL-36, IL-1β or vehicle (untreated), IL8 mRNA 
expression was measured by real-time PCR and normalised to RPL13A levels. Data 
represents the mean +/- SD of results obtained in three independent donors, each 
stimulated in duplicate (left). Following treatment of neutrophils with IL-1β and IL-6 in 
the presence or absence of IL-36, IL8 mRNA expression was measured by real-time PCR 
and normalised to RPL13A levels. Data represents the mean +/- SD of results obtained 





To further validate these observations and confirm that neutrophils do not respond to 
IL-36 stimulation, the surface expression of the IL-36 Receptor (IL-36R) was investigated. 
Neutrophils obtained from healthy individuals (n=3) and GPP patients (n=3) were 
analysed by flow cytometry. In keeping with the stimulation results and published 
findings316, IL-36R surface expression was scarcely detectable in the neutrophils of GPP 
cases or healthy controls (Figure 5.13). Neutrophils, therefore, cannot respond to IL-36 
cytokines, indicating that the type-I-IFN signature seen in these cells is likely to reflect 




Figure 5.13 Neutrophils do not express IL-36R 
Representative flow cytometry analysis of IL36R surface expression (left) and 






5.5 IL-36R is robustly expressed in plasmacytoid dendritic cells  
To determine which cell types respond to IL-36, the surface expression of the IL-36 
Receptor (IL-36R) was systematically measured in innate immune cells. These 
experiments were carried out in collaboration with my colleague Marika Catapano.  
Peripheral blood mononuclear cells (PBMCs) obtained from healthy individuals (n=3) 
and GPP patients (n=3) were analysed by flow cytometry. Myeloid and plasmacytoid 
dendritic cells (mDCs and pDCs) showed robust IL-36R surface expression, with the 
highest receptor levels observed in the pDCs of GPP patients (Figure 5.14).  Importantly, 
pDCs are the main producers of type-I-IFN (especially IFN-α) in the immune 
system195,317,318. Thus, the flow cytometry results suggest that IL-36 may influence IFN-









Figure 5.14 The IL-36 receptor is robustly expressed in dendritic cells 
(A-C) Representative flow cytometry plots of IL36R+ cells in six leukocyte populations. 
Fluorescence minus one (FMO) controls are shown for each population. The following 
cell types were analysed: (A) innate lymphoid cells (lineage- (CD3-, CD4-, CD19-, CD20-, 
CD56-), CD127+); (B) monocytes (CD3-, CD20-, CD19-, CD56-) separated into classical 
(CD16-, CD14high), intermediate (CD16+, CD14+) and pro-inflammatory (CD16high, CD14-) 
populations; (C) pDCs (lineage-, HLADR+, CD123+, CD11c-) and mDCs (lineage-, HLADR+, 
CD123-, CD11c+). (D) Histograms illustrating the percentage of IL36R+ cells in six 
leukocyte populations. Data are shown as mean +/- SEM. No significant differences were 
observed between GPP cases and healthy donors. CTR: healthy controls; ILCs: Innate 






5.6 IL-36 potentiates IFN-α production by up-regulating the expression of PLSCR1  
Building on the flow cytometry results, the hypothesis that IL-36 potentiates type-I-IFN 
production in pDCs was investigated. The following experiments were carried out in 
collaboration with Marika Catapano.  
PBMCs obtained from healthy donors (n=3) were pre-treated with IL-36α or vehicle and 
stimulated with CpG-containing DNA (CpG), a Toll-like receptor (TLR)-9 ligand which 
drives IFN- production by pDCs319. Type-I-IFN activation was then assessed by 
measuring the expression of the five ISGs by real-time PCR. The experiment 
demonstrated that IL-36 potentiates the response to CpG, as the expression of the IFN 
signature genes was higher in cells treated with IL-36α and CpG, compared to those 





Figure 5.15 IL-36 up-regulates expression of ISGs downstream of TLR-9 
After pre-treatment with IL-36 or vehicle (6h), PBMCs from healthy donors were 
stimulated with CpG for 6h. ISGs expression was then measured by real-time PCR and 
normalised to B2M levels. Data is shown as the mean +/- SEM of results obtained in 
three independent donors, each stimulated in triplicate. *P<0.05; **P<0.01 (Friedman’s 





To further explore the relevance of these findings, the mechanisms whereby IL-36 
potentiates TLR9- dependent IFN responses were investigated. Of note, the results of 
PBMC stimulations showed that IL-36α can up-regulate PLSCR1 expression even in the 
absence of CpG (Figure 5.15). This is of interest, given that PLSCR1 encodes a 
phospholipid scramblase mediating TLR-9 translocation to the endosomal 
compartment320. The effect of IL-36 on PLSCR1 was therefore investigated in more 
detail. 
Fresh PBMCs were obtained from 5 additional healthy donors and treated with IL-36α 
The results validated the previous experiments and confirmed that IL-36 up-regulates 
PLSCR1 expression (P=0.03) (Figure 5.16). Moreover, flow cytometry analysis of IL-36 
treated pDCs demonstrated a significant increase in PLSCR1 protein levels (Figure 5.17), 




Figure 5.16 IL-36 upregulates PLSCR1 expression in PBMCs 
After treating PBMCs from additional healthy donors with IL-36α or vehicle, PLSCR1 
expression was measured by real-time PCR and normalised to B2M levels. Data is 
shown as the mean +/- SEM of results obtained in five independent donors, each 
stimulated in triplicate.  *P<0.05 (Wilcoxon signed-rank test). 
 
 
Figure 5.17 IL-36 upregulates PLSCR1 protein expression in pDCs 
After treating pDCs with IL-36αα or vehicle, PLSCR1 mean fluorescence intensity (MFI) 
was measured by flow-cytometry. The panel on the left shows a representative 
histogram, while the plot on the right illustrates the results (mean +/- SEM) obtained 




Finally, the mechanism whereby IL-36 up-regulates PLSCR1 was explored. Given that 
PLSCR1 is an IFN-stimulated gene, an involvement of STAT1 was hypothesised. This was 
supported by the identification of a STAT1 binding site within the gene promoter. Since 
IL-36 can signal through mitogen-activated protein kinase (MAPK), and a cross-talk 
between STAT1 and MAPK has been previously demonstrated314,321, the latter pathway 
was selected for further investigation. PBMCs were pre-incubated with a MAPK inhibitor 
(SB-203580) and then stimulated with IL-36α. Real-time PCR demonstrated that the 
effect of IL-36α on PLSCR1 expression was abolished in cells that had been pre-treated 













Figure 5.18 MAPK inhibition abolishes the effects of IL-36 on PLSCR1 expression 
After pre-treating PBMCs with SB203580 (MAPKi) or vehicle, the cells where 
stimulated with IL-36α. PLSCR1 expression was then measured by real-time PCR and 
normalised to B2M levels. Data are shown as the mean +/- SEM of results obtained 
in four independent donors, each stimulated in triplicate. *P<0.05 (Friedman’s test 













While the GPP transcriptome has been investigated at the skin level123,127,322, circulating 
neutrophils have received little attention, despite their pathogenic role in systemic 
inflammation. The final part of my study aimed to fill this research gap and elucidate the 
transcriptional networks that cause neutrophil activation in GPP. 
Difficulties in isolating neutrophils from fresh blood were initially encountered. A 
literature review of purification protocols was then undertaken and identified two main 
methodologies: density gradient and magnetic separation323–325. After testing both 
approaches, the latter was chosen for its reproducibility and yield of highly pure cells. 
Of note, Calzetti et al. recently showed that neutrophil isolated with our method of 
choice contain very low numbers of slan+CD16+ cells that may, under some conditions 
express IFN regulated genes323. Unfortunately, by the time this finding was published it 
was not possible for me to adapt my isolation technique. However, the possibility of a 
slan+CD16+ contamination should be kept in mind and considered as a possible limitation 
to my study. 
The protocol for RNA isolation also required some optimization. In fact, the 
contamination of RNA samples with genomic DNA caused a 2-month delay in the 
project. However, once the appropriate DNase treatment was applied, the DNA could 
be removed without compromising RNA integrity. RNA sequencing then produced high 
quality results, as confirmed by the read QC (average mapped reads: 96%) and the 
comparison with the data generated by the Blueprint Consortium237. 
The differential-expression analysis and follow-up studies revealed a distinctive type-I-
IFN signature in the neutrophils of patients affected by GPP and severe PsV. This did not 
correlate with patient ethnicity or disease treatment. Of note, an increase in type-I-IFN 
activity has been previously associated with several inflammatory conditions such as 
systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS) and Chronic 
atypical neutrophilic dermatosis with lipodystrophy and elevated temperature 
(CANDLE)326,327. These diseases, which are now classified as Type-I-Interferonopathies, 
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present with severe skin lesions and prominent systemic upset, caused by abnormal IFN 
levels. Of note, neutrophils play a key role in the development of Type-I-
Interferonopathies, particularly at the skin level, where extensive neutrophil infiltration 
is observed328. Therefore, the phenotypic similarities between GPP, PsV and IFN-driven 
diseases further substantiate our results. 
Given that IL-36 is a key disease driver in GPP and has also been implicated in the 
pathogenesis of PsV123,127,314,329–333, we hypothesised that the up-regulation of type-I IFN 
genes was a consequence of abnormal IL-36 activity. However, flow-cytometry 
experiments and ex-vivo stimulations demonstrated that blood neutrophils do not 
respond to the cytokine due to a lack of IL-36R surface expression. While these findings 
confirmed previous results by Foster et al.316, the recently published discovery of a 
synergistic effect of IL-6 and IL-1β on IL-36 responses could not be replicated315. A 
possible explanation for this discrepancy could be that our experiments were based on 
shorter neutrophil stimulations. Indeed, the extended incubations described in Wang et 
al. (>24h in total) were, in our hands, detrimental to neutrophil viability. 
Further flow cytometry experiments demonstrated for the first time that IL-36R is 
strongly expressed in pDCs, the main producers of IFN- in the immune 
system195,317,318 This suggests that circulating IL-36 could affect IFN-α production by 
pDCs, which in turn would promote the activation of type-I-IFN genes in patient 
neutrophils. In keeping with this hypothesis, real-time PCR and flow-cytometry 
experiments demonstrated that IL-36 acts directly on pDCs, where it up-regulates the 
expression of PLSCR1. This gene encodes phospholipid scramblase 1, a protein that 
interacts with TLR-9 and mediates its trafficking to the endosomal compartment 
320,334,335. Importantly, siRNA knockdown of PLSCR1 inhibits type-I-IFN production in 
human pDCs. It is therefore reasonable to hypothesise that PLSCR1 up-regulation would 
have an opposite effect. This would set in motion a feed-forward loop, where PLSCR1 
enhances IFN-α production, which subsequently induces further PLSCR1 transcription 
(Figure 5.19). Interestingly, PLSCR1 is also up-regulated in SLE, which suggests that this 
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protein might have a pathogenic role in other type-I IFN mediated diseases, beyond 
psoriasis336. 
 
Figure 5.19 Proposed pathogenic model 
IL-36 produced by mDCs up-regulates PLSCR1 in pDCs, enhancing IFN-α release via 
TLR-9. In turn, IFN-α induces further PLSCR1 transcription, thus promoting a positive 




It is important to notice that the 8 GPP cases selected for RNA-sequencing had been 
previously genotyped. While three patients carried variants in IL36RN, this did not 
correlate with the uncovered type-I IFN signature and therefore broadens the scope of 
our finding, suggesting the presence of an underlying disease mechanism regardless of 
the patient mutation status. Moreover, while our PCA results showed that the two males 
cluster separately from the rest of the samples, a trend that has so far never been 
reported, this has been kept into consideration when computing the differential 
expression analysis, as sex was used as a covariate. 
It is possible that IL-36 could influence type-I-IFN production through the up-regulation 
of other genes. Of note, real-time PCR experiments showed that IL-36 does not directly 
affect the expression of TLR9 nor does it up-regulate IFN signalling mediators such as 
IRF1, IRF3 or IRF7 (data not shown). However, the effect of IL-36 on other 
innate regulators cannot be excluded and will have to be investigated in a more 
systematic fashion. In fact, the RNA-sequencing of IL-36 stimulated PBMCs is currently 
underway in the Capon lab and is expected to elucidate the effects of the cytokine on 
other type-I IFN related genes. 
In conclusion, the computational analyses presented in this chapter identified a 
prominent type-I-IFN signature in the neutrophils of patients affected by GPP and severe 
PsV. Follow-up studies showed that the activation of type-I-IFN responses was driven by 
increased IL-36/IFN-α signalling in pDCs.  
Since GPP and PsV both present with severe extra-cutaneous manifestations, it could be 
hypothesised that IL-36-driven type-I-IFN activity contributes to systemic disease 
symptoms. In PsV, for example, chronic IL-36 and type-I IFN up-regulation may be 
involved in the onset of atherosclerosis and psoriatic arthritis, two disease co-
morbidities that have been linked to abnormal type-I IFN activity9,10,97,337,338. 
Of note, type-I-IFN blockers such as Anifrolumab are already being trialled for the 
treatment of SLE and other type-I interferonopathies339–345. Although the IFN-a blocker 
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Sifalimumab did not show therapeutic efficiency in PsV, other agents could potentially 





6 FINAL DISCUSSION 
While the treatment of psoriasis has hugely benefited from our improved understanding 
of disease pathogenesis, the management of severe clinical variants (most notably 
pustular psoriasis and recalcitrant PsV) remains problematic, as these conditions are 
only partially understood at the immunological level91. The role of neutrophils, in 
particular, has received little attention, since most studies have focused on 
keratinocytes, dendritic cells and T lymphocyte sub-populations1. In this context, the 
objective of my PhD was to apply genetic and transcriptomic approaches to the study of 
neutrophil activation in psoriasis. The results reported in chapters 3, 4 and 5 highlight 
the potential of these strategies, but also their limitations. 
6.1 Genetic studies 
Although neutrophil accumulation in the stratum corneum and stratum spinosum is 
seen in all psoriasis subtypes, this phenomenon is particularly prominent in pustular 
forms of the disease, where systemic neutrophilia can also be observed. In fact, one of 
the main effects of IL36RN disease alleles is the up-regulation of IL-8, a powerful 
neutrophil chemo-attractant. On the basis of these observations, we proposed that 
pustular psoriasis would represent an ideal model for the study of neutrophil activation 
in psoriasis. We further hypothesised that the identification of new disease genes would 
uncover further regulators of neutrophil functions. 
In keeping with our initial proposition, this study identified disease alleles in two genes, 
(PRR13 and MPO) that appear to contribute to pustular psoriasis by disrupting 
neutrophil homeostasis and survival. While this success underscores the biological 
insights that can be obtained through the genetic analysis of rare and severe 
phenotypes, there might be limited scope for further discoveries. 
To find additional genetic determinants of pustular psoriasis, the Capon group has 
recently exome sequenced 100 unrelated PPP individuals (briefly described in chapter 
4). The analysis of this dataset, however, has shown that the disease is extremely 
heterogeneous, with no single gene accounting for a substantial fraction of affected 
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individuals. Further work by our lab also demonstrated key clinical and genetic 
differences between individuals affected by PPP and GPP103. Thus, it appears that locus 
and phenotypic heterogeneity within and across pustular psoriasis subtypes can greatly 
hinder the discovery of novel genetic determinants of the disease.   
Given the rarity of pustular psoriasis, this problem can only be overcome by ascertaining 
larger patient cohorts through multi-centre collaborations. This will boost the power of 
exome sequencing studies and increase the prospect of ascertaining familial cases. To 
facilitate this process, our group has contributed to the set-up of the European Rare and 
Severe Psoriasis Expert Network (ERASPEN), which aims to standardise diagnostic 
criteria as well as protocols for patient recruitment and phenotyping349. The work of 
ERASPEN members has already enabled the ascertainment and characterisation of an 
extended clinical resource103, so that plans are now in place to extend the reach of the 
Consortium beyond Europe. 
The use of immune phenotyping techniques, which should also be standardised across 
recruiting centres, could aid to define patient subsets that are more homogeneous and 
amenable to genetic analysis. Here, the 2031-2A>C MPO mutation was uncovered in 2 
subjects who presented with elevated neutrophil counts, despite receiving systemic 
treatment. In the future, the screening of affected individuals based on specific cell and 
protein markers could help select the most appropriate candidates for sequencing 
studies. 
Finally, the use of public repositories can be of great help when patient numbers are 
limited. For example, freely accessible databases such as ClinVar350 and GeneMatcher351 
enable clinicians and researchers to report putative mutations and early genotype-
phenotype correlations, thus aiding in the identification of novel disease genes. Here, 
the hypothesis that PRR13 mutations are a likely cause of GPP was only substantiated 
once the 100,000 Genomes Project270 was queried. Then, data reported by the 
Genotype-Tissue Expression (GTex) consortium239, the Blueprint237 and Fantom5 
projects238 as well as the GWAS catalogue240 helped to frame the hypothesis that the 
gene plays an important role in neutrophil biology. Similarly, data from the UK 
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Biobank244,298 and the GWAS catalogue demonstrated an association between MPO 
mutations and neutrophil count variation.  
Of note, the genomes of 50,000 UK Biobank participants are currently being sequenced, 
with plans to extend this analysis to the entire cohort. Thus, the wealth of publicly 
available genetic data is only set to increase in the coming years. 
6.2 Transcriptomic approaches 
As a supplement to the gene discovery approaches, this study used transcription 
profiling of patient cells to obtain further insights into the pathogenic role of 
neutrophils. 
By undertaking RNA-sequencing in GPP patients and healthy controls, we demonstrated 
that type-I-IFN responses are abnormally active in the PMNs of affected individuals. 
Importantly, this finding was validated in a severe PsV cohort, demonstrating the validity 
of investigating pustular psoriasis as a broadly relevant model of recalcitrant disease. 
Mechanistic ex-vivo experiments then showed that the up-regulation of type-I-IFN 
signalling is mediated by an IL-36/TLR-9 axis that is active in pDCs. A manuscript 
describing these findings has been recently accepted for publication by the Journal of 
Investigative Dermatology (see “Publication arising from this thesis”).  
The above results might also be relevant to the pathogenesis of other inflammatory 
disorders characterised by IL-36 over-expression. Diseases presenting with joint 
inflammation are an interesting example. In fact, Boutet et al. found that IL-36 is up-
regulated in approximately 20% of individuals suffering from rheumatoid arthritis 
(RA)352, while Wright et al. detected a type-I interferon signature in RA patient 
neutrophils353. The IL-36/TLR9/IFN-α axis could also contribute to the pathogenesis of 
PsA, as high levels of IL-36α and low levels of IL-36Ra are found in inflamed synovium354. 
Finally, individuals affected by SLE (a well-established Interferonopathy) show markedly 
increased serum IL-36 levels and significantly decreased IL-36Ra production, compared 
to healthy controls355. Taken together, these observations suggest that the IL-36/type-I 
IFN axis may also be an important driver of joint diseases. The group is therefore 
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establishing collaborations with academic rheumatologists to facilitate the recruitment 
of relevant patient resources and pursue this new research avenue.   
While the focus on a single cell type (whole-blood untouched neutrophils) removed 
important confounders from the differential expression analysis, it is important to bear 
in mind that PMNs are not a homogeneous population. In fact, neutrophils undergo 
important phenotypic changes during their life cycle356. These include an increase in 
CXCR4 and a decrease in L selectin (CD62L) and CD47 surface expression, as well as a 
reduction in the size and number of granules (see Figure 1.6 and Figure 1.7)142. At the 
transcriptional level, these changes affect several signalling pathways (cell activation, 
adhesion, migration, microbial detection and apoptosis), which are differently activated 
between aging and freshly released neutrophils357. Thus, the samples used in my 
experiments likely included both fresh and aged PMNs. Of note, inflammatory mediators 
(e.g. cytokines and microbial products) increase the numbers and lifespan of circulating 
neutrophils. Hence, GPP samples might have contained higher percentages of fresh and 
activated neutrophils, compared to healthy controls.  
The presence of neutrophils migrating towards different tissues also contributes to the 
heterogeneity of PMNs. In this context, our observation that type-I-IFN activation was 
detectable in systemic (GPP and severe PsV) but not in localised forms of psoriasis (PPP 
and ACH), suggests that the neutrophils driving the IFN signature might not be those 
that are poised to extravasate to the skin.  
While the IFN scores were elevated in the GPP and PsV cohorts, there was heterogeneity 
within both groups. In fact, most patients could be classified as IFN-high or IFN-low, an 
observation which could affect treatment choice and response, as discussed in section 
6.3.  
Finally, the diversity of circulating PMN is compounded by the presence of a distinct 
subset, known as low-density neutrophils (LDNs)358. Unlike other PMNs, these are found 




LDNs express surface markers that are specific to mature neutrophils 
(CD15high/CD14low/CD10+/CD16+)360, but show a distinctive transcriptional profile. For 
example, the LDNs of SLE patients express higher levels of serine proteases and 
bactericidal proteins compared to their healthy counterparts361, but the same does not 
apply to normal-density SLE neutrophils362. In addition, SLE LDNs have an increased 
tendency to form NETs 362. 
Here, magnetic separation rather than density gradient centrifugation was used to 
isolate PMNs from whole blood. We can therefore assume that both normal and low-
density neutrophil populations were present in the samples used for RNA-sequencing. 
Of note, the numbers of circulating LDNs have been shown to correlate with the severity 
of skin and vascular inflammation in psoriasis363. Moreover, LDNs have been shown to 
have enhanced capacity to synthetize IFN. Thus, it is tempting to speculate that LDNs 
may be driving, or at least significantly contributing to the type-I-IFN signature observed 
in severe psoriasis.  
Given the numerous sources of heterogeneity within the PMN compartment, the results 
of this study should be followed-up with methods that afford better resolution of the 
underlying sub-populations. These could include multi-dimensional immune 
phenotyping by time of flight cytometry (CyTOF) and single cell RNA-sequencing. Such 
approaches would help to dissect the specific neutrophil populations that contribute to 
the systemic and cutaneous manifestations of psoriasis, assisting in patient diagnosis, 
and in the identification of markers of treatment response. 
6.3 Future directions 
In recent years, genome- and transcriptome-wide approaches have been increasingly 
applied to the study of drug responses and treatment resistance.  In this context, Wright 
et al. showed that higher expression of IFN-signalling genes correlates with a positive 
outcome of TNF inhibitor therapy in RA353. These authors subsequently identified a set 
of 23 genes that could be used as biomarkers of response to TNF blockers364. Given that 
the TNF inhibitor adalimumab (which is now also available as a low-cost biosimilar) is 
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still a mainstay of psoriasis treatment, these observations warrant further analyses of 
IL-36 serum levels and type-I IFN genes in consecutive patient series. Such studies would 
have the potential to uncover novel predictors of drug response in psoriasis. 
All the experiments described in this thesis have been complicated to some extent by 
the difficulty of working with neutrophils. This was particularly apparent in the follow-
up of gene identification findings, where the short life of PMNs prevented me from 
executing experiments to recapitulate the effects of disease alleles. Since neutrophils 
can only be kept in culture for very short periods of time, they cannot be manipulated 
with RNAi or CRISPR-based methods that are routinely used in other cell types365–367. As 
a results, researchers have been investigating the biology of PMNs by generating 
knockouts in animal models and cell lines, such as HL-60 and PLB-985368–374. Both 
approaches, however, have their limitations. There are well documented differences 
between murine and human immune responses375, and immortalised cell lines do not 
fully reproduce the features of their primary counterparts. HL-60 cells, for example, are 
unable to mount an effective intracellular respiratory burst and lack LL-37/hCAP-18 
protein expression367,376–378. 
In this context, individuals harbouring loss of function mutations in neutrophil-related 
genes can be considered as very informative “human knockouts”. While logistic issues 
(e.g. the difficulty of shipping fresh blood from overseas) have limited the analysis of 
patient neutrophils in this study, the group is trying to overcome these difficulties by 
identifying further, UK-based individuals bearing disease alleles. Protocols for the ex-
vivo assessment of neutrophil proliferation and apoptosis are also being optimised. This 
work will allow the lab to thoroughly characterise rare MPO and PRR13 knockouts, with 
the potential to investigate the role of these genes in neutrophil biology and, ultimately, 
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Appendix II: Table of all PCR and real-time PCR primers 
Target Primer ID Sequence (5’ to 3’) Annealing T (°C) Application 
GLI3 Exon 15 
GLI3 Ex15 F CCAGCAGTACCGCCTCAA 
62 PCR and Sanger sequencing 
GLI3 Ex15 R CCGCGTGTAATTCTGAAGCA 
ITGB6 Exon 11 
ITGB6 Ex11 F CCCCTCAAATCTGCAAGTGT 
62 PCR and Sanger sequencing 
ITGB6 Ex11 R TGGAGACCAAACCAGCAAAT 
MAN2B2 Exon 18 
MAN2B2 Ex18 F GAGTTCGTGGTGTGTCTGC 
64 PCR and Sanger sequencing 
MAN2B2 Ex18 R GTTCAGAGTAGGAAAGCAGCC 
MPO Exon 1 
MPO Ex1 F CTTCCTCTACCTCACCCCAC 
62 PCR and Sanger sequencing 
MPO Ex1 R CTATCAGGCCCCAGAGCTAG 
MPO Exon 2 
MPO Ex2 F TTCCTAGCTCTGGGGCCT 
62 PCR and Sanger sequencing 
MPO Ex2 R CCTCTCCCACCTTCAAGCT 
MPO Exon 3 
MPO Ex3 F CAAAGCCTTGCCTCTGTCTG 
62 PCR and Sanger sequencing 
MPO Ex3 R TGGAGGAAGAAGTTGAGGGG 
MPO Exon 4-5 
MPO Ex4-5 F CCCCTCAACTTCTTCCTCCA 
62 PCR and Sanger sequencing 
MPO Ex4-5 R TCAGCTGATCAGTGGGGAAG 
213 
 
MPO Exon 6 
MPO Ex6 F GCCAGCTGATCTCCGTGT 
62 PCR and Sanger sequencing 
MPO Ex6 R CAGCGTCTGGGAAAGGAAAC 
MPO Exon 7 
MPO Ex7 F CTGCTCATTAACCCTGCACC 
62 PCR and Sanger sequencing 
MPO Ex7 R CCACAAGCTGCTCACAAACA 
MPO Exon 8 
MPO Ex8 F GGGGTTTCAGTGGAGCAAAT 
62 PCR and Sanger sequencing 
MPO Ex8 R TCAACCCTCCCAACACCAAT 
MPO Exon 9 
MPO Ex9 F CCAAGAGCAGGCAGAGACT 
64 PCR and Sanger sequencing 
MPO Ex9 R AGGCTAGAGAGTCAGACCAGA 
MPO Exon 10 
MPO Ex10 F TCTCGAATCCTCCTGACCCT 
64 PCR and Sanger sequencing 
MPO Ex10 R TCTAATATGCTTTGGAGAGGGC 
MPO Exon 11 
MPO Ex11 F TCTCCAGTGACCTCCCCA 
62 PCR and Sanger sequencing 
MPO Ex11 R AGGAGGAAATTTGGGCTCCA 
MPO Exon 12 
MPO Ex12 F ATATCCTGGGAGCAGCACAA 
62 PCR and Sanger sequencing 
MPO Ex12 R CATTTTCTCAGCTGCACCCA 
PITPNM3 Exon 8 
PITPNM3 Ex8 F ATGAAGGGGTTGGTTTGTGC 
64 PCR and Sanger sequencing 
PITPNM3 Ex8 R AGTGCTTATCTATGGGCCCC 
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PRR13 Exon 2 
PRR13 Ex2 F CTGTGGGGTGGAAGACGTTA 
62 PCR and Sanger sequencing 
PRR13 Ex2 R GCACTGGTCAGCTCTAGACT 
PRR13 Exon 3 
PRR13 Ex3 F TGTCTCCCCTACCCTCCATT 
62 PCR and Sanger sequencing 
PRR13 Ex3 R ATTGTCATCCCTCACGTCCA 
PRR13 Exon 4 
PRR13 Ex4 F TCAAGACTCCTGACCTTCTTAG 
62 PCR and Sanger sequencing 
PRR13 Ex4 R CCATGGCAATCCTCTTCCCA 
PTCH1 Exon 14 
PTCH1 Ex14 F GTCAGAGCTGTGTAAAATGGGT 
64 PCR and Sanger sequencing 
PTCH1 Ex14 R CTGATGAACTCCAAAGGTTCTGT 
SDK1 Exon 18 
SDK1 Ex18 F ACACTTCCTCGGTCTCAGTG 
64 PCR and Sanger sequencing 
SDK1 Ex18 R CAAGGTCAAGACGCCCTGTA 
SVIL Exon 18 
SVIL Ex18 F TCACTCATGAAATGCTGCAGG 
64 PCR and Sanger sequencing 
SVIL Ex18 F ATGGACACACACACACTGAC 
TMEM184A Exon 9 
TMEM184A Ex9 F GATGGTGGGGCTCATACACT 
62 PCR and Sanger sequencing 
TMEM184A Ex9 F CTGGGTCCCTACAGCACTG 
IFI6 
IFI6 qF CCATCTATCAGCAGGCTCCG 
60 Real time PCR 




IFIT3 qF GCACAGACCTAACAGCACCC 
60 Real time PCR 
IFIT3 qR TTGGTGACCTCACTCATGATGG 
IFITM3 
IFITM3 qF TCGCCTACTCCGTGAAGTCTA 
60 Real time PCR 
IFITM3 qR CACTGGGATGACGATGAGCA 
IL8 
IL8 qF TTGGCAGCCTTCCTGATTTC 
60 Real time PCR 
IL8 qR AACTTCTCCACAACCCTCT 
OASL 
OASL qF GTACCAGCAGAGGGCACG 
60 Real time PCR 
OASL qR GGAACCTGGAAGGACAGACG 
PLSCR1 
PLSCR1 qF CGGCAGCCAGAGAACTGTTTTA 
60 Real time PCR 
PLSCR1 qR AGGAGGATACCCAACTGGCA 
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Appendix IV: Stepwise filtering of whole-exome sequence profiles from the 19 





Appendix V: Differentially expressed genes detected in the neutrophils of the 
2031-2A>C homozygous GPP patient  
Symbol log2FoldChange FDR 
PBK 5.044394 1.7E-155 
GPR33 5.044394 1.7E-155 
COL14A1 4.78136 1.2E-105 
GUCY1A2 4.459432 3.77E-65 
SLC10A4 4.459432 3.77E-65 
DEFB1 4.459432 3.77E-65 
DPP10 4.459432 3.77E-65 
PURG 4.459432 3.77E-65 
CALCB 4.459432 3.77E-65 
DUOXA1 4.459432 3.77E-65 
BDKRB2 4.459432 3.77E-65 
DEFA3 4.430254 2.58E-62 
METTL7B 3.944858 5.82E-29 
NNMT 3.944858 5.82E-29 
SLC22A16 3.718818 8.89E-20 
CES1 3.702288 3.24E-19 
USP2 3.459432 2.4E-12 
C11orf45 3.459432 2.4E-12 
CLEC3B 3.459432 2.4E-12 
MAGEL2 3.459432 2.4E-12 
FRAS1 3.459432 2.4E-12 
MUC12 3.459432 2.4E-12 
SLIT3 3.459432 2.4E-12 
ALPK2 3.459432 2.4E-12 
HCN4 3.459432 2.4E-12 
IGFBP5 3.459432 2.4E-12 
C9orf47 3.459432 2.4E-12 
GLRA3 3.459432 2.4E-12 
TERT 3.459432 2.4E-12 
CLDN1 3.459432 2.4E-12 
PLEKHS1 3.459432 2.4E-12 
MISP 3.459432 2.4E-12 
KSR2 3.459432 2.4E-12 
PRSS16 3.459432 2.4E-12 
LRRC66 3.459432 2.4E-12 
SLC26A7 3.459432 2.4E-12 
MUSK 3.459432 2.4E-12 
PDYN 3.459432 2.4E-12 
SCG2 3.459432 2.4E-12 
MEPE 3.459432 2.4E-12 
SLC7A13 3.459432 2.4E-12 
ZNF474 3.459432 2.4E-12 
SHC2 3.459432 2.4E-12 
219 
 
SUN3 3.459432 2.4E-12 
EN2 3.459432 2.4E-12 
ATP4B 3.459432 2.4E-12 
BMP4 3.459432 2.4E-12 
RASGEF1C 3.459432 2.4E-12 
ACTL6B 3.459432 2.4E-12 
SLC22A3 3.459432 2.4E-12 
KLRC2 3.459432 2.4E-12 
CXCL13 3.459432 2.4E-12 
VCX 3.459432 2.4E-12 
OR5K2 3.459432 2.4E-12 
KITLG 3.459432 2.4E-12 
TTC36 3.459432 2.4E-12 
IFNB1 3.459432 2.4E-12 
DPPA5 3.459432 2.4E-12 
C6orf99 3.459432 2.4E-12 
SLC10A6 3.459432 2.4E-12 
LHB 3.459432 2.4E-12 
CXCL11 3.459432 2.4E-12 
WFDC2 3.459432 2.4E-12 
CAPN11 3.459432 2.4E-12 
XAGE3 3.459432 2.4E-12 
MLN 3.459432 2.4E-12 
IGFL3 3.459432 2.4E-12 
SPINK1 3.459432 2.4E-12 
HIST1H2BM 3.459432 2.4E-12 
SLC22A31 3.459432 2.4E-12 
DIRAS2 3.459432 2.4E-12 
PGA3 3.459432 2.4E-12 
FIGNL2 3.459431 2.4E-12 
BCAR1 3.211504 1.93E-07 
CRYGD 3.169925 8.83E-07 
AZU1 3.163082 1.12E-06 
NRP1 3.137504 2.72E-06 
ELANE 3.090839 1.25E-05 
PXMP2 3.044394 5.17E-05 
LURAP1L 3.044394 5.17E-05 
ABCA8 2.974005 0.000371 
TPSD1 2.974005 0.000371 
EDA2R 2.974005 0.000371 
CABP1 2.974005 0.000371 
GPR15 2.954196 0.000623 
BUB1B 2.888275 0.003144 
PTCRA 2.874469 0.004326 
C2orf80 2.874469 0.004326 
 MARCH2 2.874469 0.004326 
NDNF 2.874469 0.004326 
STEAP1B 2.874469 0.004326 
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OR52I2 2.874469 0.004326 
GRK1 2.874469 0.004326 
SMIM10 2.78136 0.031601 




Appendix VI: 231 genes differentially expressed in neutrophils from 8 GPP vs. 
11 healthy controls 
Symbol log2FoldChange P value FDR 
CYP26B1 9.172412148 6.27E-06 0.002025496 
OTOF 5.119228745 4.50E-08 0.000137377 
OAS2 3.971808127 3.38E-07 0.000375607 
SIGLEC1 3.947811981 2.34E-05 0.004503355 
USP18 3.841053847 5.04E-06 0.001709095 
RSAD2 3.663108849 2.90E-07 0.000354599 
IFI44L 3.563097345 6.66E-07 0.000488218 
OAS1 3.523123021 3.76E-06 0.001444593 
OAS3 3.41407656 2.19E-06 0.001028476 
GBP1P1 3.328636236 2.35E-07 0.000318987 
LY6E 3.308108285 3.40E-06 0.001434257 
SPATS2L 3.271775597 9.52E-07 0.000567181 
IFI44 3.21792139 7.32E-07 0.000488218 
RTP4 3.105936328 4.81E-07 0.000419908 
CMPK2 3.055439406 2.77E-06 0.001208097 
ISG15 3.028183431 7.59E-07 0.000488218 
EPSTI1 3.003631939 9.98E-06 0.002836422 
SEPT4 2.944237993 2.08E-08 8.48E-05 
FSTL4 2.764056435 0.000400287 0.026431925 
AGRN 2.755875361 4.16E-05 0.006279419 
DDX60 2.538926661 4.51E-06 0.001666504 
MT2A 2.514422494 5.75E-08 0.000140394 
IFI6 2.507376228 1.99E-05 0.004267589 
NRIR 2.458692631 5.80E-05 0.00762578 
RMI2 2.412486832 2.11E-07 0.000318987 
IFIT1 2.341066217 8.61E-05 0.009744028 
LAMP3 2.310196414 0.000298783 0.02212082 
HERC5 2.243206042 3.41E-05 0.005449044 
XAF1 2.21414774 3.34E-05 0.005445064 
MTRNR2L8 2.074454003 0.00032389 0.023274373 
SERPING1 2.054662518 1.38E-06 0.000702275 
MX1 2.008222687 0.00063619 0.035649963 
BATF2 2.002474113 8.48E-06 0.002590667 
OASL 1.955295475 6.84E-07 0.000488218 
CARD17 1.89526733 2.60E-05 0.00472263 
ATF3 1.87642956 1.84E-05 0.004008361 
TRIM22 1.837133962 1.09E-07 0.000222672 
PNPT1 1.827403125 0.000146834 0.014235937 
ZNF496 1.767046002 6.03E-05 0.007840177 
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SOCS1 1.762221129 6.50E-06 0.002035366 
DHX58 1.745220861 8.79E-05 0.009765761 
TIMM10 1.737338305 0.00038316 0.026043408 
IFIT3 1.73483868 6.51E-05 0.008112721 
FRMD3 1.711113474 6.39E-05 0.008047376 
GBP5 1.680531557 2.37E-05 0.004503355 
BST2 1.619525415 2.19E-05 0.004369047 
GBP1 1.611339308 1.15E-05 0.003096475 
HERC6 1.597937324 0.000179746 0.016265027 
PLSCR1 1.544410476 2.40E-05 0.004503355 
CASP7 1.534666214 8.90E-05 0.009800224 
LHFPL2 1.523816094 4.64E-06 0.001666504 
TFEC 1.510789858 0.000357379 0.02500654 
MOV10 1.502862096 1.17E-05 0.003096475 
FGF13 1.502339718 0.000287129 0.02178617 
PDCD1LG2 1.498961218 0.000514936 0.030987477 
KCNH3 1.49789933 0.00051133 0.030922786 
IFIT5 1.492253759 0.000198352 0.017278784 
PARP12 1.476740184 0.0001245 0.012569356 
RSPH9 1.470266601 0.000132769 0.013079894 
GADD45A 1.458655659 0.000609295 0.034840457 
EXOC3L1 1.458276278 0.000362168 0.025137738 
IFI35 1.443433488 2.67E-05 0.00472263 
GPR84 1.441671885 0.000999832 0.04644086 
FBXO6 1.440837799 1.31E-06 0.000698126 
PLVAP 1.439279424 0.00065625 0.036150616 
GYG1 1.433990899 0.000893309 0.043625102 
ANKRD22 1.433983216 4.50E-07 0.000419908 
PPM1K 1.427949724 0.000732806 0.039091511 
OLAH 1.405226179 0.000774575 0.040675997 
LINC00968 1.399872758 8.08E-05 0.0093955 
CD2AP 1.397288889 2.15E-05 0.004369047 
APOL6 1.396735209 4.14E-05 0.006279419 
CD274 1.372119138 2.50E-05 0.004621926 
GBP6 1.365253514 2.06E-05 0.004337684 
SPATC1 1.354692662 0.000868531 0.043120296 
IFIT2 1.344909309 0.000275355 0.021289443 
P2RY14 1.326831635 0.000113672 0.012041279 
PARP10 1.325405223 3.78E-06 0.001444593 
ZBP1 1.32482501 9.29E-06 0.002766958 
FCGR1A 1.317629758 4.49E-05 0.006399585 
ANXA2R 1.311304513 1.02E-06 0.000567181 
SAMD9L 1.309580254 2.98E-05 0.00505346 
KIAA0895L 1.302366152 0.00050729 0.030846181 
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CMAHP 1.280619965 0.000170584 0.015551166 
STAT2 1.279120204 7.63E-05 0.009067873 
TMEM62 1.278234659 1.39E-05 0.003276561 
AIM2 1.272582865 0.000126204 0.012636938 
GCH1 1.268234096 3.52E-05 0.005449044 
UBE2L6 1.267529814 1.60E-05 0.003564108 
AANAT 1.266669793 3.50E-05 0.005449044 
KPTN 1.252416073 7.44E-05 0.009067873 
PML 1.220691205 0.000280986 0.021588219 
GRAMD1B 1.213561027 4.43E-05 0.006399585 
EIF2AK2 1.212456821 0.000120418 0.012466353 
RNF144A 1.2106128 0.000284576 0.021727356 
SP140 1.20790437 0.00010958 0.011809536 
LILRA5 1.200638097 0.000217577 0.018330454 
TLDC2 1.192035868 0.000313643 0.022942887 
CMTR1 1.185436073 0.000486149 0.03050535 
EFCAB2 1.18052117 2.88E-05 0.004960046 
FRMD4B 1.167068583 0.000823488 0.041840852 
PCGF5 1.165649202 5.81E-05 0.00762578 
C5 1.162588266 1.31E-05 0.003248412 
SYNPO2 1.130480611 0.000557197 0.032882701 
CARD14 1.127423802 0.000397318 0.02637844 
RNF213 1.120286036 0.000210641 0.018090676 
EXT1 1.092510749 1.12E-05 0.003096475 
SAMHD1 1.088511452 0.000496936 0.03050535 
ASPHD2 1.077181925 8.54E-05 0.009744028 
ZCCHC2 1.071297761 0.00111444 0.049868115 
SSPN 1.052259363 8.45E-05 0.009739882 
ANXA5 1.051622007 0.000245605 0.019609877 
DDX58 1.047786872 0.000229388 0.018806751 
STOML1 1.047490268 0.000548996 0.032555971 
TNFAIP6 1.041869796 0.000495858 0.03050535 
SPTSSA 1.038312831 0.000870785 0.043120296 
VAMP5 1.038295865 0.000143683 0.014041867 
IRF7 1.037956611 0.000224668 0.018544223 
NT5C3A 1.037285357 1.78E-07 0.000310716 
KLF4 1.023918066 0.000829156 0.041840852 
RARRES3 1.012704298 0.000486544 0.03050535 
CACNA1A 1.008040885 2.20E-05 0.004369047 
TNFSF13B 1.003385229 0.000532886 0.0317548 
SCO2 0.998373457 0.000198592 0.017278784 
RHBDF2 0.991076103 1.31E-05 0.003248412 
FCGR1B 0.987986558 0.000471187 0.029979297 
TOR1B 0.983658892 0.000488411 0.03050535 
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UBE2F 0.982310352 0.000586514 0.033796465 
LINC01270 0.970905226 0.000997495 0.04644086 
GIMAP2 0.965919995 8.00E-05 0.009395055 
NEK11 0.940478444 0.000318401 0.023152279 
ODF3B 0.928607387 0.000123543 0.012569356 
ZC3HAV1 0.925168614 0.000167536 0.015504698 
FANCL 0.913034414 0.000254294 0.020041653 
FANCA 0.912148836 0.000812271 0.041517588 
MDK 0.91128109 0.001104422 0.049784564 
VPS9D1 0.905923093 6.60E-05 0.008147868 
CNP 0.904153596 0.000993786 0.04644086 
DRAP1 0.878907907 0.000391563 0.02637844 
KLHDC7B 0.877180454 1.36E-05 0.003258484 
STAT1 0.869897453 0.000628592 0.035649963 
CNIH4 0.869149679 0.000117527 0.01227099 
VPS9D1-AS1 0.868483281 8.73E-05 0.009765761 
GPR160 0.86503306 1.60E-05 0.003564108 
TMSB10 0.860653865 1.33E-05 0.003248412 
PARP9 0.858895586 0.000103644 0.01130458 
NASP 0.857743411 2.22E-05 0.004369047 
ISG20 0.840318544 2.65E-05 0.00472263 
COPG2 0.838048423 0.000967808 0.045647637 
NLRC5 0.836908327 1.25E-05 0.003248412 
KIAA1958 0.833798743 0.000924866 0.044395601 
IFI16 0.832350065 0.000373172 0.025755225 
ARHGAP24 0.830986669 0.000153733 0.014446194 
TDRD7 0.823932363 0.000829064 0.041840852 
RBM43 0.811593154 0.000571785 0.033268441 
CARD16 0.802449754 0.000528426 0.031643362 
MSL3 0.795148856 0.000455724 0.029147276 
IL18R1 0.784017801 0.000752002 0.039941094 
EPAS1 0.778843151 0.000779788 0.040708915 
SESTD1 0.773683913 0.000231977 0.018892219 
DUSP3 0.769938634 5.05E-05 0.006803082 
NOD1 0.751345287 0.000448603 0.028861116 
SNX20 0.738685074 7.65E-05 0.009067873 
EPB41L5 0.737614314 0.000122092 0.012533433 
PHF11 0.736538584 0.000189075 0.016737288 
OBFC1 0.729353987 0.000656961 0.036150616 
STX11 0.725850843 2.02E-06 0.000989427 
GIMAP4 0.709501528 0.000492613 0.03050535 
PSMB9 0.705399798 0.00018206 0.016353292 
TRIM69 0.702990532 6.18E-05 0.007946945 
GBP2 0.697778501 4.87E-05 0.006686955 
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TAP1 0.694168739 0.000242001 0.019449252 
LGALS3BP 0.68711756 0.000801578 0.041425218 
CASP1 0.668810281 6.25E-05 0.007946945 
TRIM38 0.665362102 0.000114341 0.012041279 
TMEM170B 0.661466083 0.000188423 0.016737288 
C18orf25 0.655366038 3.75E-07 0.000381997 
PHACTR2 0.650048481 0.000997671 0.04644086 
SRBD1 0.643872457 0.001078789 0.049173475 
ACOT9 0.635180714 0.000322153 0.023274373 
LRRC46 0.634002664 3.27E-05 0.005398871 
GSTK1 0.626735822 0.000507538 0.030846181 
TXN 0.625004267 0.000110207 0.011809536 
AFF1 0.615612791 4.85E-05 0.006686955 
SIAH2 0.596116122 9.53E-06 0.002770752 
C4orf3 0.584110058 0.001004416 0.046477048 
SPATA13 0.583286873 2.88E-05 0.004960046 
JAG1 0.580393657 0.000394962 0.02637844 
DAPP1 0.55931579 0.000337492 0.024073345 
TYMP 0.558459135 0.000808486 0.041497774 
HEXDC 0.553808905 0.000291449 0.021895219 
RAB12 0.547963099 0.000787092 0.040915392 
TCAIM 0.543945782 0.000896357 0.043625102 
FAM46C 0.543479462 0.000293581 0.021895219 
ERLIN1 0.542717998 0.00043665 0.028372938 
CLEC2B 0.542113635 0.000382774 0.026043408 
CARS2 0.536302284 4.26E-05 0.006342136 
TIPARP 0.520407717 0.000922971 0.044395601 
DPYD 0.513882555 4.51E-05 0.006399585 
LY96 0.501502866 0.000855325 0.042822351 
PDCD11 -0.5037905 0.000666236 0.036496611 
SYNGAP1 -0.506270024 0.000887589 0.04354535 
SLBP -0.515947183 0.000803682 0.041425218 
C2CD2L -0.547227699 4.31E-05 0.006342136 
CEP104 -0.575412769 0.000358231 0.02500654 
GNPDA1 -0.593530531 0.000293944 0.021895219 
MFNG -0.59705505 0.000340921 0.024073345 
DDX28 -0.613373428 0.000267114 0.020917076 
SEMA6C -0.630243096 0.000571903 0.033268441 
SSBP3 -0.634790609 0.000922404 0.044395601 
AGAP3 -0.675683931 0.000775827 0.040675997 
NFATC3 -0.701629022 1.39E-09 8.50E-06 
BOD1 -0.70236116 1.60E-05 0.003564108 
OBSCN -0.807600057 7.63E-05 0.009067873 
FBXL16 -0.954345541 0.000768664 0.040649346 
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ZAP70 -1.043941491 0.000688563 0.03738438 
P2RY10 -1.103321241 0.000634441 0.035649963 
HSPG2 -1.105324054 0.000491941 0.03050535 
MYCL -1.148689702 0.000150584 0.014371374 
CD5 -1.299678648 4.99E-06 0.001709095 
RHPN2 -1.301153916 0.000221208 0.018508707 
ESRP2 -1.331327558 3.45E-05 0.005449044 
CCDC163P -1.377483528 5.07E-05 0.006803082 
FADS1 -1.438401712 3.56E-06 0.001444593 
CD160 -1.452242814 0.000698563 0.037759519 
CLIC3 -1.465532635 0.00093954 0.044486117 
GSTM4 -1.475580157 0.000718722 0.03867799 
GSTM2 -1.717932525 3.15E-05 0.005268772 
MYOM2 -2.019043881 0.000418001 0.027306408 
FAM3B -3.637480697 0.000678806 0.037019155 
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ABSTRACT
Psoriasis is an immune-mediated skin disorder associated with severe systemic co-morbidities. While 
IL-36 is a key disease driver, the pathogenic role of this cytokine has mainly been investigated in skin. 
Thus, its effects on systemic immunity and extra-cutaneous disease manifestations remain poorly 
understood. 
To address this issue, we investigated the consequences of excessive IL-36 activity in circulating 
immune cells. We initially focused our attention on generalised pustular psoriasis (GPP), a clinical 
variant associated with pervasive up-regulation of IL-36 signalling. By undertaking blood and 
neutrophil RNA-sequencing, we demonstrated that affected individuals display a prominent Type-I IFN 
signature, which correlates with abnormal IL-36 activity. We then validated the association between 
IL-36 de-regulation and Type-I IFN over-expression in patients with severe psoriasis vulgaris (PsV). 
We also found that the activation of Type-I IFN genes was associated with extra-cutaneous morbidity, 
in both GPP and PsV. Finally, we undertook mechanistic experiments, demonstrating that IL-36 acts 
directly on plasmacytoid dendritic cells (pDCs), where it potentiates Toll-like Receptor (TLR)-9 
activation and IFN-α production. This effect was mediated by the up-regulation of PLSCR1, a 
phospholipid scramblase mediating endosomal TLR-9 translocation. 
These findings identify an IL-36/Type-I IFN axis contributing to extra-cutaneous inflammation in 
psoriasis.
Key words: 
Generalized pustular psoriasis, psoriasis vulgaris, systemic inflammation, IL-36, Type-I IFN, PLSCR1
Abbreviations: CAPS, cryopyrin associated periodic syndrome; DEG, differentially expressed genes; 
FC, fold change; GPP, generalised pustular psoriasis; IFN, interferon; IL-36, interleukin-36; IL36R, IL-
36 receptor; IL36RN: IL-36 receptor antagonist; MAPK, mitogen-activated protein kinases; pDCs, 
plasmacytoid dendritic cells; PLSCR1, Phospholipid Scramblase 1; PsV: psoriasis vulgaris; TLR- 9: 
Toll-like receptor- 9
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INTRODUCTION
Interleukin-36α, -β and -γ (hence IL-36) are group of IL-1 family cytokines that are mainly produced 
by keratinocytes, monocytes and dendritic cells (Bassoy et al., 2018). IL-36 signalling plays an 
important role in epithelial immune homeostasis and its de-regulation has been repeatedly implicated 
in the pathogenesis of psoriasis vulgaris (PsV), a common and chronic, immune-mediated skin disorder 
(Bassoy et al., 2018). 
Numerous studies have shown that IL-36 responses are elevated in PsV skin (Mahil et al., 2017, 
Quaranta et al., 2014, Swindell et al., 2015) where they stimulate chemokine production and amplify 
the effects of IL-17 signalling (Mahil et al., 2017). Animal studies have also demonstrated that IL-36 
promotes the activation of dendritic cells and the polarization of T lymphocytes into Th17 cells (Tortola 
et al., 2012). Thus, the mechanisms whereby IL-36 contributes to cutaneous inflammation have been 
extensively investigated. Its effects on circulating leukocytes, however, remain poorly understood.
We and others have shown that recessive mutations of the IL-36 receptor antagonist (IL36RN) are 
associated with generalised pustular psoriasis (GPP), a disease variant characterized by severe extra-
cutaneous symptoms (Marrakchi et al., 2011, Onoufriadis et al., 2011). In fact, GPP patients suffer from 
flares of skin pustulation that are often accompanied by systemic upset (fever, elevation of acute phase 
reactants and neutrophilia) (Burden and Kirby, 2016). This suggests that IL-36 signalling is likely to 
influence immune responses beyond skin.
Extra-cutaneous co-morbidities are also well documented in PsV, as individuals suffering from severe 
disease are at high risk of psoriatic arthritis, metabolic syndrome and atherosclerosis (Burden and Kirby, 
2016, Fang et al., 2016, Shah et al., 2017). It has therefore been proposed that PsV is a systemic disease, 
manifesting with skin, joint and vascular inflammation (Davidovici et al., 2010, Reich, 2012). 
In this context, we hypothesise that abnormal IL-36 signalling has extra-cutaneous effects in both GPP 
and PsV, driving acute systemic flares in the former and contributing to a state of chronic systemic 
inflammation in the latter. To explore this model, we integrated the transcription profiling of patient 
leukocytes with ex-vivo IL-36 stimulations. We show that IL-36 potentiates Toll-like receptor (TLR)- 
9 activation and enhances the production of Type-I IFN, a cytokine that contributes to systemic 
immunity, arthritis and atherosclerosis.
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RESULTS
Expression profiling identifies a Type-I IFN signature in GPP and PsV whole-blood samples
We reasoned that GPP would represent an ideal model in which to investigate the systemic effects of 
IL-36, given the well-established link with IL36RN mutations (Marrakchi et al., 2011, Onoufriadis et 
al., 2011) and enhanced IL-36 activity (Johnston et al., 2016). We therefore undertook whole-blood 
RNA-sequencing in 9 affected individuals and 7 healthy controls (Supplementary Table S1 a). While 
the deconvolution of transcription profiles showed that leukocyte frequencies were comparable in cases 
vs. controls (Supplementary Table S1 b), differential expression analysis identified 111 genes that were 
over-expressed (fold change≥1.5; FDR< 0.05) in patients (Figure 1 a, Supplementary Table S2 a). As 
expected, genes that can be induced by IL-36 (IL1B, PI3, VNN2, TNFAIP6, SERPINB1) were 
collectively up-regulated in cases vs. controls (P=0.019) (Figure 1 b). Of note, the analysis of a publicly 
available PsV dataset (Wang et al., 2014) identified a moderate, but statistically significant, over-
expression of the same genes in patient whole-blood (P=0.001) (Figure 1 b), suggesting that IL-36 may 
have systemic effects in PsV. 
To further explore the biological significance of our findings, we mapped the genes up-regulated in 
GPP to the blood co-expression modules described by Li et al (Li et al., 2014). We found that the over-
expressed genes were significantly enriched among modules related to innate immune activation (e.g. 
enriched in activated dendritic cells, FDR<0.005) and antiviral responses (e.g. type I IFN response; 
FDR<0.05) (Figure 1 c). These findings were validated by Ingenuity Pathway Analysis (IPA), which 
identified interferon signalling as the most significantly enriched pathway (FDR<5x10-6) (Figure 1 d). 
An upstream regulator analysis also highlighted IRF7, STAT1 and STAT3 as the transcriptional 
activators that are most strongly associated with gene over-expression (FDR<10-10 for all) (Figure 1 e, 
Supplementary Table S2 c). This is of interest since proteins are critical mediators of IFN signal 
transduction and IFN-α production by pDCs (Honda et al., 2005).
Finally, the analysis of two publicly available datasets (Liu et al., 2012, Rodero et al., 2017) 
demonstrated a significant overlap (P<10-10) between the genes that are up-regulated in GPP and those 
that are over-expressed in autoinflammatory syndromes caused by abnormal activation of Type-I IFN 
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responses (Figure 1 f). Of note, no overlap was found with the up-regulated genes detected in cryopyrin 
associated periodic syndrome (CAPS), a disease caused by excessive IL-1 activity, which was analysed 
as a negative control (Supplementary Figure S1). Thus, the presence of a Type-I IFN signature in GPP 
leukocytes is supported by several lines of evidence. 
To further investigate the relevance of these observations we built an interferon score by measuring the 
aggregate expression of 5 genes (IFI6, IFIT3, IFITM3, OASL, PLSCR1), which were up-regulated in 
the GPP dataset and annotated as Type-I IFN dependent in the interferome database (Rusinova et al., 
2013). As expected, the score was elevated in GPP cases, compared to controls. A similar increase was 
observed in the publicly available PsV dataset (Figure 1 g). Importantly, we found that the interferon 
score documented in GPP and PsV significantly correlated with the up-regulation of IL-36 related genes 
(P<0.01) (Figure 1 h). Thus, we have shown that systemic Type-I IFN responses are abnormally active 
in psoriasis, which may be linked to increased IL-36 production.
The Type-I IFN signature is driven by gene up-regulation in neutrophils
The presence of heterogeneous cell populations in whole-blood can complicate the interpretation of 
transcription profiling experiments. We therefore sought to validate our results through an independent 
analysis of a single cell type. We focused our attention on neutrophils, as they play a critical role in 
systemic inflammation and can be activated by Type-I IFN (Zimmermann et al., 2016). 
We obtained fresh blood samples from 8 GPP cases and 11 controls (Supplementary Table S1 a). 
Following neutrophil isolation and RNA-sequencing, we detected 200 up-regulated genes (Figure 2 a, 
Supplementary Table S2 b). The analysis of transcriptional networks identified Type-I interferon 
response as the most significantly enriched module (FDR<10-12), followed by innate antiviral response 
and antiviral interferon signature (FDR<10-10) (Figure 2 b). IPA also demonstrated a marked 
enrichment of pathways related to interferon signalling (FDR<10-11) (Figure 2 c) and highlighted IRF7 
and STAT1 as the most likely drivers of gene up-regulation (FDR<10-30) (Figure 2 d, Supplementary 
Table S2 d). In keeping with these findings, interferon scores were elevated in GPP cases compared to 
controls (P=0.02) (Figure 2 e). These observations validate the results obtained in whole-blood and 
suggest that the Type-I IFN signature is driven at least in part, by gene up-regulation in neutrophils.
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The Type-I IFN signature can be validated in extended PsV and GPP datasets
We next sought to validate the type I IFN signature through the analysis of further affected individuals. 
We examined neutrophils obtained from 17 GPP cases (including 8 newly recruited cases) and 16 PsV 
patients suffering from severe disease (average Psoriasis Area and Severity Index: 17.9). We also 
analysed two control groups including 9 individuals affected by CAPS and 26 healthy volunteers. Real-
time PCR demonstrated that the interferon score was significantly increased in GPP and PsV cases 
compared to healthy controls (P<0.005). Conversely, and in keeping with the specificity of our 
observations, the scores of CAPS patients were within the normal range defined in unaffected 
individuals (Figure 3 a).  
Of note, medical records showed that GPP patients with high IFN scores were more likely to experience 
systemic flares than those with low scores (88% vs 33%; P=0.049). Likewise, the prevalence of 
psoriatic arthritis was higher among PsV subjects with high IFN scores (67% vs 18%; P=0.03) (Figure 
3 b).  
Thus, the Type-I IFN signature detected by RNA-sequencing can be validated in independent PsV and 
GPP samples, where it is associated with extra-cutaneous morbidity.
The IL-36 receptor is expressed on the surface of plasmacytoid dendritic cells 
We next hypothesised that IL-36 has a direct effect on Type-I IFN producing cells. To investigate this 
possibility, we systematically examined the surface expression of the IL-36 receptor (IL36R) in innate 
immune cells. In keeping with published findings (Foster et al., 2014), we found that IL36R was barely 
detectable on the surface of healthy neutrophils (Figure 4 a), suggesting that the effects of IL-36 on 
these cells are mediated by the activation of different immune population(s).
We also showed that IL36R+ cell numbers were low among innate lymphoid cells (Figure 4 b) and in 
monocytes (Figure 4 c). Higher IL36R levels were observed in myeloid (mDC) and plasmacytoid 
dendritic cells (pDCs) (Figure 4 d, Supplementary Figure S2), with the largest percentage of IL36R+ 
cells detected in the pDCs of GPP patients (Figure 4 e). Thus, we have shown that IL-36R is robustly 
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expressed in pDCs, which are the main producers of IFN-α (a member of the Type-I IFN family) in the 
immune system.
IL-36 potentiates IFN-α production in response to Toll-like receptor 9 stimulation
Based on the results obtained in the above experiments, we hypothesised that IL-36 potentiates Type-I 
IFN production by pDCs. To investigate this possibility, we pre-treated PBMCs obtained from healthy 
donors with IL-36 or vehicle. We then stimulated the cells with CpG-containing DNA (hence CpG), a 
TLR-9 ligand which induces IFN-α release by pDCs. Finally, we measured the up-regulation of the IFN 
signature genes as a readout of Type-I IFN production. While CpG increased the expression of most 
signature genes, its effect was more pronounced in cells that had been pre-incubated with IL-36 (P<0.05 
for IFIT3, OASL and PLSCR1) (Figure 5 a). This observation was validated by direct measurements of 
IFN-α production, showing increased cytokine release following IL-36 pre-treatment (Figure 5 b). 
Finally, flow cytometry documented an increased proportion of IFNα+ pDCs among the cells that had 
been stimulated with IL-36 and CpG, compared to those that had been exposed to CpG alone (Figure 5 
c). Thus, multiple experimental readouts support the notion that IL-36 up-regulates TLR-9 dependent 
IFN-α release.
IL-36 up-regulates PLSCR1, a known TLR-9 transporter 
We next sought to define the mechanisms whereby IL-36 enhances cytokine production downstream of 
TLR-9. A closer inspection of the PBMC stimulation results showed that IL-36 treatment up-regulates 
PLSCR1, even in the absence of CpG. This is of interest, as the gene encodes phospholipid scramblase 
1, a protein which regulates TLR-9 trafficking to the endosomal compartment (Talukder et al., 2012).
To further explore the link between IL-36 and PLSCR1, we first validated our initial observation in 
additional donors (Figure 6 a). Next, we demonstrated that IL-36 treatment increases PLSCR1 protein 
levels in isolated pDCs, showing a direct effect of the cytokine on these cells (P<0.05) (Figure 6 b). 
Finally, we investigated the mechanism whereby IL-36 up-regulates PLSCR1. As expected for an IFN 
signature gene, an analysis of the PLSCR1 promoter uncovered a STAT1 binding site. Given that IL-
36 can signal through mitogen-activated protein kinases (MAPK) (Bassoy et al., 2018), and that there 
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have been reports of cross-talk between STAT1 and MAPK signalling (Zhang et al., 2004), we reasoned 
that the latter pathway was likely to be involved. Real-time PCR experiments confirmed this hypothesis, 
as the SB-203580 MAPK inhibitor abolished the effect of IL-36 on PLSCR1 expression (Figure 6 c).
Thus, we have demonstrated that IL-36 can act directly on pDCs, where it up-regulates PLSCR1, in a 
MAPK-dependent fashion.
DISCUSSION
While PsV has been historically described as a dermatological condition, the importance of extra-
cutaneous co-morbidities is increasingly recognised (Armstrong et al., 2013). Of note, the prevalence 
of most co-morbid conditions increases with the severity and the duration of the disease (Burden and 
Kirby, 2016, Egeberg et al., 2017). There is therefore a dose-dependent association between cutaneous 
and extra-cutaneous inflammation, which suggests a shared systemic pathogenesis. The underlying 
pathways, however, remain poorly understood.
Here, we demonstrated that IL-36 signalling is enhanced in the leukocytes of PsV patients, where 
abnormal IL-36 activity correlates with Type-I IFN over-expression. While many of the genes that are 
induced by IL-36 are also up-regulated by IL-1, this set of shared targets does not include mediators of 
Type-I IFN production (Swindell et al., 2018). Accordingly, we found that IFN signature genes are not 
over-expressed in CAPS, a condition caused by excessive IL-1 signalling. Thus, IL-1 is unlikely to play 
a significant role in promoting Type-I IFN responses in psoriasis. 
Several studies have found that Type-I IFN is a mediator of vascular inflammation, which promotes the 
recruitment of leukocytes to atherosclerotic plaques (Goossens et al., 2010, Niessner et al., 2007). 
Experiments carried out in animal models have also shown that TLR-9 dependent Type-I IFN 
production is a key driver of systemic autoimmunity (Di Domizio et al., 2012).
In keeping with these observations, signatures of excessive Type-I IFN activity have been documented 
in various diseases presenting with prominent systemic involvement. One notable example is systemic 
lupus erythematosus (SLE), a disorder associated with skin and joint inflammation, accelerated 
atherosclerosis and up-regulation of genes such as IFI6 and OASL (El-Sherbiny et al., 2018). Of interest, 
three independent studies have reported that IL-36 serum levels correlate with disease activity in SLE 
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(Chu et al., 2015, Ismail et al., 2018, Mai et al., 2018), which further reinforces the link between IL-36 
and Type-I IFN. Our work adds to these observations and provides mechanistic insights into the 
underlying pathways.
Our computational and experimental results implicate pDCs as the most likely mediators of IL-36 
activity. First, we identified IRF7 as one of the most significant drivers of differential gene expression 
in GPP. Second, we demonstrated that IL-36R levels are highest in pDCs, especially among GPP 
patients. Of note, it has long been established that pDCs accumulate within psoriatic skin lesions, where 
they contribute to early disease processes alongside slanDC (Hansel et al., 2011, Nestle et al., 2005). It 
has also been reported that IL36R is abundantly expressed in various classes of skin-resident DC 
(Dietrich et al., 2016). Thus, it is tempting to speculate that IL-36 mediated pDC activation may also 
have a pathogenic role in skin.
Our results show that the effects of IL-36 on pDCs are mediated at least in part by PLSCR1 up-
regulation. Interestingly, PLSCR1 siRNA knockout inhibits Type I IFN production by human pDCs 
(Talukder et al., 2012), so it is reasonable to hypothesise that an increase in gene expression would have 
the opposite effect. While the PLSCR1 induction observed in our IL-36 stimulation experiments was 
modest (1.5-2.0 fold), it might be sufficient to activate a feed-forward loop whereby up-regulated 
PLSCR1 promotes the production of Type-I IFN, which in turn induces further PLSCR1 transcription. 
In fact, self-amplifying loops are a key feature of Type-I IFN signalling, as they are required for robust 
antiviral responses (Hall and Rosen, 2010).
We cannot exclude the possibility that additional IL-36 responsive genes or cell types may also 
contribute to the up-regulation of Type-I IFN. However, we have found that IL-36 does not affect the 
expression of TLR9 or that of key downstream genes (IRF1, IRF3, IRF7; data not shown). We have also 
observed that genes driving other antiviral pathways (DDX58/RIG-I, IFIH1/MDA5, 
TMEM173/STING) are not up-regulated in PsV or GPP whole-blood. 
While our pDC stimulations were carried out with a synthetic TLR-9 agonist, the identity of the agents 
that cause IFN-α production in patients remains to be determined. In lesional skin, pDCs are activated 
by self-nucleic acids released by apoptotic keratinocytes and bound to the LL-37 antimicrobial peptide 
(Lande et al., 2007). Our transcriptomic data, however, suggests that this mechanism is unlikely to be 
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relevant at the systemic level. While CAMP (the gene encoding LL-37) was up-regulated in psoriatic 
skin, it was not over-expressed in GPP or PsV whole-blood. Moreover, there was no correlation between 
CAMP whole-blood expression and the up-regulation of Type-I IFN genes (r<0.1). Thus, the agents that 
activate the circulating pDC of psoriatic patients may be different from those that are present in skin.   
In conclusion, we have identified an IL-36/TLR-9 axis which up-regulates systemic Type-I IFN 
production in psoriasis (Figure 6 d). In GPP patients, the effects of IL-36 signalling are amplified by 
inherited IL36RN mutations, a phenomenon which is likely to account for the severe nature of systemic 
flares. In PsV, the Th17-dependent up-regulation of IL-36 cytokines is associated with a less 
pronounced transcriptional signature and with signs of chronic systemic inflammation. 
Given that IL-36 is down-regulated by IL-17 inhibitors such as secukinumab (Kolbinger et al., 2017), 
it is possible that treatment of psoriasis with IL-17 antagonists might also modulate Type-I IFN 
production. Of note, the effects of direct IL-36 inhibition are currently being investigated in clinical 
trials, with promising results obtained in a Phase I study (Bachelez, 2018). In this context, our work 
suggests that IL-36 antagonists have the potential to improve systemic Type I IFN up-regulation and 
extra-cutaneous manifestations of psoriasis.   
METHODS
Human subjects
The study was performed according to the principles of the Declaration of Helsinki. Patients were 
ascertained at St John’s Institute of Dermatology and Royal Free Hospital (London, UK), Glasgow 
Western Infirmary (Glasgow, UK), Salford Royal Foundation Trust (Manchester, UK) and Hospital 
Sultanah Aminah (Johor Bahru, Malaysia). The study was approved by the ethics committees of 
participating institutions and written informed consent was obtained from all participants. 
Nine unrelated GPP patients and 7 healthy controls were recruited for whole-blood RNA-sequencing, 
while neutrophil RNA-sequencing was carried out in 8 GPP patients and 11 healthy controls. Five 
controls and six cases were common to both studies (Supplementary Table S1 a). For the validation of 
neutrophil RNA-sequencing results, fresh blood was obtained from 17 GPP, 26 control, 9 CAPS and 
17 PsV individuals (Supplementary Table S3). All PsV patients suffered from moderate-to-severe 
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disease (Psoriasis Area Severity Index >10) and were recruited from the same centre (Severe psoriasis 
service, St John’s Institute of Dermatology). Patients presenting with joint pain were referred to an 
expert rheumatologist, who diagnosed PsA, when applicable. The IL36RN gene was screened in all GPP 
cases and mutations were identified in 4 individuals (Supplementary Table S1 a). 
RNA sequencing data analysis
The raw sequence data generated in house and that retrieved from public repositories (Supplementary 
Table S4) were processed with the same computational pipeline (described in supplementary methods), 
in order to standardise the data analysis process. Genes were considered up-regulated if the fold change 
exceeded 1.5 (FDR<0.05). When RNA-sequencing and microarray data were compared, the analysis 
focused on the 100 genes that were most significantly up-regulated in each sample, in order to account 
for the different sensitivity of the two platforms.
Genes up-regulated in GPP were used as input for pathway and upstream regulator enrichment analyses 
(IPA, Qiagen). STAT1- STAT3- and IRF7-centered networks were visualised with the igraph v1.0.1 R 
Package.
The transcriptional modules that were active in our datasets were selected from the library published by 
Li et al (Li et al., 2014). The enrichment_test function was then applied to the lists of up-regulated 
genes. 
The interferon score was built using the five Type-I IFN dependent genes that were most up-regulated 
in GPP whole-blood (PLSCR1, OALS, IFI6, IFIT3, IFITM3). As IL-36 dependent genes have not been 
systematically characterised in leukocytes, the IL-36 score was based on the analysis of five genes 
which were strongly induced by IL-36 in keratinocytes (Mahil et al., 2017) and robustly expressed in 
whole-blood (IL1B, PI3, VNN2, TNFAIP6, SERPINB1). Both scores were derived by normalising 
RPKM values to a calibrator sample and then computing the median expression of the five genes. 
Statistics
Differences between patient and control cytokine scores were assessed using an unpaired t-test or one-
way ANOVA, as appropriate. To account for donor variability in cytokine responses, IL-36/CpG 
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stimulations were analysed with non-parametric methods (Wilcoxon signed-rank test for comparisons 
between two groups and Friedman’s test for comparison between three groups), as these do not assume 
equal variance among samples. The correlation between cytokine scores was calculated using Spearman 
method. The significance of overlaps observed in Venn diagrams was computed with a hyper-geometric 
test and confirmed by bootstrap analysis. Fisher’s exact test was used to compare the clinical features 
of patients with high and low IFN scores. 
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FIGURE LEGENDS
Figure 1. Transcription profiling of GPP and PsV whole-blood uncovers a Type-I IFN signature 
that correlates with IL-36 activity. (a) Identification of genes that are differentially expressed in GPP. 
Horizontal and vertical lines represent significance and fold change thresholds, respectively. The genes 
underlying the IFN score are in red. (b) Higher expression of IL-36 dependent genes in whole-blood of 
GPP and PsV patients, compared to controls (CTR). (c) Transcriptional modules enriched among genes 
up-regulated in GPP. The FDR for each module is reported, with the underlying up-regulated genes 
shown as grey cells. (d) Enriched pathways detected among genes over-expressed in GPP. (e) Key 
transcriptional factors driving gene over-expression in GPP. (f) Overlap between the genes that are up-
regulated in GPP and IFNpathies. (g) Elevated IFN score in whole-blood samples of GPP and PsV 
patients, compared to controls (CTR). (h) IL-36 and IFN scores are significantly correlated, in both 
GPP and PsV patients. Dashed regression lines are plotted with 95% confidence intervals (grey areas). 
The data in (b) and (g) are presented as mean +/- SD; *P<0.05, **P<0.01 (unpaired t-test).
Figure 2. Transcription profiling of GPP neutrophils confirms the presence of a Type-I IFN 
signature (a) Identification of genes that are differentially expressed in GPP. Horizontal and vertical 
lines represent significance and fold change thresholds, respectively. (b) Transcriptional modules 
enriched among the genes that are up-regulated in GPP. The FDR for each module is reported, with the 
underlying up-regulated genes shown as grey cells. (c) Enriched pathways detected among the genes 
that are up-regulated in GPP. IFN-related pathways are highlighted in bold (d) Upstream regulator 
analysis showing that IRF7 and STAT1 drive the up-regulation of numerous genes that are over-
expressed in GPP. (e) Elevated IFN score in the neutrophils of GPP patients, compared to controls. The 
data are presented as mean +/- SD; *P<0.05 (unpaired t-test). 
Figure 3. Validation of the Type-I IFN signature in extended datasets (a) Elevated IFN score in the 
neutrophils of GPP and PsV patients, compared to healthy individuals. CAPS cases were analysed as 
negative controls. The data are presented as mean +/- standard deviation; **P<0.01 and ***P<0.001 
(one-way ANOVA followed by Dunnett’s post-test). (b) Left: systemic flares are more prevalent in 
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GPP patients with high interferon scores (n=8) compared to those with low interferon scores (n=9). 
Right: psoriatic arthritis (PsA) is more prevalent in PsV patients with high interferon scores (n=6) 
compared to those with low interferon scores (n=11). In both groups, the cut-off between high and low 
scores was defined as the median +2SD of the values observed in healthy controls. *P<0.05 (Fisher’s 
exact test). 
Figure 4. The IL-36 receptor is preferentially expressed by pDCs. (a-e) Representative flow 
cytometry plots showing IL36R surface expression, compared to fluorescence minus one (FMO) 
controls. (a) neutrophils (gated as CD14+, CD15+, CD16+ cells); (b) innate lymphoid cells (lineage- 
(CD3-, CD4-, CD19-, CD20-, CD56-), CD127+); (c) monocytes (CD3-, CD20-, CD19-, CD56-) separated 
into classical (CD16-, CD14high), intermediate (CD16+, CD14+) and pro-inflammatory (CD16high, 
CD14-) populations; (d) pDCs (lineage-, HLADR+, CD123+, CD11c-) and mDCs (lineage-, HLADR+, 
CD123-, CD11c+). (e) Histogram showing the percentage IL36R+ cells in each leukocyte population. 
Data were obtained in at least 3 GPP cases and 3 sex-matched controls. Results are presented as mean 
+/- SEM. No significant differences were observed between GPP cases and healthy donors.
Figure 5. IL-36 enhances the production of IFN-α downstream of Toll-like receptor 9. (a) PBMCs 
were stimulated with CpG for 6h, in the presence or absence of IL-36 pre-treatment (6h). The expression 
of interferon signature genes was measured by real-time PCR. Data represent the mean +/- SEM of 
results obtained in three independent donors, each stimulated in triplicate. (b) Following PBMC 
stimulation, IFN-α production was measured by ELISA. Data represent the mean +/- SEM of results 
obtained in two independent donors, each stimulated in triplicate. (c) Following PBMC stimulation, the 
percentage of IFNα+ pDCs was determined by flow cytometry.  A representative set of plots is shown 
(left), together with the data obtained in 3 independent healthy donors (right). *P<0.05; **P<0.01 
(Friedman’s test, with Dunn’s post-test). 
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Figure 6. IL-36 up-regulates PLSCR1 (a) Following treatment of PBMCs with IL-36, PLSCR1 
expression was measured by real-time PCR. (b) Following IL-36 treatment of pDCs, PLSCR1 mean 
fluorescence intensity (MFI) was measured by flow-cytometry, in gated PSLCR1+ pDCs. A 
representative histogram is shown on the left. (c) Following pre-treatment with SB203580 (MAPKi), 
PBMCs where stimulated with IL-36. PLSCR1 expression was then determined by real-time PCR. (d) 
Proposed pathogenic model.  Interleukin-36 produced by mDC up-regulates PLSCR1 in pDCs, 
potentiating TLR-9 dependent IFN-α release. IFN-α induces further PLSCR1 transcription, thus 
propagating an inflammatory feed-forward loop. All data are shown as mean +/- SEM of results 
obtained in at least 3 donors, each stimulated in triplicate. *P<0.05 (Wilcoxon signed-rank test (a, b) 
and Friedman’s test with Dunn’s post-test (c)) 
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